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“You, me, or nobody is gonna hit as hard as life. But it ain't about how hard 
you hit. It's about how hard you can get hit and keep moving forward; how 
much you can take and keep moving forward. That's how winning is done! 
Now, if you know what you're worth, then go out and get what you're worth. 
But you gotta be willing to take the hits, and not pointing fingers saying you 
ain't where you wanna be because of him, or her, or anybody. Cowards do that 
and that ain't you. ” 
 
Silvester Stallone, Rocky Balboa 
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ABSTRACT 
With 1 685 210 new cases in 2016 in United States (American Cancer Society), 
cancer poses a serious challenge for the patients, the healthcare system and families 
of patients considering that 595 690 people will die from the disease.  
Long time has passed since surgery was the only option available and rudimental 
chemotherapy was attempted with arsenic-based compounds. The evolution of 
therapies relied on technological breakthroughs such as the optimization of 
radiation therapy and the development of monoclonal antibodies. 
In the last decades, a new class of therapies raised particular interest thanks to the 
ability to promote long-lasting complete responses. Immune therapy exploits the 
patient´s own immune system to find and kill tumor cells. Once immunological 
memory is established, this can potentially grant long term protection. 
Nevertheless, the results of immunotherapies are often inconsistent as we observe 
a number of complete remissions together with patient that completely fail to 
respond to the therapy. Uncovering the mechanisms of such difference is the 
primary aim of researchers that try to optimize the strategies to ultimately increase 
the number of responders. 
In this thesis three main strategies will be reviewed, studied and finally combined: 
i) oncolytic adenoviruses; ii) cancer vaccines and iii) immune checkpoint inhibitors.  
In Study I, we developed an innovative cancer vaccine platform based on oncolytic 
adenoviruses. Classic oncolytic viruses rely on their ability to lyse tumors cells and 
release antigens in order to prime tumor-specific responses. However, this process 
is not optimal and does not offers control, hence the immunogenic potential of 
viruses is not maximized. To overcome this limitation, we used the adenovirus as 
a carrier able to deliver peptides to antigen presenting cells. The Virus-peptide 
complex (i.e. PeptiCRAd) was build with electrostatic interactions, thus preserving 
the virus ability to infect and kill tumors cells. In addition, we showed that 
PeptiCRAd was able to reduce the growth of B16OVA and B16F10 tumors by 
inducing antigen specific responses through the activation of dendritic cells. 
Ultimately, we showed its potential in humanized mice engrafted with both human 
   
 
   
 
21 
melanomas and human peripheral blood mononuclear cells (PBMCs). Our 
PeptiCRAd platform eradicated the tumors of humanized mice while a normal 
oncolytic virus led to stable disease after treatment. Consistently, we found an 
increased number of human T-cells against the targeted tumor antigen (MAGE-
A3) in mice treated with PeptiCRAd compared to mice treated with a normal 
oncolytic adenovirus. These results underline the potential of the platform for 
clinical testing. A clinical trial is currently being designed by Valo Therapeutics, a 
spin-off company from the University of Helsinki, which is the owner of the patent 
deriving from the work described in the study.  
In Study II we addressed the problem of optimizing the peptides formulations to 
be used in cancer vaccines. The design of improved peptides is time consuming 
and usually relies on few in silico tools with poor integration of data. To address 
this problem, we set up an in silico framework that uses multiple in silico tools such 
as MHC-I affinity and immunogenicity predictions. In addition, to study the cross-
reactivity of T-cells against the wild type epitope and their improved-mutated 
forms we used molecular dynamics simulations. 
We showed that while binding affinity is usually a good predictor of 
immunogenicity, T-Cell Receptor (TCR)-engagement prediction is less accurate. 
Molecular dynamics simulations were used to predict the 3D conformation of the 
peptides-MHC complexes. This allowed us to directly compare how mutating 
specific residues would not only change the orientation of the peptide within the 
MHC-binding pocket, but it would re-shape the whole portion of the MHC 
molecule that is recognized by the TCRs. This gave us suggestions on the 
differences in anti-tumor efficacy observed when testing several forms of 
SIINFEKL and TRP2180-188 peptides in both B16OVA and B16F10 in vivo models. 
Study III is where we addressed the problem of combining in an efficient way 
different approaches. In fact, our aim was to increase the response to checkpoint 
inhibitors by improving the infiltration of tumors by immune cells. To this end, 
we used the pro-inflammatory properties of the oncolytic vaccine platform 
described in Study I, since it has been shown that treatment with oncolytic viruses 
increases the presence of tumor-infiltrating lymphocytes (TILs). Combination of 
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PeptiCRAd with PD-L1 blockade proved to increase the survival of melanoma-
bearing mice compared to monotherapy with PD-L1 or PeptiCRAd. In addition, 
anti-tumor efficacy was observed also in a poorly immunogenic in vivo model of 
breast cancer. Immune phenotypic analysis revealed that the combination of 
viruses and checkpoint inhibition increases the presence of TILs with a non-
exhausted state (PD-1+ TIM-3-). In a translational in vitro model, we tested the 
combination therapy, demonstrating that PBMCs, primed with antigen-specific 
PeptiCRAd, showed better killing of human melanoma cells when in presence of 
anti-PD-L1 antibody. Hence checkpoint inhibition well synergized with the 
immune activating properties of the oncolytic vaccine. 
 
Taken together, the findings described in this thesis highlight the necessity of 
combination therapies to increase the number of responders to immunotherapy. 
This is a critical aspect to enlarge the number of responding patients and to 
maximize the benefits of immunotherapies, considering that immunotherapeutic 
approaches are reaching the market with unprecedented speed.  
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REVIEW OF LITERATURE 
1. Introduction 
With 3584094 articles available on PubMed, cancer biology represents one of the 
most studied fields of oncology. The oldest scientific report available by using 
these keywords was written by Dr. Benjamin Rush in 1787. The article, published 
on the London Journal of Medicine, describes the efficacy of a “magical unguent” 
that a colleague, Dr. Marint Hugh, carefully applied to several types of tumors. 
While some of them were completely cured, others did not respond to the therapy. 
Fascinated by the properties of the formulation, Dr. Rush tried to reproduce the 
results, although with no success. Determined to understand the reasons behind 
his failure, he decided to take a closer look at the drug that Dr. Hugh simply 
described as a mixture of natural substances extracted from plants. Of interest, is 
the method applied by Dr. Rush when investigating the composition of the drug. 
His empirical approach suggested him a caustic substance, which he later found to 
be arsenic [1]. 
This interesting story is one of the many that researchers and doctors used to share 
when studying what nowadays would look like a primordial approach at curing a 
disease. However, what it is of extreme interest is the foundation of such 
experimentation and study: the idea that cancer cells could be eliminated by a toxic 
molecule.  
After two centuries, chemotherapy still represents one of the main treatment for 
cancer. Treatment with chemical compounds able to cause cell death is used in 
approximately 28-38 % of cases of metastatic melanoma that fail to respond to 
immunotherapy and/or targeted therapy, while radiation therapy in 35-38 % of 
cases [2]. However, the idea that direct lysis of tumor cells would be sufficient to 
cause a complete response might be considered old fashioned. Often, modern 
therapies aim at multimodal approaches where, chemotherapy is mixed with 
radiotherapy or biological drugs. As cancer biology evolved, new mechanisms of 
tumor-resistance emerged and the interplay between malignant cells and the host 
immune system became a critical aspect to consider when designing novel cancer 
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therapies. Nowadays we know that while tumors are mostly characterized by 
genetic mutations that confer to cells the ability to escape control mechanisms, a 
key factor of tumor progression is the lack of recognition by our immune system. 
In fact, the sustained proliferative signalling is only one of the hallmarks of 
cancer[3]. Many other aspects contribute to the general malignant nature of a cell. 
Among these, the ability to avoid immune destruction is of interest. 
Therefore, restoring the recognition of tumors by our immune system is the main 
aim of cancer immunotherapy. Being awarded the title of “breakthrough of the year” 
by the prestigious scientific journal Science in 2013 [4], cancer immunotherapy has 
largely widened the number of available options to treat cancer. Rather than relying 
on the activity of small molecules or radiation, the idea to use the patient’s immune 
system is appealing as it would result in long lasting responses. However, an 
increasing number of clinical studies suggests that immune therapy can be, and 
should be, combined with classic approaches to overcome the suppressive 
environment that allows for the escape of malignant cells from immune 
surveillance.  
After a brief review of classic cancer therapies the following paragraphs will 
provide an overview on several immune therapies, including the use of 
adenoviruses for the treatment of cancer. 
2. Cancer Treatments 
2.1. Surgery, chemotherapy and radiotherapy 
The type of malignancy and its stage often dictate the most suitable therapy. 
Typically, the simplest solution is offered by surgery, where the tumor is simply 
removed.  In fact, according to data available in the National Cancer Data Base 
(NCDB; 2017), surgery represents the preferred monotherapy for first course 
treatment (Fig 1A) among all types of tumors. In fact, chemotherapy or 
radiotherapy alone account for only the 5.24 and 4.64 % of first course treatments 
respectively. Interestingly, a combination of two or more approaches is used in 
28.2 % of the cases. 
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The ability to physically remove the tumor, however, is affected by the stage of the 
disease. It is easy to imagine that with more advanced patients, the tumor mass 
might be heavily infiltrated in the healthy tissue or that the metastatic nature of the 
disease makes surgery a less appealing choice. In fact, by analysing the data 
according to the stage of the disease, a clear trend emerges: the percentage of 
patients that receives only surgery decreases drastically when comparing late stages 
with earlier ones (Fig 1B). For instance, while at stage 0 or I an average of 50 % 
of patients is treated with surgery only, at stage IV only 5 % of patients receives 
surgery as monotherapy.  Indeed, combination therapy (orange portion) or 
chemotherapy (black portion) are preferred at later stages, accounting for 22.6 and 
13.5 % of cases respectively. 
 
Figure 1. Distribution of the treatment of cancer. A) Therapies chosen as first course treatment after diagnosis. Data 
include all types of tumors.  B) Distribution of therapies across the stages of the disease. Data have been collected from 
the National Cancer Database (NCDB). 
 
For the reasons discussed above, chemotherapy and radiotherapy are often 
preferred to treat metastatic or late stage diseases. The possibility to target non-
reachable lesions and individual residual tumor cells after surgery is one of the 
main advantages of these strategies. 
Chemo and Radio therapy rely often on the inhibition of cell cycle through the 
damage to DNA and this event is often followed by cell death [5]. There is a wide 
variety of compounds which have been studied into the clinic. For instance, 
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chemotherapy in advanced non-small cell lung cancer (NSCLC) has been 
historically characterized by the use of platin-based compounds that bind and 
cross-link DNA strands. Carboplatin or Cisplatin have been adopted as preferred 
therapy, often in combination with other alkylating agents. However, the median 
survival benefit is only of six weeks compared to the standard of care [6]. To 
increase its efficacy, platinum-based chemotherapy can be combined with the so 
called "third-generation agents". Among those, it is worth mentioning pemetrexed, 
which is a folate antimetabolite. This drug inhibits several enzymes involved into 
the synthesis of purine and pyrimidine, thus it prevents the formation of DNA and 
RNA resulting into the arrest of cell proliferation [7]. Similarly, cyclophosphamide 
acts as a cross-linker and causes DNA damage leading to apoptosis of cells [8].  
In addition to cause direct damage to genomic DNA, another strategy is 
represented by interfering with the progress of cell cycle. Enzymes such as 
Topoisomerases (I and II) play a pivotal role in cell proliferation and their 
inhibitors have proved to decrease the progression of tumors successfully [9]. 
Doxorubicin is an anthracycline antibiotic that stabilizes the DNA-Topoisomerase 
complex, thus preventing the release of DNA strands. Approved by FDA for the 
treatment of brain tumors, several formulations have been successfully tested to 
improve the bio distribution and safety profile. For instance, doxorubicin has been 
encapsulated into conventional or PEGylated liposomes showing an improved 
safety profile along with a better bio distribution [10]. 
As previously anticipated, chemotherapy and radiotherapy share a similar 
mechanism of action.   About 50% of cancer patients is treated with radiations 
during the disease, whether as monotherapy or in combination with other 
treatments. Ionizing radiation (IR) is the most commonly used type of radiation 
therapy that causes DNA damage, resulting in apoptosis. The radiation source is 
usually external, and the radiation beams are shaped to focus on the lesion rather 
than surrounding healthy tissues. Similarly, brachytherapy relies on small implants 
that emits radiations which are placed close to the disease site. In both cases the 
main aim is to damage tumor cells while sparing healthy ones. Nevertheless, an 
area larger than the lesion is targeted to ensure the coverage of all the malignant 
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tissue, especially if radiations are given as adjuvant therapy after surgery; this 
usually provides the option to kill residual cells. 
As reviewed, both chemotherapy and radiation therapy heavily rely on DNA 
damage-induced apoptosis. However, this pathway is often mutated into tumor 
cells, thus resistance mechanisms arise making these approaches less effective for 
advanced diseases.  
 
2.2. Immunotherapy 
The therapeutic strategies which have been briefly summarized into the previous 
paragraph rely on the use of drugs to directly kill tumor cells. On the contrary, 
immunotherapy aims at stimulating the patient's own immune system and let 
immune cells recognize and eradicate malignant ones. This is an interesting strategy 
because it can create an immunological memory which can potentially provide 
protection from relapses and efficacy against metastatic diseases. 
The methods used to modulate the immune system of patients determines the 
mode of action and mechanism. While some approaches rely on drugs that are 
“ready to work” when infused (such as monoclonal antibodies), other strategies 
exploit the full potential of the immune system and anti-tumor responses are 
created in vivo. 
 
2.2.1. Biological response modifiers (BRMs) 
This class of drugs is composed of biological molecules that regulate functions of 
our immune system. The aim is to upregulate inflammatory pathways and stimulate 
anti-tumor responses in an unspecific way. As examples, I will discuss about 
interleukins (ILs) and granulocyte and macrophages colony stimulating factor 
(GM-CSF).  
The year 1976 marked a turning point into the history of immune therapy with the 
discovery of IL-2 as a T-lymphocyte growth factor. The availability of purified IL-
2 allowed for more detailed studies about the differentiation and activation of T-
cell and NK cells. Interestingly, the importance of IL-2 was firstly assessed in mice 
with defective production of T-regulatory cells (Tregs). Defects in IL-2 production 
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led to a reduced number of Tregs, thus development of abnormal autoimmunity 
[11]. In fact, Tregs are equipped to readily respond to low levels of IL-2 [12] and 
blockade of IL-2 receptor signalling has been exploited to dampen the activity of 
this immune suppressive subset of T-cells [12]. At the same time, IL-2 is important 
for the function of effector cells and generation of memory ones as well. In fact, 
IL-2 is produced by antigen-activated T-cells as early as 1 hour after the stimulation 
of T-cell receptor (TCR) [13]. 
Despite the opposing roles of IL-2 in the regulation of T-cell function, the 
potential benefits of boosting immune responses led to its use into the clinic. Since 
low levels of IL-2 favour the expansion of Tregs, high dose IL-2 has been tested 
into patients with metastatic renal cell carcinoma (mRCC) with an overall response 
rate of 10 % and a complete response rate of only 5 % [14]. Interestingly, the 
combination of IL-2 with blockade of CD40 reduced the levels of Tregs and 
myeloid-derived suppressor cells (MDSCs) in tumor tissues [15]. In other studies, 
IL-2 has been modified to bind with higher affinity its receptor on naïve T-cells 
(IL-2Ra) rather than the receptor isoform on Tregs (IL-2Rb) [16]. In addition to 
IL-2, the cytokine family of γ chain (γc) comprises IL-7, IL-15 and IL-21, which 
support of differentiation, proliferation and long term-survival of T-cells. IL-15 is 
of interest since it has been showed to be essential to maintain the memory 
phenotype of CD8+ T-cells [17]. In addition, when combined with IL-21, both 
cytokines can provide support to anti-tumor immunity [18]. 
Interleukins are not the only example of BMRs that have been used to modulate 
the immune system functions. Colony Stimulating Factors increase the 
proliferation, maturation and homing of antigen presenting cells (APCs). In fact, 
mice lacking GM-CSF showed defects in anti-bacterial responses due to sub 
optimal function of macrophages and dendritic cells [19]. Of interest, is the ability 
of GM-CSF to promote the generation of a subtype of DCs that would support 
T-helper Type I cells [20]. In clinical studies, GM-CSF has been used to potentiate 
T-cell responses in combination with IL-2 therapy; administration of IL-2, IFN-
alpha and GM-CSF to patients with mRCC resulted in 19 % of overall responses 
[21, 22]. In a subsequent study Verra and colleagues found an increased number 
   
 
   
 
29 
of tumor-infiltrating T-cells and mature DC in tumor samples from the patients 
that received the cytokine cocktail compared to control group [23]. The effect that 
GM-CSF has upon APCs makes it an attractive molecule to include in vaccination 
strategies (which will be discussed in the following paragraphs) [24]. 
IL-2 and GM-CSF are only two of the wide selection of BRMs that are used for 
immune therapy. However, their long-term use provides the perfect example of 
how naturally available immune modulators can re-shape the tumor 
microenvironment and affect the function of T-cells.  
 
2.2.2. Cell Therapy for cancer 
Biological drugs that relieve immune suppression within the tumor 
microenvironment can evoke rather general immune responses. This can be 
beneficial when tumor antigens are unknown. However, the efficacy and specificity 
of the therapy can be limited. In addition, biodistribution of the molecules and 
their ability to reach immune cells are important factors to consider. These 
challenges can be addressed by direct modification of immune cells which are 
isolated from the patient. The isolated immune cells can be modified to potentiate 
their activation state or to redirect them against specific targets. 
 
2.2.2.1. Dendritic Cell Therapy 
The tumor immunity cycle starts with the uptake of tumor antigens by APCs which 
migrate to the nearest lymph node to present epitopes to T-cells. Hence, the 
activated and antigen experienced T-cells move into the tumor tissue to kill 
malignant cells. The lysis of tumor cells causes the release of new proteins which 
are then picked up again by APCs. 
The above-mentioned cycle is a theoretical and rather naïve simplification of how 
the immune system and tumor cells communicate with each other. It is very 
appropriate to talk about “communication” since tumor cells can readily respond 
to inflammatory signals with immune suppressive ones, escaping the immune 
surveillance by silencing immune functions.  
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One of the strategies that tumor cells use to escape immune responses is to make 
antigen presentation ineffective. In fact, tumor cells can secrete a wide variety of 
suppressive cytokines that limits the maturation of APCs. For instance, even in 
presence of antigen presentation an immature DC is not able to prime an immune 
response. In fact, naïve T-cells are fully activated only if they are provided with 
sufficient co-stimulatory signals. Interestingly, presentation of antigens without 
proper co-stimulation can establish tolerance of T-cells towards the antigen. To 
overcome these limitations, DCs have been engineered by using genetic 
modification or transduction with recombinant viruses [25].  
Mature DCs express the main co-stimulatory molecules CD80 and CD86 which 
bind the receptor CD28 on T-cells and promotes their full activation. DC 
maturation is usually achieved by stimulation of pattern recognition receptors 
(PRRs) which are activated by danger signals from pathogens or dying cells. 
However, tumor cells can secrete immune suppressive molecules to prevent DC 
maturation. Transforming growth factor β (TGF-β) and IL-10 are among the most 
potent immune suppressive mediators and can promote apoptosis of T-cells and 
DCs. Modifying DCs to make them resistant to TGF-β mediated suppression is 
an attractive strategy. For instance, transducing DCs with GM-CSF can induce the 
upregulation of B-cell lymphoma extra-large (Bcl-xL) molecule that increases the 
resistance of DCs to apoptosis. In addition, DCs can be made unresponsive to 
TGF-β by directly modifying its receptor as Wang and colleagues demonstrated 
and this approached can be applied directly by in vivo transduction of DCs with the 
dominant-negative mutant of the TGF-β receptor[25].  
The presentation of antigens by DCs can be enhanced by transducing them with 
the desired proteins. These will be produced, processed and presented to T-cells 
on MHC-I. Blalock and colleagues engineered DCs to express MART-1, tyrosinase 
and MAGE-A6 tumor antigens by using adenoviral vectors.  The engineered DCs 
are activated by the adenoviral pathogen associated molecular patterns (PAMPs) 
and can present efficiently the epitopes to T-cells, activating both CD8+ and 
CD4+ T-lymphocytes [26]. A recent study has shown how expression of the 
Notch ligand Delta-like-1 (DDL) in DCs promoted their maturation and increased 
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T-cell responses by polarization of T-helper cells towards type I [27]. Similarly, 
lentiviral vectors have been used to engineer DCs with both tumor antigens and 
stimulatory molecules. Daenthanasanmak and colleagues have used a lentivirus to 
make DCs constitutively express GM-CSF, IFN-α and the antigen pp65 from 
cytomegalovirus (CMV). This strategy promoted CMV specific responses and 
created memory cytotoxic T-lymphocytes highlighting the potential of engineered 
DCs [28]. 
To conclude this brief overview of DC-therapy, it is worth mentioning the clinical 
success of this approach for the treatment of prostate cancer. Sipuleucel-T (on the 
market as Provenge) is an active cellular immunotherapy which relies on ex vivo 
activation of autologous dendritic cells with a recombinant fusion protein 
(PA2024). The PA2024 protein is composed of prostatic acid phosphatase (which 
acts as tumor specific antigen) and GM-CSF (which acts as maturation factor for 
DCs). Mature DCs are then reinfused into the patients to activate tumor-specific 
T-cells. In a randomized clinical trial, treated patients experienced a reduction of 
risk of death of 41 % compared to placebo (hazard ratio of 0.59, 95 % confidence 
interval). Although statistical significance was not reached, a second trial showed 
a trend towards increased survival of treated patients. Interestingly, immunological 
analysis revealed high titers of antibodies against the anti PA2024 antigen and T-
cell proliferative responses to the protein. Hence, the limited efficacy of the 
therapy might not be caused by lack of immune stimulation [29]. 
 
2.2.2.2. T-cell Therapy 
In the previous paragraph, I reviewed few examples of how the first step of the 
tumor immunity cycle can be improved by engineering DCs to prime T-
lymphocytes in vivo. However, an even more direct approach is represented by 
modification of T-cells, thus bypassing in vivo antigen presentation [30]. 
T-cells are usually isolated from peripheral blood mononuclear cells (PBMCs) 
obtained from the patient. Then, purified lymphocytes are stimulated in vitro with 
specific tumor antigens and pro-inflammatory cytokines. Alternatively, T-cells are 
transduced with molecules that change their antigen-specificity, making them 
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tumor specific. After these modifications, engineered T-cells are reinfused into the 
patient and they home to the closest lymph node or tumor tissue where they exert 
their effector function [31]. 
The easiest type of T-cell therapy is represented by ex vivo expansion of antigen-
specific T-cells from the total pool of lymphocytes. This is achieved by incubation 
of PBMCs or purified T-cells with DCs which present tumor epitopes with proper 
co-stimulation. After the bulk expansion phase, epitope-specific T-cells are 
isolated by pentamer staining from the pool of T-cells or PBMCs. Single clones 
can be cultured and expanded for therapeutic use or further characterization. This 
strategy is used to overcome the immune suppressive signals that T-cells encounter 
into the tumor microenvironment and that prevent their full activation.   
The expansion of antigen-specific T-cells from the total pool of PBMCs is very 
challenging since the frequency of tumor-specific T-cells is very low into the blood 
stream. Hence, a more efficient approach is based upon isolation of T-cells directly 
from the tumor tissue. The rationale is that tumor-reactive cytotoxic T-
lymphocytes might be enriched already into immunogenic tumor lesions [32]. 
Thus, expansion and re-activation of tumor infiltrating lymphocytes (TILs) with 
IL-2 or other pro-inflammatory cytokines might be much more efficient. 
Interestingly, TILs can also be modified to express pro-inflammatory cytokines 
that would enhance their activation[33]. This strategy has been pioneered by 
Steven Rosenberg and impressive results have been achieved for the treatment of 
melanoma, considered one of the most immunogenic tumors. The first T-cell 
therapy trial was performed in 1989 to assess the safety of infusion of TILs 
engineered to carry resistance to neomycin, which acted as an identification marker 
for infused cells. All five melanoma patients included into the study showed no 
signs of toxicity or infection by the viral vector used to modify the cells. As regards 
the efficacy of the therapy, even if the trial was not designed to assess clinical 
benefit, 3 patients out of the 5 included into the study showed objective responses 
including one complete response [34]. 
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The strategies described previously rely on pre-existing antigen-specific T-cells 
which are activated or expanded ex vivo. However, T-cells can be engineered to 
recognize a chosen epitope. Tumor-reactive T-cells can be created by transducing 
T-cell receptors (TCRs) chains or chimeric-antigen receptors (CARs) with a known 
specificity. The main difference is that while CAR-T cells are engineered to 
recognize surface proteins through an antibody-like receptor, TCR-specific T-cells 
can recognize intracellular proteins which are processed and presented onto the 
MHC-I molecules. 
TCR-specific T-cells are transduced with both the alpha and beta chains of a TCR 
of known specificity. The T-cells express both chains from the transduced genes 
and they assemble as heterodimers within the cytoplasm together with CD8/CD4 
and CD3 proteins to ensure the transduction of the signal. The TCR of MART-1 
specific T-cell clones have been among the first ones to be identified and used to 
create MART-1 specific T-cells in vitro [35]. A small trial revealed a relative efficacy 
in advanced melanoma patients that received adoptive cell transfer (ACT) of 
engineered T-cells [36]. Gp100 TCR specific T-cells were compared to MART-1 
specific TCR T cells in the clinical study; targeting MART-1 resulted into 30% of 
responses while treatment with gp100 specific cells resulted in 19 % of responses 
[37]. Similarly, TCR-specific T-cells against the viral antigen E6 have been used to 
target carcinomas caused by infection of Human Papilloma Virus (HPV). Despite 
the limited responses, all responding patients showed robust levels of memory cells 
within the E6 specific TCR T-cells, suggesting that this phenotype might be 
correlated with an improved outcome (ClinicalTrials.gov Identifier: 
NCT02280811). NY-ESO-1 TCR specific T-cell have been also evaluated in 
patients with synovial cell sarcomas and melanomas. A recent follow up study 
reported between 50 and 66 % of objective responses in treated patients with 3 
and 5-year survival ranging from 14 up 38 % [38]. 
One advantage of using TCR-specific T-cells is the possibility to target intra-
cellular tumor antigens thanks to the presentation of epitopes on MHC molecules. 
Nevertheless, the identification of TCRs and their specificity is rather cumbersome 
and requires careful validation. A more direct approach is represented by giving to 
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T-cells the possibility to use an antibody-like receptor to recognize proteins and 
surface antigens, hence bypassing MHC-presentation of epitopes. CAR-T cells use 
a chimeric receptor composed by a surface immunoglobulin fused with the 
intracellular transduction domain of the CD3 molecule. Additional domains can 
be added to the intracellular portion to potentiate the transduction of the signal. 
The latest generation of CAR-T cells include both CD28 and 4-IBB intracellular 
domains which provide co-stimulation upon antigen recognition and prolong the 
survival of T-cells. One of the most successful examples of this strategy is the use 
of anti-CD19 CAR-T cells for the treatment of leukaemia and lymphomas [39]. 
CD19 is a lineage marker of B-cells and it is maintained through their malignant 
transformation [40], thus it represents an ideal target for T-cell therapy. In 2010 
the group led by Steven Rosenberg reported a case of durable remission 
(ClinicalTrials.gov Identifier: NCT00924326) due to eradication of CD19 positive 
clones following CAR-T cell therapy [41]. However, in the same year another study 
reported that the efficacy of the therapy might have been reduced by the poor in 
vivo persistence of infused cells. In fact, Jensen and colleagues performed a small 
phase I trial where they could observe a marked reduction in levels of infused T-
cells as early as 24 hours post-infusion. This suggested either apoptosis of 
engineered cells or an anti-transgene immune response [42]. Nevertheless, the 
persistence of CAR-T cells can be enhanced by pre-conditioning with 
cyclophosphamide, to reduce the tumor burden at the time of infusion [42]. In 
addition, an increase in half-life of infused cells can be obtained by preliminary 
lympho-depletion, however, this results into cytokine release syndrome (CRS), 
where potent cytokines are secreted following activation of the receptor [43]. While 
corticosteroids or cytokine antagonists are available to contrast the CRS, this 
massive cytokine production is usually a good prognostic factor as it is a sign of 
potent T-cell activation [44]. 
Despite these limitations, the use of CAR-T cell therapy for the treatment of B-
cell lymphomas has been approved by the Food and Drug Administration (FDA) 
[45]. The approval of Yescarta from the FDA is an historical success for cancer 
cell therapy, receiving the status of priority review and breakthrough therapy 
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during the approval process 
(https://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm581
216.htm). 
 
2.2.3. Monoclonal antibodies 
Antibodies offer a versatile platform for cancer therapy. They can act as signals for 
cell-mediated killing, they can deliver molecules to precise cell populations or they 
can block the interaction of ligands with their receptors. 
Antibody dependent cell-mediated cytotoxicity (ADCC) is exploited to treat 
tumors with known surface antigens [46]. After the binding of the immunoglobulin 
to the target, the Fc portion of the antibody is recognized by Natural Killer (NK) 
cells through the Fcγ receptors (FcγRIIIA and FcγIIC), resulting in secretion of 
perforin, granzimes or TNF molecules which mediate cell death [47].  
The first antibody for the treatment of cancer was developed by Cheung and 
colleagues in 1985. The target of the 3F8 clone, a murine IgG3 antibody [48], was 
GD2, an antigen often overexpressed by neuroblastoma and melanoma cells [49]. 
The work of Cheung and colleagues fuelled enthusiasms around this class of 
molecules and many more clones were developed with the aim to enhance the 
efficacy of the treatment or reduce side effects. In addition, therapeutic use of this 
antibody has been combined with cytokines to enhance the cell-mediated 
cytotoxicity. In fat, anti-GD2 MAb has been combined with IL-2, GM-CSF and 
13-cis-retinoic-acid (CRA) improving the overall survival of treated patients [50]. 
Despite being the first antibody to be developed for clinical use, the anti-GD2 
MAb did not have the same success of the anti-human epidermal growth factor 
receptor (HER) 2 immunoglobulin (Trastuzumab), which marked a milestone in 
the history of biological drugs [51, 52]. HER-2 positive tumors are characterized 
by a robust proliferative potential[53] and they are associated with a poor 
prognosis. Hence, blocking the activity of HER-2 was thought to be the best 
clinical strategy for the treatment of HER-2 positive breast cancer. Consistent to 
the initial idea behind Trastuzumab, the drug would block the dimerization of 
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HER-2 monomers, thus reducing the proliferative signalling. However, later 
studies found the activity of the antibody to be largely mediated by ADCC [54].  
 
2.2.3.1. Checkpoint Inhibitors 
In addition to mediate ADCC, antibodies can disrupt the function of receptors 
and ligands, thus inhibiting specific molecular pathways. One class of antibodies 
that raised interest due to the impressive results is the Immune Checkpoint 
Inhibitors which act upon inhibitory pathways that suppress the function of 
antigen-specific T-cells that infiltrate tumors [55, 56]. These pathways are activated 
by the engagement of immune checkpoint which induce T-cell exhaustion. These 
immune suppressive pathways are physiologically used to control and resolve the 
immune response [57, 58] and pioneering studies have been performed on chronic 
infections of viruses [59]. It has been shown that continuous antigen recognition 
due to persistence of pathogens into the host, shifts T-cells from an effector 
phenotype to an anergic one, with severe impairment of their killer function [60, 
61] [62] [63-65]. 
Among the most relevant immune checkpoint receptors it is worth mentioning 
programmed cell death protein 1 (PD-1), lymphocyte activation gene 3 (Lag-3) and 
T-cell immunoglobulin and mucin-domain containing-3 (TIM-3) which are the 
most studied into the clinic nowadays. 
PD-1 is a glycosylated protein which has been first identified on the surface of 
activated T-cells. In fact, very low levels of PD-1 were found in thymocytes and 
cells from spleen and lymph nodes in normal conditions. However, upon 
treatment with anti-CD3 Mab or Concanavalin A, PD-1 was readily detected on 
T-cells [66]. Engagement of PD-1 by one of its ligands, PD-L1 and PD-L2, 
prevents T-cell activation and this pathway is used to maintain peripheral tolerance, 
explaining the diffused expression of PD ligands on different cells. In particular, 
PD-L1 is expressed by T and B lymphocytes as well as macrophages, mesenchymal 
stem cells and bone marrow-derived mast cells [67]. In addition, this molecule can 
be found on non-immune cells such the vascular endothelium and keratinocytes. 
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Interestingly PD-L2 expression is confined to DCs, macrophages and peritoneal 
B-cells [68].  
Overexpression of PD-L1 is a mechanism of resistance of tumors[56]. In fact, the 
PD-1/PD-L1 pathway is exploited by cancer cells to drive T-lymphocytes into 
exhaustion and Spranger and colleagues demonstrated that upregulation of PD-L1 
in the tumor microenvironment is caused by production of IFNγ by CD8 T-
lymphocytes indeed [69]. In fact, mice lacking the IFNγ receptor 1 showed an 
increased presence of TILs [70]. This paradoxical scenario, where CD8 T-cells 
foster the upregulation of their own inhibitor highlights the complex challenge of 
immune therapy and the fine balance between pro and anti-inflammatory signals. 
Blockade of immune checkpoint showed promising results with patients 
experiencing durable responses and long-term remissions, however, many patients 
fail to respond or develop resistance over time [63]. For instance, treatment with 
Ipilimumab during the phase III clinical study resulted into a response rate of only 
10.9% and a disease control rate of 28.5%. Similarly, blockade of PD-1 by 
Nivolumab in patients with non-small cell lung cancer, melanoma and renal cell 
carcinoma resulted into a response rate ranging from 18 to 27 %. On the contrary, 
another independent study showed a response rate of 51 % in patients with 
advanced melanoma, despite only 9 % of the patients experiencing complete 
responses [63]. 
The absence of anti-tumor immunity and poor immune infiltration of tumors play 
a key role into the inconsistent response to ICIs [71]. Hence, it is important to 
screen patients to know their immune profile before the initiation of the therapy. 
A “cold” tumor is unlikely to respond to ICIs, while a “hot” tumor, rich of TILs 
and with a high mutational burden would respond better to the therapy [72, 73]. 
This aspect is of extreme importance since it is widely accepted that ICIs do not 
create immune responses, but they protect pre-existing immune responses from 
inactivation by the TME. In addition, several studies suggested that ICIs can 
partially mediate ADCC. For instance, the anti-CTLA-4 Ipilimumab can bind 
CTLA-4 on regulatory T-cells, marking them for killing [74]. Similarly, expression 
of PD-L1 on tumor cells can enhance their killing through ADCC [75].  
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The versatility of ICIs paves the way to combinations with drugs that actively 
promote immune responses. One of the most attractive combination, which is 
evaluated into Study III of this thesis, is the association of ICIs with cancer 
vaccines. In fact, cancer vaccines have historically been used to prime antigen-
specific responses (see following paragraphs), but their success into the clinic has 
been modest. With the new knowledge about the tumor microenvironment it is 
now clear that priming naïve T-cells is not sufficient to achieve anti-tumor efficacy. 
The T-cells which have been primed and expanded with the cancer vaccine need 
to be protected from inactivation by using immune checkpoint inhibitors. As 
reviewed, poorly infiltrated tumors fail to respond to checkpoint blockade, thus 
therapies able to attract immune cells would synergize with this class of drugs. For 
this reason, in Study III we chose oncolytic viruses as cancer vaccine platform due 
to their ability to prime antigen-specific responses and increase the immune 
infiltration of tumors (as demonstrated in Study I). 
 
2.2.4. Cancer vaccines 
 The idea that exposure of the immune system to a non-virulent form of a 
pathogen would build a protective immunological memory is extremely appealing 
for cancer as well. However, in the oncology field it is impossible to predict when 
and where tumor cells would occur (unless the patient suffers from specific rare 
syndromes) and which would be the antigenic signatures of those lesions; thus, 
cancer vaccines are typically for therapeutic use. Hence, the term "vaccine" is 
referred to a formulation which usually include a strong adjuvant and tumor 
proteins or peptides which prime the immune system [76].  
An ideal tumor antigen is expressed exclusively by malignant cells and features 
highly immunogenic mutations that produce neo-epitopes; these proteins are 
defined as Tumor Specific Antigens (TSAs). Unfortunately, this is a rare scenario 
and most of the known tumor antigens which have been tested into the clinic are 
shared with healthy cells. For instance, proteins such as HER-2, glycoprotein 100 
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(gp100), Telomerase or Tyrisonase Related Proteins [77]are found in normal 
tissues as well, hence they are defined Tumor Associated Antigens (TAAs). 
TAAs are not specifically expressed into tumor cells, but they can be found on 
healthy tissues. For this reason, most of the TAAs-reactive T-cells are deleted 
during the thymic selection to avoid self-responses and cells who escape the 
selection are kept inactivated by the peripheral tolerance through the activity of T-
regulatory cells [78-80]. Despite these limitations, several studies highlighted the 
potential of targeting TAAs. The efficacy of vaccination against gp100 has been 
demonstrated in several pre-clinical studies: mice pre-immunized with a fusion 
protein featuring gp100 and the chemokine macrophage inflammatory protein 3 
alpha (MIP3a) showed a reduced growth of B16F10 tumors [81]. This fusion 
construct has been evaluated also in therapeutic settings by Gordy and colleagues 
who found that therapeutic use of this fusion protein increased the survival of mice 
and reduced the size of their tumors[82]. In addition, despite no clear differences 
in the number of infiltrating TILs were found, the number of gp100 reactive T-
cells was increased in the study group. A separate study explored the possibility of 
fusing the gp100 protein to the CD40L cytokine to deliver the antigen specifically 
to DCs. Therapeutic vaccination reduced the growth of B16F10 tumors and the 
effect was potentiated by the addition of other cytokines such as IL-12 and GM-
CSF to the formulation [83]. 
Tumor-specific antigens (TSAs) are exclusively expressed by malignant cells and 
they feature neo-epitopes, cancer testis antigens and embryonic antigens. Cancer 
Testis Antigens are proteins usually found in the germinal tissues and rarely 
expressed in the brain and other organs at low level. However, their expression 
can be atypically activated in tumors such as melanomas [84]. For instance, 
melanoma associated antigens (MAGE) are a cluster of genes on the chromosome 
Xq28 and their products have been found non-small cell lung cancer (NSCLC), 
bladder cancer, sarcomas and head and neck cancer[84]. The immunogenicity of 
the MAGE proteins has been proven in different studies, although no MAGE-
targeting vaccines are commercialized at the moment. Naturally occurring anti-
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MAGE T-cells have low frequencies, however, anti-MAGE TILs could be 
potentially expanded from tumors of patients [85] highlighting the potential of this 
antigen. In fact, a clinical study performed in 1995 recorded the regression of 
tumors in patients vaccinated with a peptide from the MAGE-A3 protein [86]. 
Another clinical study revealed the presence of TILs against MAGE-A10 in 
patients with hepatocellular carcinoma [87].  
In the context of lung cancer, several antigens are expressed by malignant cells and 
can be targeted by cancer vaccines. MAGE-A4 and NY-ESO-1 have been found 
in samples from patients with NSCLC which showed T-cell infiltration [88]. A 
phase I study tested a liposomal formulation of a peptide vaccine against the 
MUC1 antigen in advanced stage IIIB/IV NSCLC patients recording a modest 
induction of MUC1 specific T-lymphocytes in 5 out of 12 evaluable patients. In 
particular, an increase in median survival was observed with higher doses of 
vaccine (200 ug) [89]. Interestingly, studies in mouse models revealed a relative 
inefficacy of the strategy since chemically induced tumors into C57 mice were 
unresponsive to the combination of vaccine and low-dose cyclophosphamide [90]. 
Consistently, a recent randomized, double-blind placebo controlled phase III trial, 
the therapy failed to show efficacy when used as maintenance therapy following 
chemotherapy [91].  
Taken together, the above-mentioned strategies highlight the complex scenario in 
which cancer vaccines operate. On one side, the efficacy of the therapy is partially 
determined by the ability to induce antigen-specific responses; on the other side, 
antigen-specific T-cells which are induced by the vaccination schedule, are usually 
inactivated by the heavy immune suppressive environment within tumors. These 
problems can be addressed by increasing the immunogenicity of the peptides 
included into the formulation, by using more immunogenic adjuvant platforms or 
by combining the vaccine with immune checkpoint inhibitors. 
 
2.2.4.1. Heteroclitic peptides 
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Vaccination with peptides might be ineffective if the chosen epitope shows poor 
binding to MHC molecules [92]. In fact, the sequence of the epitope and the spatial 
conformation of the lateral chains of each single residue determine the interaction 
with the MHC binding pocket and the patterns are usually known for different 
MHC molecules [93-95]. While some residues might be more important for MHC 
binding (position 2 or 8) other might be more relevant for TCR engagement [96]. 
The knowledge of binding preferences for each MHC/HLA allowed researcher to 
optimize the amino acidic sequence, mutating single residues, to improve the 
overall binding affinity of the peptide. The mutated peptides, defined as 
heteroclitic peptides, often show an increased immunogenicity due to the more 
efficient presentation on MHC [97]. 
One of the first studies to show that modified epitopes could be more 
immunogenic of their natural counterparts was performed by Overwijk and 
colleagues in 1998. They showed that immunization of mice with the human the 
gp100 resulted in specific CD8+ T-cell responses, while the murine gp100 was 
non-immunogenic [98]. Similarly, the NY-ESO-1 peptide 157-165 was modified 
in its carboxyl-terminal cysteine to study its ability to expand T-cells clones specific 
for this peptide. Chen and colleagues demonstrated that three heteroclitic peptides 
were able to be recognized 100 times more efficiently than the wild-type sequence 
[99]. Similarly, the ITDQVPFSV epitope derived from the human gp100 tumor 
antigen was also studied by replacing the T in position 2 with an M. The gp100209 
2M heteroclitic peptide was more efficiently presented than its natural counterpart 
and induced increased T-cell proliferation and IFNγ secretion [100]. 
An important aspect to consider when using heteroclitic peptides is the ability of 
the expanded T-cell clones to cross-react with the initial non-mutated epitope. This 
cross-reactivity is necessary to preserve anti-tumor activity against the original 
peptide which is presented by target cells [101]. In fact, a validation step should 
always be included when studying these peptides. As shown by Speiser and 
colleagues, heteroclitic peptides might engage T-cell clones with a reduced affinity 
for the natural peptide, thus resulting in non-optimal immune responses [102]. 
However, whether or not this represents a real limitation to the use of modified 
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epitopes remains to be determined. In fact, the engagement of T-cell clones with 
lower affinity might actually be at the basis of the efficacy of this class of peptides. 
In particular, these low-avidity clones might be not heavily suppressed by the 
peripheral tolerance. In addition, only low avidity clones against TAAs survive the 
thymic selection and are available to target TAAs. This model is demonstrated in 
Study II of this thesis and also supported by a study showing that tolerance towards 
a peptide can be broken with treatment with modified analogues indeed [103]. 
The study of these peptide is often time consuming and cumbersome. Hence 
bioinformatics tools are needed. Among the common methods we find the 
prediction of binding affinity of the peptides to MHC molecules through web-
based tools and molecular modelling [104]. However, no structured framework has 
been proposed or established and we tried to address this aspect in Study II by 
proposing an improved framework based on the use of both artificial-neural 
network tool and molecular dynamics simulation. 
 
3. Adenoviruses for cancer immunotherapy 
3.1. Viruses for cancer therapy 
In the context of immunotherapy, strong adjuvants are needed to overcome the 
suppressive TME. For this reason, viruses have been studied as agents able to 
promote a pro-inflammatory environment which is potentially able to relieve 
immune suppression and activate antigen presenting cells due to the infection of 
tumor tissue.  
In this section of the thesis I will review oncolytic viruses with a particular focus 
on adenoviruses, which have been at the center of the studies of this thesis. 
 
3.2. Adenoviruses 
Adenoviruses were first discovered by Rowe and colleagues studying human 
adenoid cells [105]. They feature a double-stranded DNA genome of about 36 kb 
packaged into an icosahedral structure named capsid. Adenoviruses are mainly 
responsible for infection of respiratory tracts and nearly 50 serotypes are known 
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so far. The serotypes are classified into 6 subgroups (A-F) with the most 
extensively studied being the subgroup C with serotype 2 adenovirus (Ad2) and 
serotype 5 adenovirus (Ad5). 
 The virion of adenoviruses is a non-enveloped particle about 70-90 nm in size 
with an outer protein shell (capsid) surrounding an inner nucleoprotein core. The 
capsid is formed by 240 hexons and 12 pentons. The penton by five monomeric 
polypeptides (polypeptide III) act as the base for a trimeric protein, the fiber 
(polypeptide IV) (Figure 2). The fiber is responsible for the binding of the 
adenovirus receptor on the target cells and it is different among different serotypes. 
Moreover, the capsid is composed by several minor components, including protein 
IIIa, pVI, pVIII and pIX. 
 
 
Figure 2. Adenovirus structure. The double strand DNA, inside the virion, is bound to several proteins. The capsid 
is composed by hexons and pentons, along with other minor proteins (e.g. pIIIa and pIX). The fiber, responsible for 
the recognition of the receptor on the cell membrane is linked to the viral capsid through the penton. 
The viral genome is packed into the viral core and it features inverted terminal 
repeats (ITR) at the extremities which bind the terminal proteins (TP) [105]. The 
TP protect the DNA from the activity of endonucleases in the host cell. The 
genome is associated with other proteins like the basic protein VII and a small 
peptide termed mu [106], with the function to stabilize the DNA into the capsid. 
Another protein, the protein V, act as a linker between DNA and the capsid [107]. 
The virions contain also some copies of protease (Pr) that cleaves many of the 
structural pre-proteins into their mature forms during the last stage of viral 
assembly. 
Adenovirus infection cycle (Figure 3) consists of two distinct phases, known as 
“early” and “late”. The “early” phase occurs in 6-8 hours after the infection. This 
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phase comprises the entry of the virus into host cell, its release in cytoplasm, the 
passage of viral genome into the nucleus and the transcription and translation of 
some viral genes, named early genes. In this phase, the virus enters into host cell 
and, through products of early genes, modulates cell metabolism to facilitate the 
replication of viral genome and the expression of late genes. The second phase is 
the “late” phase which can take about 4-6 hours after the beginning of the 
transcription of the late genes. 
 
Figure 3. The adenovirus life cycle. Different stages of the infection cicle of adenoviruses. The adsorption is mediated by 
the binding of the Fiber to the adenovirus receptor (CAR). Then the virus is internalized by a clatrin-mediated 
endocytosis process, promoted by the interaction between the Penton and Integrins. Once in the cell, the virus blocks all 
cell’s activities and takes control over cell metabolism, in order to start the production of new virions that will be released 
by cell lysis. 
The initial attachment of the virion particles to cell surface occurs through a high 
affinity binding between a portion of the fiber (knob domain) and a cell receptor. 
The first receptor identified was shown to be identical to that for Coxackie B virus 
and has therefore been termed Coxackie/adenovirus receptor (CAR) [108]. This 
receptor is expressed on the basolateral membrane of several epithelial cells in 
different tissues. With a size of 46 kDa it belongs to the immunoglobulin 
superfamily. CAR receptors are essentials for virus adsorption to the target cell, 
except for the adenoviruses of group B. These viruses bind another cellular 
receptor, the CD46, a complement regulatory protein. Therefore, the adenoviruses 
of group B are capable to infect some cells, like hematopoietic cells, dendritic cells 
and malignant tumor cells, which are resistant to the infection by adenoviruses 
using CAR as the primary attachment receptor. All these data suggest that receptor 
recognition could be a key factor involved in cell tropism and that, with 
appropriate fiber engineering, modification of knob domain, by binding it to 
antibodies, could give us the option to target different tissues [109, 110]. After the 
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interaction between the fiber knob and CAR on cell surface, an RGC motif, 
exposed on the penton base [111], interacts with cellular αv integrins [112], in 
particular integrins αvβ3 and αvβ5 (Figure 4).  
 
Figure 4. Mechanism of virus internalization. After the interaction of fiber knob domain and penton RGD motif with 
CAR and integrins, the virus is then internalized by clathrin covered endosomes. Then, the virus quit endosome and, 
using dynein cell transport system, arrives to the nuclear pores. The viral DNA then passes through the nuclear 
membrane. 
The virus is then internalized through a clatrin-mediated endocytosis. This event 
is the direct consequence of the activation of many different pathways: Rho 
GTPase family activation due to phoshoinositide-3-OH kinase activity; MAPK 
activation and consequent interleuchin-8 production.  
In the acidic environment of the endosome, the virus-encoded protease mediates 
the dismemberment of the viral capsid through the proteolysis of the protein VI, 
which induces, in turn, the escape of virions to the cytoplasm (Figure 4). 
The transport to the nucleus involves dynein and microtubules [113], and seems 
to be mediated by the cellular protein p32 [114], which binds to the virus core 
   
 
   
 
46 
(constituted by the DNA and its associated proteins TP, mu, proteins VII and V). 
Protein p32 binds the nuclear lamin B to permit the dissociation between the viral 
DNA and the linked proteins.  
 
3.2.1. Transduction, transcription and biodistribution 
The transcription of adenoviral genes can be divided in two phases, early and late, 
occurring before or after viral DNA replication. The first viral transcribed gene is 
E1, which encodes for two products: E1A and E1B, each of them producing 
multiple proteins by way of differential mRNA processing. Two E1A transcripts 
are produced during early infection, encoding the 289R protein and 243R protein. 
These proteins have the function to modulate the cellular metabolism to make the 
cell more susceptible to virus replication. In order to do this, they act as trans-
activators on the other early adenovirus genes and induce the cells to enter in S 
phase [115]. Indeed, both 289R and 243R protein are able to sequester Rb protein 
(Retinoblastoma protein), bounded to the transcriptional factor E2F, allowing the 
release of this factor and the activation of its target genes necessary for driving the 
cell into S phase [116]. Moreover, E1A proteins can also bind proteins involved in 
the control of cell cycle, such as cyclin-dependent-kinase-inhibitor p21, or factors 
mediating chromatin structure like p400, pCAF and p300/CBP. The E1B gene 
product 55K (E1B-55K) acts blocking p53-dependent apoptosis by directly 
binding p53, accumulated during cell cycle deregulation by E1A, and inhibiting its 
ability to induce expression of proapoptotic genes [117]. Instead, the other product 
of E1B gene, E1B-19K, blocks the pathway of programmed cell death binding 
directly the proapoptotic proteins Bak and Bax [118]. These mechanisms are 
essential to keep the cell alive as long as possible in order to permit the virus 
replication. The E2 gene products (E2A and E2B) are proteins that are necessary 
for the replication of viral genome and the ensuring transcription of late genes, the 
latters are a DNA polymerase, the pre-terminal protein (pTP) and the 72-kDa 
single stranded DNA binding protein (DBP). The E3 gene expression is 
indispensable for subverting the host defense mechanism, allowing the persistence 
of the viral antigen, preventing the translocation of MHC class I (major 
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histocompatibility complex) molecules to the cell surface by sequestering them in 
the endoplasmic reticulum [119]. Moreover, the E3-10.4K, 14.5K and 14.7K 
proteins inhibit the apoptotic pathway inducing the clearance of TNF-α, Fas ligand 
(FasL) and TRAIL receptors from the cell membrane. The gene products derived 
from the E4 cassette are involved in cell cycle control, promote virus replication 
and shut-off the host protein synthesis [120]. 
During the last steps of early phase of the adenovirus infection, the viral DNA 
replication begins but requires sequences within the ITRs as origin of replication. 
Moreover, because the viral genome does not have telomeres, the integrity of 
DNA ends is ensured by the viral protein pTP. This protein is covalently linked to 
the 5’ end of each genome strand and acts as a primer for the viral DNA 
polymerase. The genes are encoded on both strands of DNA in a series of 
overlapping transcription units. 
After viral DNA replication, transcription of late genes begins (Figure 10). A key 
role in the control of this phase is played by the major late promoter (MLP), which 
is attenuated during the early stage of infection. In fact, during the “early phase”, 
the basal level of transcription is low while, after the viral DNA replication and the 
high expression of IVa2 and IX genes, the transcription via the MLP is fully 
functional. From the MLP, 5 genes (L1-L5) (Figure 10) are transcribed as single 
pre-mRNAs, each one encoding from 15 to 20 different mRNAs by differential 
splicing and polyadenylation. 
These transcripts encode structural proteins and other proteins involved in virion 
assembly. The virion assembly takes place in the nucleus, but the hexon 
trimerization begins in the cytoplasm and, subsequently, the hexon trimers, move 
to the nucleus where they are associated with pentons and minor proteins to form 
the capsid [121]. The viral genome encapsidation requires the L1-52/55K, IVa2, 
L4-33K proteins and the packaging signal, which consists in a series of seven (A1-
A7) repeats, enriched in AT, at the lets end of the adenoviral DNA. These events 
are accompanied by changes in the nuclear structure. About 30 hours after 
infection, the host cell is lysed in a process involving the ADP protein (adenovirus 
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death protein), a product of E3 gene, which is expressed only during the late phase 
of infection and is transcribed from MPL rather than E3 promoter [122]. 
Coxsackievirus and adenovirus receptor (CAR) was described as the receptor on 
the cell membrane for subgroup C and B adenoviruses (Ads) [108, 123]. After the 
initial interaction between CAR and the fiber protein of the capsid, the engagement 
of integrin αv with the penton base leads to internalization of Ads [112]. However, 
Ads can also take advantage of a CAR-independent mechanism that involves 
different coagulation factors, such as coagulation factor X (FX), coagulation factor 
IX (FIX) and the complement factor C4BP (ref). The vitamin K-dependent FX is 
positively charged thus it is able to bind the negative hexon protein on the surface 
of Ads. More specifically, the serine protease domain of the FX interacts with the 
hypervariable regions (HVRs) of the hexon protein. With the FX on their surface, 
Ads can interact with the heparan sulfate proteoglycans (HSPGs) on the cellular 
membrane of hepatocytes [124]. The ablation of the formation of functional FX, 
with warfarin administration prior to Ad vector injection, resulted in a decreased 
infection of liver [125]. This model has been confirmed in non-human primates 
[126]. Similarly, FIX and C4BP bind to the fiber of Ads, promoting interactions 
with HSPGs and low-density lipoprotein receptor-related protein (LRP) [127]. 
Based on this knowledge, different strategies have been developed to re-target Ad 
vectors to different tissues and to avoid liver pooling.  
 
3.2.2. Adenovirus Immunogenicity 
The primary aim of our immune system is to protect us from pathogens and it has 
evolved to efficiently recognize viruses and bacteria. The eradication of a viral 
infection requires physiological changes into our body to facilitate the trafficking 
of lymphocytes to the site of infection and efficient elimination of infected cells. 
For this reason, the inflammation process is at the center of anti-viral responses 
and it is ignited by the production of potent immune modulatory molecules such 
as cytokines and chemokines. Therefore, there is a strong rationale for the use of 
viruses as drugs able to tilt the tumor microenvironment towards an inflammatory 
state, hence promoting the infiltration of immune cells within the tumor. In 
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addition, viruses that can replicate within the tumor tissue, participate actively to 
the tumor immunity cycle by lysing tumors cells, causing the release of tumor 
antigens which are picked up by APCs. The same APCs can also phagocyte viral 
particles, which engage innate immunity receptors and activate the cells. Hence, 
tumor antigens might be presented in a context of co-stimulation, rich of pathogen 
associated molecular patterns (PAMPs) and danger associated molecular patterns 
(DAMPs). 
Recent data on the tumor microenvironment supports the idea that immune 
infiltration is a key component of anti-tumor immunity and the ability of viruses 
to turn cold tumors into hot tumors, enriched with immune cells, is an attractive 
characteristic of oncolytic viruses. In the following paragraphs I will review some 
of the main immunological features of viruses. 
 
Adenoviruses are able to engage multiple mechanisms of defence through the 
activation of the complement system or the release of cytokines. These 
mechanisms are promoted by the recognition of the viral capsid thus the immune 
activation is not entirely associated with viral replication.  
First and second generation adenoviral vectors feature the deletion of important 
genes and viral promoters that prevents the start of the replication cycle, such as 
the E1, E2 and E3 viral genes [128]. Nevertheless, these replication-deficient 
vectors are still able to cause lethal toxicity. In fact, in 2003 the first clinical trial 
for the gene therapy ended with the death of an 18-year-old patient which received 
a first-generation adenoviral vector encoding for the ornithine transcarbamylase 
(OTC). The patient suffering from OTC deficiency, was part of a phase I clinical 
trial evaluating the safety of the gene therapy. Following the injection of 6x1011 
vp/kg, symptoms of acute toxicity appeared as early as 18 hours post infusion. The 
patient showed an altered mental state which later developed into biochemically 
detectable abnormalities such as the disseminated intravascular coagulation and 
multiple organ failure. The clinician recorded the death of the patient 98 hours 
post injection [129]. 
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The early appearance of toxicity with high serum levels of inflammatory cytokines 
such as IL-6 suggested a replication independent mechanism of toxicity. This 
theory was later confirmed by a pioneering study of gutless vectors, also defined 
as Helder Dependent Adenoviral Vectors (HD-Ad). HD-Ad are devoid of all viral 
genes, thus no viral protein can be produced; however, they are still able to express 
the transgene due to an external promoter within the expression cassette in their 
genome. Hence, they represent the safest type of adenoviral vector. Brunetti-Pierri 
and colleagues defined the limiting doses in non-human primates, which served as 
guidelines for future human studies. They treated one animal with 5.6x1012 vp/kg 
and a second animal with 1.1x1013 vp/kg. The animal injected with the lowest dose 
showed signs of acute toxicity: cyanosis, dyspnoea, reduced activity and elevated 
body temperature. However, 24 hours post injection the animal fully recovered 
and no other signs of toxicity were recorded. On the contrary, the animal treated 
with the highest dose of vector showed heavy signs of toxicity including vomiting, 
dyspnoea, lethargy and increased heart rate which forced researchers to euthanize 
the animal due to poor conditions [130]. This study confirmed that the toxicity of 
adenoviral vectors is independent from viral replication and is mainly caused by 
activation of innate immunity pathways.  
Adenoviral particles induce the production of Type-I-interferons in infected cells. 
In addition, transfection of primary keratinocytes showed upregulation of IL-6, 
IL-1 alpha and IL-8; TNF-alpha was also upregulated upon adenoviral infection. 
These results were confirmed in vitro and ex vivo and the production of these 
cytokines was confirmed also in vivo as early as 48 hours post injection of the 
adenoviral vector encoding for the green fluorescent protein (GFP) [131]. 
Moreover, the production of inflammatory cytokines, thrombocytopenia is also 
recorded upon injection of adenoviruses into the blood stream of mice as well as 
increased levels of IL-12 [132].  
Once injected into the blood stream, the viral particles are readily decorated by 
coagulation factors, complement elements and neutralizing antibodies. These 
interactions are crucial for the initiation of immune responses as this process tags 
the virus for immune recognition. The adenovirus binds the coagulation factor X 
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(FX) and adenoviruses devoid of the FX binding site fail to activate pro-
inflammatory networks [133]. The complement fragment 3 (C3) participates to the 
anti-viral response by binding the virion and acting as a danger signal, leading to 
the activation of transcriptional factors which mediate the production of cytokines; 
C3 also efficiently directs the viral capsid to proteasomal degradation [134]. Pattern 
Recognition Receptors (PRRs) participate to the antiviral response also. Toll-like 
Receptors (TLRs) are key elements of innate immunity and their importance is 
highlighted by their implication in autoimmune disease [135]. Of the 10 TLR which 
are members of the family, four recognize nucleic acids: TLR3 senses dsRNA 
[136], TLR7 and TLR8 recognize ssRNA  [137, 138], while TLR9 senses dsDNA. 
These TLRs that recognize genomic material are extremely important for anti-viral 
responses. In particular, TLR9 activates myeloid differentiation primary response 
gene 88 (MyD88) which ultimately stimulates nuclear factor kB (NF- kB) [139]. 
These transcription factors induce the expression of cytokines and chemokines to 
potentiate the immune response, promoting the maturation of APCs [140]. This 
event is crucial for the initiation of anti-viral adaptive immune responses. DNA-
viruses, such as, hepatitis B virus (HBV) are sensed by TLR9 [141] and it was 
demonstrated that the DNA of adenoviral vectors is able to activate TLR9 leading 
to production of IL-6 from macrophages[110].  
In summary, adenoviruses activate a wide variety of innate immune pathways 
thanks to their PAMPs which stimulate PRRs. This provides strong pro-
inflammatory stimuli which are typical of viral infections. In some cases, viruses 
have been modified to allow their selective replication only in cancer cells, hence 
they can potentially provide DAMPs as they induce immunogenic cells death in 
infected cells which increase the immune activation. For this reason, adenoviruses 
have been used for immunotherapy of cancer as a tool to shift the tumor 
microenviroment towards an inflammatory state, thus breaking the immune 
suppression. 
 
3.3. Adenoviruses for cancer therapy and oncolytic adenoviruses 
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As reviewed into the previous paragraph, adenoviruses can activate the immune 
system efficiently. However, those immunological aspects acquired relevance only 
in the last decades. In fact, lysis of tumor cells was thought to be the main and only 
mechanism of action of oncolytic viruses since the first studies of the field. 
At the start of last century, an italian doctor reported the complete remission of a 
case of cervical cancer after a strong viral infection of the patient [142]. In 1922 
Levatidi and Nicolau documented the lysis of murine tumors by vaccinia virus 
[143]. Similarly, measles infection were linked to tumor regression and, in the 
middle of the 20th century, attenuated rabies virus were successfully used to treat 
cancer patients [144]. 
The ability of viruses to infect and kill cancer cells has been object of several 
studies. For instance, reovirus shows a natural tropism for tumor cells and it has 
been combined with both radiation and chemo therapies [145]. Similarly, 
adenoviruses can infect tumor cells, however, this process is not tumor-specific, 
thus healthy cells are also target of infection. To overcome this limitation, 
researchers developed several strategies to prevent the lysis of healthy cells while 
enhancing the safety profile of such agents. The first approach relies on targeting 
biologically relevant differences between tumor and normal cells, such as the lack 
of cell defence mechanisms. 
Conventional adenoviruses express several proteins that inhibit the activity of 
products of gatekeeper genes, such as p53 and retinoblastoma proteins. In 
particular, the viral E1B 55KD disrupts p53 while retinoblastoma protein is 
inactivated by the viral E1A protein [146, 147] 
(Figure X). Consequently, an adenovirus lacking the E1B gene would not be able 
to complete its replication cycle within normal cells. However, malignant cells lack 
functional p53 or Rb proteins, thus E1-deleted adenoviruses would still be able to 
replicate in p53-defective tumors. 
Exploiting the lack of cell defence mechanism led to the production of the first 
oncolytic adenovirus (OAd) for clinical use. ONYX-015 is an adenovirus which 
lacks the E1B 55D gene, hence it is able to replicate only in tumors lacking p53 [148, 
149]. This model, however, has been challenged several times by researchers who 
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demonstrated that the ONYX-015 virus can replicate in tumor cells with intact 
p53 pathways. Interestingly, Geoerger and colleagues demonstrated that several 
patients-derived primary glioblastoma cells lines, showing a wild type p53, were 
actually more susceptible to viral lysis in vivo [150]. Similar to ONYX-015, E1A-
deleted OAds exploit the lack of functional Rb protein in tumors. A deletion of 24 
bases (D24) in the E1A gene prevents the binding of the E1A protein to Rb. For 
this reason, Ad5-D24 viruses are unable to replicate in healthy cells, but they can 
efficiently kill tumor cells as demonstrated in vitro and in vivo. As shown by Fuayo 
and colleagues, a single dose of Ad5-D24 virus was able to reduce by 66% the 
growth of subcutaneous human tumors in nude mice [151].  
In addition to target specific mutations and lack of gatekeeper genes, another 
interesting strategy is represented by having the viral replication under the control 
of tumor-specific promoters of overexpressed pathways. For instance, the viral 
E1A gene can be placed under the regulation of hypoxia responsive elements 
(HRE). Following this strategy, Wang and colleagues exploited the higher activity 
of hypoxia-related proteins and promoters that tumor cells need to survive in low-
oxygen concentrations [152]. To this end, they produced an OAd with E1 genes 
under the control of a hypoxia responsive element (HRE) and human telomerase 
transcriptase (hTERT). This virus showed an improved efficacy against lung cancer 
adenocarcinoma tumors in nude mice when compared to the wild type virus [153]. 
Similarly, hTERT and prostate specific antigen (PSA) gene promoters have been 
used to regulate the replication of an oncolytic adenovirus, restricting its lysing 
activity to prostate tumor cells [154]. Conditionally replication OAds have been 
used also to express transgene in the tumor tissue selectively. For instance, a double 
regulated adenovirus, encoding for a short-hairpin RNA against the focal adhesion 
kinase (FAK) was used to inhibit the growth of hepatocellular carcinoma in vitro 
and in vivo [155]. The versatility of genome editing techniques allowed for complex 
engineering of the adenoviral genome as shown by Xu and colleagues. The study 
evaluated the efficacy of a quadruple-regulated oncolytic adenovirus carrying three 
mutations to ensure tumor-selective replication with the addition of a tumor-
targeted expression cassette. In particular, the virus featured the D24 deletion in 
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E1A gene, which was placed under the control of the survivin promoter (SP); in 
addition, the E1B gene was entirely deleted, including the sequences encoding for 
E1B 55kDa and E1B19kDa. Finally, the pro-apoptotic protein hepatocellular 
carcinoma suppressor 1 was regulated by the alpha-feto protein promotes, to limit 
its expression to the hepatic tumor tissue. The virus showed anti-tumor efficacy 
against Huh-7 xenografts by stimulating mithocondrial apoptotic pathways [156].  
Adenoviruses show great potential due to the possibility to selectively infect and 
kill tumor cells. In addition, viruses can function as gene delivery vectors and 
infected cells can produce transgenes of interest such as suicide gene products. 
This class of genes produce viral of bacterial proteins that converts non-toxic pro-
drugs to toxic compounds that induce cell death. The most studied suicide genes 
are the cytosine deaminase gene (CD) from Escherichia coli and the herpes 
simplex virus thymidine kinase gene (HSV-tk). The CD converts the pro-drug 5-
Fluorocytosine (5-FC) to 5-Fluorouracil (5-FU), while the HSV-tk converts 
ganciclovir (GCV) to ganciclovir monophosphate, which is then converted by the 
cancer cells to ganciclovir triphosphate. For instance, adenovirus-mediated suicide 
gene therapy has been effective against prostate cancer both in vitro and in vivo [157]. 
Similarly, a replication-defective adenovirus expressing the HSV-tk suicide gene 
under the hTERT promoter has shown efficacy against human gynaecological 
tumor cell lines by induction of apoptosis [157]. In a different study, an HSV-tk-
armed adenovirus reduced by threefold the growth of orthotopic bladder cancer 
in mice compared to control treatment [158]. Interestingly, suicide gene therapy 
can be combined with the immune stimulation provided by interleukins; this 
combination elicited both innate and adaptive immunity improving the efficacy 
against local and metastatic prostate adenocarcinoma in mice [159]. 
In summary, the development of genome editing techniques allowed for complex 
engineering of adenoviruses which nowadays represent a versatile tool for cancer 
gene therapy. Replication-deficient vectors or conditionally-replication vectors 
could be used to selectively lyse tumor cells or deliver transgenes to specific cell 
types. Nevertheless, the most successful application of viruses from an 
immunotherapeutic point of view is represented by oncolytic viruses armed with 
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cytokines and immune modulators able to re-shape the immunological landscape 
of tumors. This aspect will be discussed in the next paragraph. 
 
3.4. Adenoviruses for cancer immunotherapy: state of the art 
The ability of oncolytic adenoviruses to selectively replicate and kill tumor cells is 
only one of their mechanisms of action. In fact, adenoviruses can express cytokines 
or small biological drugs such as antibody-like molecules also. In addition, their 
immunogenicity provides pro-inflammatory signals that promote adaptive anti-
tumor responses. Ultimately, the infection of the tumor tissue attracts immune 
cells, hence increasing the level of immune infiltration of the lesions.  
As reviewed in previous paragraphs the tumor immunity cycle relies on the lysis of 
tumors cells to release tumor antigens and on the maturation of antigen presenting 
cells. These two processes can be greatly enhanced by oncolytic adenoviruses while 
providing danger signals for immune infiltration [160]. The viral oncolysis can 
induce danger signalling molecules in infected cells, mediating forms of 
immunogenic cell death which activates DCs and primes T-cells [161]. In fact, a 
conditionally replicating adenovirus regulated by the hTERT promoter, showed to 
induce autophagy through the inhibition of mammalian target of rapamycin 
(mTOR) pathway [162]. In addition to increase the immunogenic cell death, 
adenoviruses can engage innate immunity through by actively engaging TLR9. This 
mechanism can be exploited by enriching the viral genome with CpG island, which 
represent one of the main ligands of TLR9 receptor [163]. Treating melanoma 
bearing mice with virus resulted in an increased number of antigen-specific T-cells 
and a lower number of myeloid-derived suppressor cells compared to a 
conventional OAds [164].  
OAds can be armed with immune modulating molecules such as interleukins 
which can synergize with the oncolytic activity, hence promoting an in situ 
vaccination. For instance, OAds expressing GM-CSF can efficiently improve the 
antigen processing while foster long-lasting immunological memory that protects 
animals from rechallenge [165]. Interestingly, the analysis of data from a clinical 
investigation of a GM-CSF-expressing oncolytic virus revealed massive infiltration 
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of tumors with T-cells after treatment with OAds when comparing histological 
slides pre-versus-post treatment. Interestingly, two patients showed the presence 
of tumor reactive T-cells in PBMCs with upregulation of T-helper Type 1 genes 
[166]. Similar results have been obtained by using an human IFNγ expressing 
adenovirus vector to treat patients with cutaneous T and B cell lymphomas [167, 
168]. In a similar approach, Su et al. studied an IFNγ expressing oncolytic 
adenovirus which showed treated with control and pathological analysis revealed 
an accumulation of CD4+ cells within the tumor [169]. Other researchers explored 
the advantages of expressing tumor necrosis factor alpha (TNFa) by arming an 
oncolytic adenovirus with this gene. TNFa was able to increase the induction of 
apoptosis and necrosis in human and murine tumor models. In addition, infection 
of cell lines with this virus increased the immunogenic cell death, thus increasing 
the immune recognition [170]. CD40/CD40L regulates the cross-talking between 
DCs and T-cells by increasing the levels of MHC and co-stimulatory molecules on 
antigen presenting cells [171]; CD40L gene therapy proved to be effective in 
modulating the T-lymphocyte phenotype [172]. In fact, an OAd expressing CD40L 
promoted tumor infiltration of macrophages and T-cells [173]. Interleukins are 
able to provide strong pro-inflammatory stimuli and as reviewed in the previous 
paragraphs they can re-shape the tumor microenvironment fostering anti-tumor 
immunity [174, 175]. For instance, interleukin 24 (IL-24) has also been used to arm 
OAds, showing anti-tumor efficacy controls [176]. Interleukin-armed OAds have 
also been used in combination with T-cell therapy to provide support to TILs. In 
particular, production of TNFa and IL-2 within the tumor tissue, due to OAd-
mediated gene delivery, controlled the tumors of immunocompetent Syrian 
hamsters and protected them from an additional rechallenge with tumor cells, 
highlighting the ability of OAds to promote long-lasting immunological memory 
[177]. The same strategy delivered promising results for the treatment of 
melanoma [178]. 
Using OAds as gene delivery tools, several groups have used them to express 
MAbs into the tumor. One main advantage of this strategy is the possibility to 
deliver the antibody directly to the tumor tissue due to the delivery of transgene to 
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tumor cells. In addition, the local expression of the Mab would limit the side effects 
caused by systemic administration. Different groups constructed OAds expressing 
full Mabs specific for cytotoxic t-lymphocyte associated-antigen-4 (CTLA-4; 
CD152). These engineered vectors were able to make tumor cells produce 
functional anti-CTLA-4 Mabs [179, 180].  However, since the oncolytic viruses 
have a limited amount of deleted genes and sequences one possible limitation of 
this approach is the size of the expression cassettes that can be included into the 
viral genome. 
4. Aims of the study 
The strategies described in the literature review brought adenoviruses, cancer 
vaccines and checkpoint inhibitors to clinical testing due to the potential shown in 
pre-clinical models.  However, clinical trials revealed several limitations for each 
approach [160] that I addressed in my PhD studies:  
1. Treatment with oncolytic viruses directs the immune response towards 
the viral proteins rather than the released antigens. In addition, priming 
tumor-specific T-cells is a side effect of oncolysis rather than a controlled 
and intentional process.  
2. The antigens that the virus releases are mostly self-proteins; therefore, the 
adjuvancy of the viruses is not maximized and focused on specific targets. 
In addition, optimization of the peptides is a time-consuming process, 
which at the moment is not automated. Hence, the development of cancer 
vaccines is limited by the amount of information that can be screened and 
utilized to design the peptides.  
3. Tumor cells establish a strong immune suppressive microenvironment 
which prevents recognition by T-cells. The checkpoint inhibition can 
protect T-cells by inactivation, however, they require a pre-existing tumor 
immunity and the infiltration of tumors by immune cells. 
 
Taking into account these limitations, my PhD studies focused on developing a 
novel oncolytic vaccine platform with an enhanced immunological activity 
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compared to conventional OAds (Study I). This oncolytic vaccine platform would 
use improved and more immunogenic peptides (Study II) selected with the use of 
an automated in silico framework. Ultimately treatment with the oncolytic vaccine 
platform would increase the response to checkpoint inhibitors by providing 
inflammation and immune infiltration in tumors (Study III). 
 
MATERIALS AND METHODS 
4.1. Cell lines 
The cell lines used in the studies included in this thesis have been cultured and 
maintained according to ATCC guidelines. In particular, cells were grown in 
humidified incubators at 37°C with 5 % CO2. A549, CACO-2 and A2058 cell 
cultured in DMEM supplemented with 10 % FBS. 1 % L-glutamine and 1 % 
penicillin-streptomycin antibiotics. MDA-MB-436, B16.OVA and B16-F10 cells 
were cultured with RPMI-1640 with 10 % FBS, 1 % L-glutamine and 1% penicillin-
streptomycin. EMEM supplemented as described for other culture media was used 
for the SK-MEL-2 cell line. RMA-S cell line was culture with IMDM media 
supplemented with 10 % FBS, 1 % glutamine and 1 % penicillin-streptomycin. 
Splenocytes, peripheral blood mononuclear cells (PBMCs) and other immune cells 
were cultured with RPMI-1640 supplemented with 10 % FBS, 1 % L-glutamine, 1 
% penicillin-streptomycin, 55 uM beta-mercaptoethanol, HEPES and sodium 
pyruvate. Selection of OVA-positive clones in B16.OVA cultures was performed 
by supplementing the media with 5 mg/mL of G418 (Gentamicin).  
 
 Table 1. Cell lines used in the studies 
Cell line 
(name) 
Species Description Source Used in 
Study 
A2058 Human Melanoma ATCC1 I 
A549 Human Lung 
adenocarcinoma 
ATCC I, II, III 
B16-F10 Murine Melanoma ATCC I, II 
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B16.OVA Murine Melanoma 
expressing 
chicken 
ovalbumin 
Dr. Vile2 I, II, III 
CACO-2 Human Colorectal 
adenocarcinoma 
ATCC I 
MDA-MB-
436 
Human Triple negative 
breast cancer 
ATCC III 
RMA-S Murine Lymphoma with 
defective MHC 
presentation 
Prof. Tos 
Daemon3 
II 
SK-MEL-2 human melanoma ATCC I and III 
1American Type Culture Collection, Manasas, VA, USA 
2Provided by Professor Richard Vile, Mayo Clinic, Rochester, MN, USA 
3Provided by Prof. Toos Daemen, University of Groningen, Groningen, 
Netherlands 
 
4.2. HLA typing of PBMCs and tumor cell lines (II, IV) 
 First genomic DNA was extracted from the HS294T tumor cell line and human 
PBMCs for HLA typing. Qiagen DNeasy blood and tissue kit (Qiagen, Venlo, NL) 
was used to extract DNA by manufacturer´s instructions and the HLA genotyping 
and analysis was carried out in an EFI (European Federation for Immunogenetics) 
accredited HLA Laboratory in Haartman Institute, University of Helsinki. The 
genotyping of HLA-A, -B  and -C  genes were performed using sequence specific 
primers (Olerup SSP HLA-A-B-C Combi Tray, Applied 
Biosciences, Stockholm, SE). The reactions were performed according to 
manufacturers’ instructions providing at least four-digit resolution (for example, 
HLA-A*01:01 ). PCR reactions from agarose-gel were evaluated manually and the 
alleles were called with SCORE software. The HLA alleles were assessed using 
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HLA nomenclature release 3.5.0 (IMGT/HLA database) and carefully interpreted 
by two persons. 
 
 
4.3. Adenoviruses 
Adenoviruses used in the studies of this thesis are all human serotype 5 
adenoviruses which have been genetically modified to be cancer specific. A 
deletion of 24 bp pair (Δ24) has been introduced into the constant region CR2 of 
the E1A gene. This deletion produces an E1A protein which is unable to bind to 
Rb protein, thus disrupts the viral replication within healthy cells. However, in 
tumor cells, Rb protein is usually mutated (Sherr 1996). Therefore, despite the lack 
of functional E1A protein, the Δ24 adenovirus is still able to perform a full 
replication cycle (see Figure X). 
The adenoviruses used in the studies were produced according to the standard 
large-scale production protocol.  Briefly, all adenoviruses were propagated in A549 
cells. Hyper flasks (Corning) were seeded with 26x106 cells and after three days 
infected with 30 MOI. Three days later, when CPE reached almost 80%, cells were 
detached by vigorous tapping and centrifuged. Pellet was resuspended in 7 mL of 
OptiPRO media with 1 % FBS and lysed by four cycles of freeze-thaw. Cell lysate 
was centrifugated and supernatant was processed by ultracentrifugation on cesium 
chloride gradient. The virus was recovered and dyalised overnight in 
cryoprotective buffer. Next, the purified virus was aliquotted and stored at -80°C 
(Luo et al. 2007). 
Purified preparation of viruses were tittered by spectrophotometry OD260 to 
determine the amount of viral particles (vp) per milliliter (vp/mL). The infectious 
units (IU) per milliliter were deterined by immunocytochemistry staining (ICC) 
accodring to standard protocol (Capasso et al. 2015). The concentration of viral 
proteins was determined by the colorimetric assay of Bradford by using the Biorad 
Protein Assay Dye Reagent Concentrate (Biorad Laboratories, Hercules, CA, US). 
Viruses were also characterized by PCR and restriction enzyme analysis to verify 
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the presence of the D24 deletion and absence of contamination from wild type 
virus. 
All adenoviruses used in this study are listed in Table 2. 
Virus 
(Name) 
Transductional 
Targeting 
(Fiber) 
Transcriptional 
Targeting (E1 
modification) 
Transgene Reference Study 
Ad5-Δ24 Wt Ad5 24 bp deletion in 
E1A 
- Heise et al. 
2000 
I 
Ad5-Δ24-
CpG 
 
Wt Ad5 
 
24 bp deletion in 
E1A 
 
CpG islands Cerullo et al. 
2012 
I, II, III 
Ad5-Δ24-
GM-CSF 
 
Wt Ad5 
 
24 bp deletion in 
E1A 
 
GM-CSF Cerullo et al. 
2010 
I 
 
4.3.1. PeptiCRAd complex formation and peptides used 
In Study I, we developed a new oncolytic vaccine platform based on adenovirus. 
MHC-I restricted tumor epitopes were linked to the spongy capsid of the 
adenovirus. The interaction occurs via electrostatic interaction between the 
negatively charged capsid of the virus and the tumor epitope which is made 
positive by the addition of a poly-lysine chain at the N or C terminus of the peptidic 
sequence. The two components (I.e. the adenovirus and the polyK-peptide) are 
mixed with a ratio of 1:500 viral-to-peptide protein amount. The complex is 
allowed to form by incubating the solution for 15 minutes at room temperature. 
After 10 seconds of vortexing to ensure an heterogeneous suspension of the 
PeptiCRAd complex, the sample can be diluted into the buffer of choice which is 
needed for the experiment. Typically, MilliQ water is used for Zeta Sizer analysis; 
growth media for in vitro assays; saline solution for in vivo injections. 
The peptides used in this thesis for the preparation of different PeptiCRAds were 
SIINFEKL (OVA 257-264), SVYFFVWL (TRP2 180-188), polyK-SIINFEKL , 
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SIINFEKL-polyK, polyK-AHX-SIINFEKL, polyK-SVYFFVWL, polyK-
KVPRNQDWL (human gp100 25-33), polyK-SLFRAVITK (MAGE-A1 96-104). 
In Study I modified versions of the peptides were used, in particular: SIINFAKL 
and polyK-SIINFAKL, SIIWFEKL and polyK-SIIWFEKL, SAYFFVWL and 
polyK-SAYFFVWL, SVYFFVAL and polyK-SVYFFVAL. 
In Study III the neo-epitopes used to build the PeptiCRAds against the triple 
negative breast cancer were Tmtc2 
KKKKQGVTVLAVSAVYDIFVFHRLKMKQILP, Wdr11 
KKKKKKKKKKNDEPDLDPVQELIYDLRSQCDAIRVTK, Zfr 
KKAHIRGAKHQKVVTLHTKLGKPIPSTEP, Adamts9 
KKKKKKKDYTAAGFSSFQKLRLDLTSMQIITTD, Pan HLA-DR reactive 
epitope (PADRE) KKKKAKFVAAWTLKAAA, Mageb-1/Mageb-2 
KKKKKKAGTSIQHTLKDPI and MAGE A4 KKKKKKKKWVQENYLEY. 
All peptides were purchased from Zhejiang Ontores Biotechnologies Co. 
(Zhejiang, China). 
 
4.4. Human specimens 
In Study I and (III) we made use of human PBMCs. In Study I Buffy coats were 
ordered from the Finnish Red Cross Blood Service and PBMCs were extracted by 
Ficoll Gradient purification. 
For Study III, cryopreserved PBMCs were purchased from the bank available at 
CTL-Immunospot (Cleveland, OH, US) 
 
4.5. In silico studies 
The sequence of the epitopes was mutaded in position. Each amino acid of the 
original sequence was substituted with all other natural aminoacids. The resulting 
virtual library of analogues was then screened to determined MHC class I binding 
affinity and immunogenicity for TCRs. In particular, the two predictions were 
performed by using artificial neural networks (ANN) based methods available 
form online servers. For the prediction of the binding affinity to the MHC-I 
molecule the NetMHC 4.0 Server from the Center for Biological Sequence analysis 
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(EDIS 22, 23) was used; for the prediction of the Class I Immunogenicity the 
server available at the Immune Epitope Database and Analysis Resource (IEDB) 
was used (EDIS 24). 
The results of the two predictions were ranked according to MHC-I binding 
affinity and binders with an IC50 lower than the wild type epitope were considered 
for further studies. Data on Class I Immunogenicity was taken into account when 
considering peptides with similar affinity to the MHC-I binding pocket. 
The epitopes with strongest in silico properties were then subjected to molecular 
dynamics simulations. The crystal structure of the SIINFEKL-epitope within the 
murine H-2Kb molecule deposited at the RCSB Protein Data Bank[181] was used 
as starting point to simulate all the peptides studied [182].The interactions of the 
epitopes with the MHC-I binding pocket (within the alpha chain of MHC 
molecule) was simulated for 300 ns. The structure resulted to be the most 
represented was chosen to be predictive of the peptide-MHC-I complex spatial 
conformation.  
 
4.6. In vitro studies 
4.6.1. Zeta potential and dynamic light scattering 
Samples were prepared as described in the previous section. Each sample was then 
vortexed and diluted to a final volume of 700 µl with sterile Milli-Q water adjusted 
to pH 7.4, after which the sample was transferred to a polystyrene disposable 
cuvette to determine the size of the complexes. Afterward, the sample was 
recovered from the cuvette and transferred to a DTS1070 disposable capillary cell 
(Malvern, Worcestershire, UK) for zeta potential measurements. All 
measurements were performed at 25°C with a Zetasizer Nano ZS (Malvern). 
 
4.6.2. Viability Assay (MTS) 
Tumor cells were seeded at 1 × 104  cells per well on 96-well plates. On the next 
day, viruses were diluted in growth media with 2% fetal calf serum, cells were 
infected for 1 h at 37 °C and then incubated in 5% FCS containing media at 37 °C 
for 3 to 5 days. Cell viability was determined by MTS assay according to the 
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manufacturer's protocol (Cell Titer 96 Aqueous One Solution Cell Proliferation 
Assay; Promega, Nacka, Sweden), measuring optical density with 
spectrophotometer at 490 nm. 
 
4.6.3. Infectivity assay (immunocytochemistry (ICC) assay) (IV) 
Tumor cells were seeded at 2 × 105 cells per well on 24-well plates in 3 or 5 
replicates. On the following day, the cells were infected with 100 µl of viral 
dilutions. The plates were centrifuged for 90 minutes at 1000 rcf at +37°C and 
then transferred to the incubators for 48 hours. After the incubation period, the 
culture medium was removed and cells were fixed with 250 µl of ice-cold methanol 
for 15 minutes. Once methanol was disposed, cells were washed 3 times with 300 
µl of PBS supplemented with 1% Bovine Serum Albumin (BSA). Afterwards, cells 
were stained with 250 µl of 1:2000 diluted mouse monoclonal antihexon antibody 
(Novus Biologicals, Littleton, CO, US) for 1 hour at RT in the dark. Cells were 
washed and stained with 250 µl of 1:500 diluted Biotin-Streptiavidin-conjugated 
goat anti-mouse antibody with PBS/1% BSA for 1 hour at RT in the dark. Cells 
were then incubated for 30 minutes at RT with 250 µl of 1:200 diluted extravidin-
peroxidase (Sigma-Aldrich, St. Louis, MO, US). Cells were washed extensively and 
DAB staining solution (Sigma-Aldrich, St. Louis, MO, US) was prepared according 
to manufacturer´s instruction. A total of 250 l of DAB staining solution was 
applied to each well. Cells were monitored 
under microscope for the appearance of dark spots. When optimal signal to noise 
ratio was reached the reaction was quenched by addition of PBS/1% BSA (500 µl 
per well). For each replicate (i.e. well) 5 images of non-overlapping fields were 
acquired using an AMG EVO XL microscope. For determining the infectious titer, 
the following formula was used: 𝐼𝑛𝑓𝑒𝑐𝑡𝑖𝑜𝑢𝑠	𝑡𝑖𝑡𝑒𝑟= 𝑥 ∗	 𝑤𝑒𝑙𝑙	𝑎𝑟𝑒𝑎𝑓𝑖𝑒𝑙𝑑	𝑎𝑟𝑒𝑎 ∗	 1𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛	𝑓𝑎𝑐𝑡𝑜𝑟∗ 	 1	𝑚𝐿𝑣𝑜𝑙𝑢𝑚𝑒	𝑜𝑓	𝑑𝑖𝑙𝑢𝑡𝑖𝑜𝑛	𝑎𝑝𝑝𝑙𝑖𝑒𝑑 
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4.6.4. Cross-presentation assay on spleenocytes 
2×106 spleenocytes in 800 µl of 10% RPMI-1640 culture media were incubated 
with 200 µl of SIINFEKL, polyK-SIINFEKL, SIINFEKL-polyK or SIINFEKL-
AHX-polyK peptide dilution (0.19 µg/µl). Alternatively, 7.9×109 vp mixed with 
37.5 µg of polyK-SIINFEKL (OVA-PeptiCRAd) in 200 µl of 10% RPMI-1640 
was applied. The PeptiCRAd complex was prepared as described previously. After 
2 h of incubation cells were washed and stained with either APC anti-mouse H-
2Kb bound to SIINFEKL or APC Mouse IgG1, κ Isotype Ctrl (BioLegend, San 
Diego, CA, USA) and the samples were analyzed by flow cytometry. 
 
4.6.5. Surface Plasmon Resonance 
Measurements were performed using a multi-parametric SPR Navi™ 220A 
instrument (Bionavis Ltd, Tampere, Finland). Milli-Q water with its pH adjusted 
to 7.4 was used as a running buffer. A constant flow rate of 30 µl/min was used 
throughout the experiments, and temperature was set to +20°C. Laser light with a 
wavelength of 670 nm was used for surface plasmon excitation. 
A sensor slide with a silicon dioxide surface was activated by 3 min of plasma 
treatment followed by coating with APTES ((3-aminopropyl)triethoxysilane) by 
incubating the sensor in 50 mM APTES in toluene solution for 1 h. The sensor 
was then placed into the SPR device, and the OAds were immobilized in situ on 
the sensor surface of the test channel by injecting 50 µg/ml OAds in Milli-Q water 
(pH 7.4) for approximately 12 min, followed by a 3 min wash with 20 mM CHAPS 
(3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate). The second flow 
channel was used as a reference and was injected with Milli-Q water (pH 7.4), 
followed by washing with CHAPS. The baseline was observed for at least 10 min 
before sample injections. PolyK-SIINFEKL or SIINFEKL was then injected into 
both flow channels of the flow cell in parallel, with increasing concentrations. 
 
4.6.6. CFSE proliferation assay on OT-I spleenocytes 
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The CD8 T-cells of C57BL/6-Tg(TcraTcrb)1100Mjb/Crl (OT-I) mice (Charles 
River have a T-cell receptor specific for the OVA-derived class I epitope 
SIINFEKL (EDIS reg 39). Spleens were collected from OT-I mice and were gently 
disrupted through 70 µM cell strainers and single cell suspensions were frozen in 
10% DMSO at -80°C. On the day of the assay, splenocytes were thawed, washed, 
resuspended in PBS. Then, splenocytes were added with CFSE (Sigma-Aldrich) 
diluted 1:100 in a volume of 1,1 mL of PBS for 10 minutes at +37°C. Labeled cells 
were washed two times in 10 mL of PBS and then resuspended in complete media. 
CFSE-labeled OT-I splenocytes were incubated for 72 hours with indicated stimuli 
(13 µM for peptides and 0,1 µg /µL for Concanavalin A) in 230 µL in 96 multiwell 
plates (V-bottom shaped). Samples were washed and incubated with Fc Block 
(Biolegend) and then stained with APC-labeled anti-CD8 and PE-labeled anti-CD3 
antibodies. Cells were washed two times, resuspended in 400 µl and analysed by 
flow cytometry. 
 
4.6.7. MHC stabilization assay with RMA-S cells 
The antigen processing-defective mutant cell line RMA-S express a very limited 
number of MHC-I molecules on their surface, and they are devoid of peptides. 
The addition of exogenous epitopes can stabilize the processing machinery and 
increase the amount of H-2Kb on the membrane. 2 x 106 RMA-S cells were 
incubated with indicated peptides at a concentration of 0,1 of 1 µg /µL in 2 mL of 
total volume. After 1,5 hours of incubation at +37°C, cells were washed with PBS 
and fixed in 4% formalin for 15 minutes at +4°C. Cells were then washed again 
with PBS and centrifuged at 1200 rpm for 5 minutes. The pellet was stained with 
a PE-labeled anti-H-2Kb antibody (Biolegend, San Diego, CA, USA). Cells were 
washed two times and suspended in 400 µL of PBS. The amount of H-2Kb on the 
membrane was quantified by a Gallios flow cytometer (Beckman Coulter). 
Geometrical mean fluorescence intensity (gMFI) was normalized to 
the negative control (RMA-S cells incubated without peptide). 
 
4.7. In vivo studies 
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 All animal experiments were performed with permission from the Experimental 
Animal Committee of the University of Helsinki and the Provincial Government 
of Southern Finland. Mice were obtained at 3-6 weeks of age and quarantined at 
least 1-2 weeks before experiments were started. Mice were kept in standard cages 
with constant food and water supply. The health status of the mice was monitored 
daily and as soon as signs of pain or distress were evident, they were euthanized. 
Mice were, at the latest, euthanized when a single tumor reached an average 
diameter of 17 mm, or 15mm in experiments where the mice had two tumors. 
Euthanasia was done by using CO2  and neck dislocation. During the experiments 
mice were anesthetized either with isoflurane inhalation or with i.p. injection of 0.5 
mg/kg medetomidine and 50 mg/kg ketamine diluted in 0.9% sodium chloride. In 
all the experiments, the formula (length × (width)2  × 0.5) was used to calculate the 
tumor volumes. 
For experiments presented in Study III, the concept of “responder”mice is 
introduced. This is not equivalent to the response rates defined by RECIST 
criteria, hence a clarification is needed. By responding mice we intend mice that 
show a considerably slower tumor growth, hence a tumor volume at the end of the 
experiment which is about one third of the maximum observed volume. 
 
4.7.1. Syngeneic melanoma models (I, II and III) 
 The in vivo efficacy and immunogenicity of the viruses were tested in 
immunocompetent C57BL/6 mice bearing syngeneic melanoma tumors. Mice 
were obtained from Harlan Laboratories Inc. (Indianapolis, IN, USA) or from 
Scanbur (Karlslunde, DK) for Study IV. In Study I, 5-week-old C57BL/6 female 
mice (N = 7 per group) received 1x105 B16-OVA cells subcutaneously on a shaved 
flank (one tumor per mouse). In the “mild” regimen experiment, the virus was 
injected intratumorally at 10 8 VP/tumor on days 0, 1, 4 and 5 and in the “high” 
regimen experiment the same amount of virus was given every other day (a total 
of 7 times) starting when tumors reached the size of ~4x4 mm. In Study II, B16-
OVA melanoma tumors were established by injecting 1 × 105 B16-OVA cells 
subcutaneously into one flank of 10-week-old female C57BL/6J mice (N = 12 per 
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group). Tumors (one tumor per mouse, ~4×4 mm in diameter) were injected i.t. 
with vaccinia viruses in a volume of 50 µl on day 0 with 3 × 106 
 
pfu/tumor and 
on day 2 with 1 × 106 pfu/tumor. Mock tumors were injected with PBS only. In 
the re-challenging experiment where the mice received a second tumor contra-
laterally, either B16-OVA cells or B16-F10 cells 3 x 105  cells, were injected 10 days 
after the first virus treatment. In Study IV, melanoma tumors were injected into 
both flanks of C57BL/6 mice. The number of tumor cells injected into each flank 
was: 3 x 105  for B16-OVA, 1 x 106 for B16-F10 and 2 x 106 for SK-MEL-2. The 
treatment of tumors started when tumors reached an average diameter of 4 mm. 
In all the experiments, the mice were administered the PeptiCRAds three times 
with a dose of 1 x 109 VP/tumor + 20 ug of total peptides amount. The details 
about the schedule of treatment can be found in each figure legend. 
 
 
4.7.2. Humanized mice (I) 
To gain better understanding of the immunogenicity and efficacy of the viruses in 
a more translational system, we used mice with human peripheral blood 
mononuclear cells (PBMCs) and human melanoma tumors. For these studies 
highly immunodeficient NSG (NOD.Cg-Prkdcscid Il2rgtm1Wjl /SzJ) mice were obtained 
from The Jackson Laboratory (Bar Harbor, Maine, CA, US). Human melanoma 
cells (HS294T in Study II or SK-MEL-2 in Study IV) were injected subcutaneously 
into both flanks of the NSG mice, 5 × 106  of HS294T cells or 2x106 of SK-MEL-
2 cells per flank. When tumors reached the average size of 4×4 mm in size, human 
PBMCs were injected intravenously into the tail vein in 200 µl of PBS, 2 × 
107 cells/mouse. Two days later virus treatments were started. In Study II, tumors 
were treated on days 0 and 6 with 1 × 106 pfu/tumor in volume of 50 µl, mock 
mice were treated with PBS only. In Study IV, tumors were treated on days 0, 2 
and 4 with 2x108  VP/tumor in 50 µl of NaCl, mock mice received NaCl only. Part 
of the mice were left without PBMCs as a study control lacking the immune 
system. 
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4.8. Ex vivo studies 
 After euthanizing the mice with CO2  and neck dislocation, tumors, spleens and 
lymph nodes of treated mice were collected into tubes containing 10% RPMI-1640 
medium, and the tubes were kept on ice until further processing. Organs were 
smashed through 70-µm cell strainers and single cell suspensions were either used 
fresh or cryo-preserved at -80° after the addition of 10 % DMSO.  
 
4.8.1. Flow cytometry 
To study the phenotype of immune cells within lymphoid organs or tumors, single 
cells suspensions were stained with fluorochrome-conjugated monoclonal 
antibodies and analyzed using a FACSAria (BD Biosciences) or Gallios (Beckmann 
Coulter) flow cytometer and FlowJo software (TreeStar, Ashland, OR, US). 
Organs were collected in complete RPMI medium and dissociated by mechanical 
disruption through 70 um filters by using a syringe plunger. Cells were then frozen 
by adding 10 % DMSO and stored at -80 °C until the day of analysis. On the day 
of analysis cells were thawed in a water bath at +37 °C, then washed in PBS and 
stained according to manufacturer protocol in presence of FcBlock antibody 
(TruStain fcX™ (anti-mouse CD16/32) Antibody; clone 93, Biolegend) to reduce 
aspecific staining. 
To study tumor-specific T cells from B16-OVA tumor bearing mice, APC-
conjugated SIINFEKL MHC-I pentamer (PROIMMUNE, Oxford, UK) was used 
together with a FITC-conjugated anti-mouse CD8 (clone KT15; PROIMMUNE, 
Oxford, UK)  and a PE-conjugated anti-mouse CD19(clone 6D5, Biolegend, San 
Diego, US) antibodies respectively to gate the CD8+ cell population and to 
subtract unspecific binding of the pentamer to B cells. Other antibodies used in 
the studies are described in detail in the corresponding publications. Other 
antibodies used into the studies include the Fc block TruStain fcX anti-mouse 
CD16/32 (clone 93; Biolegend, San Diego, US), anti CD3 (clone HIT3a; 
Biolegend, San Diego, US), anti PD-L1(clone 29E.2A3, Biolegend, San Diego, 
US), anti MHC-SIINFEKL (clone 25-D1.16, Biolegend, San Diego, US), anti 
TIM-3 (clone RMT3-23, Biolegend, San Diego, US), anti CD3 (clone GK1.5, 
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Biolegend, San Diego, US), anti PD-1 (clone 29F.1A12, Biolegend, San Diego, 
US).  
 
4.8.2. ELISpot Assay (II) 
Spleens have been collected from mice, disrupted and passed through a 70 um cell 
strainer. They were stored in -80°C in 10% DMSO. On the day of the assay, 
splenocytes were quickly thawed at +37°C. Samples were transferred into falcon 
tubes and 8 mL of complete media was slowly added. Cells were centrifuged to 
eliminate residual DMSO and resuspended in serum free CTL media 
supplemented with 1% L-glutammine and benzonase (50 U/mL). Samples were 
counted and viability was assayed by Trypan-Blue staining. Samples viability ranged 
from 80 up to 95%. Splenocytes were plated at a concentration of 2,5 x 105 or 3 x 
105 cells/well (refer to figure legends). Cells have been stimulated with 50 or 200 
ng of peptides of interest in 200 µl of final volume. PBS + 1 % DMSO and 
Concanavalin A have been used as negative and positive controls respectively. 
Stimulation was carried out for 72 hours in incubators (37°C, 5% CO2). 
Afterwards, the plates have been processed according to manufacturer´s 
instructions (CTL Immunospot, Bonn, Germany). The analysis of the plates 
(digital images production and spot evaluation) has been outsourced to CTL 
Immunospot. 
 
4.8.3. Killing assay with PBMCs 
All the PBMCs used in this work were cultured with human IL-2 at a final 
concentration of 3.3 ng/ml per 0.15x106 cells and pulsed with PeptiCRAd as 
described in the experimental procedure for 2 days. The PBMCs were added to 
the cells at ratio 10:1 and after 5 days the viability was evaluated by MTS assay in 
according to the manufacturer´s protocol (CellTiter 96 Aqueous One Solution Cell 
Proliferation Assay; Promega, Nacka, Sweden). Spectrophotometric data were 
acquired with Varioskan Flash Multimode Reader (Thermo Scientific, Carlsbad, 
CA, USA). 
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4.9. Statistics 
 In Studies I, II and III GraphPad Prism 6 (GraphPad Software, Inc., La Jolla, CA, 
US) was used to determine the statistical differences between study groups. Usually 
two-tailed Student’s t-test was used to determine differences in the in vitro and ex 
vivo experiments, but two-way ANOVA was used in some cases in Study IV 
(statistical analyses used in study IV are explained in detail in the figure legends of 
the article). A nonparametric Mann–Whitney U-test was used to determine 
statistical differences between in vivo study groups. The area under the curve 
(AUC) was used in Study III to determine the size of the tumors of humanized 
mice. Kaplan-Meier survival curves and log rank statistics were used to compare 
survival of the treated mice. Results are presented as mean ±SD, or as mean ±SEM 
for tumor growth. All P values were two-sided and considered statistically 
significant when ≤ 0.05. * P <0.05, ** P <0.01, *** P 
<0.001, **** P <0.0001. 
 
RESULTS AND DISCUSSION 
4.10. Study I. PeptiCRAd: an oncolytic adenovirus coated with MHC-I 
tumor epitopes as a novel oncolytic vaccine platform 
 
In Study I we developed a novel oncolytic vaccine platform that is able to redirect 
the immune response towards specific tumor antigens. While normal oncolytic 
viruses rely on the lysis of tumor cells to prime antigen specific responses, our 
peptide-coated conditionally replicating viruses (PeptiCRAd) act as immunogenic 
carriers of peptides to antigen presenting cells, thus maximizing the efficacy of 
oncolytic adenoviruses. 
 
4.10.1. Exploiting the negative surface charge of adenoviruses to attach positive 
tumor epitopes: formation of PeptiCRAd complex. 
The formulation of classic vaccines features adjuvants that mediate the uptake of 
antigens by APCs. For instance, aluminium enhances the penetration of protein 
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sequences through the membrane of cells. Inspired by this mechanism we 
hypothesized that physically linking short epitopes to the viral capsid would 
improve the uptake of this complex by APCs that would be activated by the 
PAMPs of the virus and simultaneously cross-present the epitopes to T-cells. 
The capsid of the adenovirus features a negative surface potential (ranging from -
30 to -20 mV according to the preparation and buffers) as measured by Malvern 
Zetasizer, hence we optimized the peptides to allow for electrostatic interaction.  
We started by considering the SIINFEKL peptide, which is a known MHC-I 
epitope of the model antigen Ovalbumin. 
We added six lysines to the initial SIINFEKL sequence (polyK-SIINFEKL), 
increasing the net charge of the peptide from 0 up to +6 at neutral pH (Study I; 
figure 2 A; solid black line). The interaction between the viral capsid and the 
peptides was confirmed by surface plasmon resonance (SPR). While the 
SIINFEKL peptide did not interact with the virus (Study I; figure 2 B, dotted 
line), the polyK-SIINFEKL peptide (black solid line) attached to the viral surface 
with a concentration-dependent efficiency. The amount of peptide required for a 
stable formulation was about 500 ug for 1 ug of viral proteins. These settings 
produced positive complexes (+18 mV) with a monodispersed composition (i.e. a 
low particle size of 120 nm) as shown in figure 2 C of Study I. This prevented 
aggregation of particles while enhancing the biocompatibility. The physical 
properties remained unaltered after 15, 30 or 45 minutes of incubation (Study I; 
figures 2 D and E). 
These data about the formulation of the PeptiCRAd complex suggest the feasibility 
of the approach and the good stability data prompted us to select the 1:500 ratio 
as the formulation to use for the subsequent experiments. 
 
4.10.2. Modified MHC-I epitopes are efficiently cross-presented by immune cells. 
The core idea of PeptiCRAd is the ability to deliver to APCs specific tumor 
peptides by using adenoviruses as adjuvant. Therefore, we tested if the modified 
SIINFEKL was still able to be cross-presented after the addition of 6 lysines to its 
sequence. By comparing a C-terminus extended SIINFEKL-polyK to a N-
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terminus extended polyK-SIINFEKL we found that the position of the polyK 
chain widely affects the cross-presentation of the peptide on MHC-I. As shown in 
figure 3 A of Study I, the N-terminus extended polyK-SIINFEKL is processed 
as efficiently as the wild type SIINFEKL epitope, while the C-terminus extended 
counterpart shows impaired processing and cross-presentation on MHC-I. We 
also observed that the presence of the virus into the formulation would not hinder 
the cross-presentation of the peptide (Study I; Figure 3 B).  
These interesting results highlight that structural changes of peptides affect their 
ability to be processed and loaded onto MHC-I molecules. We hypothesize that 
the two different forms of SIINFEKL (C-terminus and N-terminus extended) 
undergo different processing pathways.  While the C-terminus has to be processed 
by into the cytosol and then transported to the ER according to the classical 
proteasome-dependent pathway, the N-terminus can use the faster non-canonical 
cross-presentation pathway that occurs directly into endosomes thanks to the 
presence of aminopeptidases into the vesicles. 
 
4.10.3. Infectivity of PeptiCRAd in human cell lines. 
Modification of the viral capsid can have a great impact on the ability of the virion 
to enter target cells. To this end we performed killing and infectivity assays after 
infection of cancer cell lines with either naked OAd or peptide-coated OAds (i.e. 
PeptiCRAd). The long-term oncolytic activity of the virus was not hindered by the 
modification of the viral capsid as killing curves between the naked OAd and the 
PeptiCRAd were equal in all cell lines that we tested (Study I; Figure 4 A). 
However, when looking at the entry of the viruses into cells, we observed a higher 
degree of infectivity of PeptiCRAd, especially when using low-CAR cell lines 
(Study I; Figure 4 B).  
These findings highlight how modification of the viral capsid by electrostatic 
interaction does not decreases the entry of the virus into target cells, but it could 
actually favour it. Previous studies demonstrated that surface modification of 
adenoviruses could affect their transduction efficacy. We speculate that the 
positive peptides could mask the negative areas of the viral capsid, thus reducing 
   
 
   
 
74 
the repulsion between the virus and the negative cell membrane and favouring the 
interaction of the viral proteins to the cell-membrane receptors. 
 
4.10.4. PeptiCRAd elicits potent anti-tumor responses compared to normal 
oncolytic adenovirus in a neo-antigen melanoma model. 
After acquiring data about the formulation of PeptiCRAd and its in vitro 
transduction and killing properties, we tested our new oncolytic vaccine platform 
in vivo. To this end, we choose a model that would allow us to rule out any 
contribution of the oncolytic to the efficacy of the therapy. Hence, we utilised the 
syngeneic murine B16.OVA melanoma model as a neo-antigen model. This cell 
line has been engineered to express chicken ovalbumin (OVA) and can be targeted 
by eliciting immune responses against the SIINFEKL epitope (REF). Importantly, 
this cell line is not permissive to the human adenovirus serotype that we used, 
hence all observations can be attributed exclusively to the immunogenic potential 
of the PeptiCRAd platform. 
First, we asked if complexing the virus with the peptides was necessary to achieve 
the full efficacy of the therapy. Hence, we treated C57BL/6J mice bearing 
established B16.OVA tumors with either non-complexed mixture of OAd and 
SIINFEKL or the PeptiCRAd complex. Treatment with Peptide alone or the 
OAd+SIINFEKL mix slowed down the growth of tumors compared to mock. 
However, an increased control of melanomas was achieved when treating tumors 
with PeptiCRAd (Study I; Figure 5 A) after 16 days from the start of the 
treatment. Nevertheless, the rate of complete responses was still low among all 
treated groups. This could be due to the fact that targeting a single tumor antigen 
leads to the elimination of the most immunogenic clones, hence the takeover of 
resistant ones. In addition, after stopping the intratumoral therapy with viruses, 
the immune suppressive tumor microenvironment could dampen the initial anti-
tumor immunity, for example through the upregulation of immune checkpoint 
such as PD-L1. This is a well-known mechanism that tumor cells use in response 
to exposure to pro-inflammatory mediators such as IFNγ as we also demonstrated 
in the Study III of this thesis. 
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The immunological analysis revealed an increased the number of tumor-specific 
T-cells into draining lymph nodes already 7 days after the first injection of 
PeptiCRAd (Study I; figure 5 B, left panels). By day 16, the number of 
SIINFEKL-specific CD8+ T-cells increased into the spleen and, most 
importantly, tumors (Study I; figure 5 B, right panels). This suggests that the 
early activation of T-cells led to their migration into tumor tissues explaining the 
lower growth of when compared to controls. 
To deepen our knowledge of the mechanism of action we studied DCs and their 
activation state. In addition, thanks to the availability of a specific antibody 
recognizing the SIINFEKL peptide onto the H-2Kb molecule we could detect a 
specific population of DCs cross-presenting the OVA-derived epitope. Consistent 
to our results, we observed that treatment with PeptiCRAd caused the greatest 
increase overtime of DCs that were mature (CD86+) and that were cross-
presenting SIINFEKL to T-cells (Study I; Figure 5 F).  
Taken together, these data demonstrate that PeptiCRAd activated dendritic cells 
and favoured the presentation of the delivered epitope. This resulted into an 
increased proliferation of antigen-specific CTLs that would allow for an improved 
tumor control. These finding correlate with studies of vaccine systems where 
complexing the antigen to the adjuvant increased the vaccination efficacy by 
favouring the uptake of the complex by APCs. Considering that the PeptiCRAd 
platforms allows for the adsorption of the target epitopes onto the surface of an 
immunogenic virus, we believe that our system features a similar mode of action 
to other adjuvant systems such as the aluminium. 
 
4.10.5. PeptiCRAd efficacy on contralateral and untreated melanomas is boosted 
by targeting multiple antigens simultaneously. 
The results of the previous experiments prompted us to investigate whether 
PeptiCRAd could be effective when targeting a poorly immunogenic model such 
as the B16F10 melanoma. Lacking immunogenic antigens our primary aim was to 
limit the immunological escape of tumors. Hence, we decided to target two 
epitopes deriving from two different antigens which are presented by two different 
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MHC molecules. We formulated a PeptiCRAd with both the TRP2180-188 and the 
hgp10025-33 epitopes featuring the poly lysine chain to allow for their adsorption 
onto the viral capsid. Viruses decorated with only one of the epitopes were used 
as controls (i.e. TRP2-PeptiCRAd and hgp100-PeptiCRAd). In addition to the 
primary tumor on the right flank, as shown in figure 6 A of Study I, we engrafted 
a secondary tumor on the left flank after the PeptiCRAd treatment and left it 
untreated. 
Treatment with the PeptiCRAds targeting the single antigens were not effective in 
this model (Study I; figure 6 B). Surprisingly, when targeting the hgp100 antigen 
alone we observed an increased growth of tumors compared to mock. This might 
be due to a faster elimination of immunogenic clones, thus a more rapid outgrow 
of resistant tumor cells. Interestingly, when using the PeptiCRAd targeting both 
tumor antigens (i.e. TRP2-hgp100-PeptiCRAd) we were able to decrease the 
growth of the primary tumors significantly. Most importantly, the secondary 
tumors showed a reduced volume in all the animals receiving one of the 
PeptiCRAd formulations (Study I; figure 6 C). However, mice treated with the 
double-coated TRP2-hgp100-PeptiCRAd showed the lowest volume of the 
contralateral and untreated tumors. These finding suggest that the targeting two 
antigens on different MHC can reduce the immunological escape of tumors. In 
fact, pentamer staining for antigen-specific CD8+ T-cells revealed an higher anti-
tumor response against the different epitopes in mice treated with TRP2-hgp100-
PeptiCRAd (Study I; figure 6 D). Our results correlate with clinical studies where 
patients that received multi-epitopes vaccines were more likely to experience stable 
disease or partial responses. This strategy is particularly useful if tumor cells 
downregulate a certain antigen or lose the expression of an MHC allele. 
 
4.10.6. Efficacy of PeptiCRAd in humanized mice translational model. 
To conclude our pre-clinical study of the PeptiCRAd technology we decided to 
test it in humanized mice. Although challenging, this model is the most advanced 
one for testing oncolytic viruses. In fact, the presence of human tumor cell lines 
allows for the study of viral replication within the tumor microenvironment. At 
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the same time, the engraftment of patient-derived PBMCs in the mouse, allows for 
the evaluation of immunological effects of the oncolytic vaccine. To this end, triple 
knock-out NGS immune deficient mice were engrafted with the human melanoma 
cell-line SK-MEL-2 on both flanks. Then days after, PBMCs from an HLA-
matched healthy donor were isolated and injected into the tail vein of the mouse. 
Next day, we started treating mice with saline solution (Mock), or a normal 
oncolytic adenovirus expressing the GM-CSF cytokine (Ad5D24-GMCSF) or with 
a PeptiCRAd targeting the human Mage-A1 antigen (MAGE-A1 PeptiCRAd). As 
shown in figure 7 A of study I, while treatment with saline solution did not inhibit 
the growth of tumors, the normal Ad5D24-GMCSF was able to achieve the 
stabilization of melanomas. However, a more rapid tumor rejection was achieved 
by treatment with MAGE-A1 PeptiCRAd, as also proved by the analysis of the 
area under the curves (Study I; figure 7 B). Interestingly, when testing both 
oncolytic viruses in non-humanized mice (i.e. mice that were not engrafted with 
PBMCs) we could not observe dramatic differences as regards the efficacy of the 
therapies (Study I; figure 7 C). We speculate that in absence of the immune 
system, both the normal Ad5D24-GMCSF and the MAGE-A1 PeptiCRAd viruses 
could clear the tumors due to the oncolysis. However, in presence of a full immune 
system, the normal Ad5D25 virus is blocked by the antiviral response, thus losing 
its efficacy. On the contrary, PeptiCRAd can extend its beneficial effect through 
the stimulation of an antigen specific response against MAGE-A1, as we found by 
evaluating the number of antigen-specific T-cells (Study I; figure 7 D).  
 
4.11. Study II. The Epitope Improvement and Discovery System: a 
novel in silico framework to improve MHC-I epitopes 
Using wild-type tumor epitopes does not represent an optimal strategy to target 
tumor associated antigens because of the peripheral tolerance or suboptimal 
binding to HLA. For this reason, mutated versions are used (i.e. heteroclitic 
peptides) are often used as improved versions of wild-type epitopes. They might 
show improved binding affinity or increased T-cell activation. However, studying 
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the many possible sequences is time consuming. The EDIS framework is designed 
to provide automation when studying heteroclitic peptides. 
The workflow is based on different in silico tools ranging from high throughput 
prediction of HLA-binding affinity, immunogenicity and HLA-peptide stability 
simulations.  
Of extreme importance is the ability of the heteroclitic peptides to elicit a cross-
response towards the wild-type epitope, which is presented by tumors cells. At the 
moment, no in silico tool is able to predict such property, however, we propose 
the use of molecular dynamics simulation to study the structural similarities 
peptide-MHC complexes to collect insights on the cross-reactivity. 
 
4.11.1.1. Study and Improvement of the SIINFEKL epitope. 
As shown in figure 1 A of Study II, the SIINFEKL epitope acquires a specific 
conformation within the MHC-binding pocket. The lateral chains (depicted in 
blue) of residues 1, 2, 3, 5, and 8 are facing the binding pocket while residues 4, 6 
and 7 are extruding from the MHC, thus are available for screening by the TCR. 
For this reason, modification of each specific position has a different effect upon 
the properties of peptide-MCH complexes.  
To study the effect of mutations in each position, a mutational library was 
generated. Then every mutated analogue (i.e. heteroclitic peptide) was analyzed by 
using prediction servers for its binding affinity to the murine H-2Kb MHC 
molecule and the recognition of the peptide-MHC (pMHC) complex from the T-
cells (Immonogenicity score, IS).  
A shown in figure 1 B of study II, all analogues sharing a mutation at the first 
position (XIINFEKL; blue) or at the second position (SXINFEKL; red) feature a 
much worse MHC-binding affinity (higher IC50) compared to the native sequence 
(red dashed line). Consistently, all the analogues featuring a mutation at the eighth 
residue (dark blue), known to be an important binding anchor, show the lowest 
affinity. Interestingly, most of the mutations at the sixth position (SIINFXKL) 
would produce analogues with a higher affinity for the H-2Kb molecule compared 
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to the wild type SIINFEKL. This demonstrated that the SIINFEKL epitope is 
already optimized for binding the MHC. As regards the immunogenicity and the 
TCR recognition, we could appreciate that this parameter was not affected by 
mutating the first three residues (Study II; Figure 1 C). This is consistent with the 
theory that the residues that are sunk into the MHC-binding pocket are not readily 
accessible by the T-cell, thus might not be determinant for the TCR engagement. 
On the contrary, mutation at the fourth or sixth positions could improve the 
predicted immunogenicity of the epitope, especially when inserting aminoacids 
with large lateral chains, such as E, F, I or W (supplementary figures 1 B and C; 
red dots).  
Next, to evaluate the cross-reactivity between the native SIINFEKL and the most 
promising heteroclitic peptides, we used molecular dynamics simulations. We 
chose two mutated forms of SIINFEKL that were predicted to feature an 
improved IC50 (SIINFAKL) or an improved immunogenicity (SIIWFEKL), as 
shown in figures 1 D and E of study II. 
As shown in figure 2 A of study II both the SIINFAKL (red solid) and the 
SIIWFEKL (cyan solid) differ in their spatial orientation when compared to the 
wild type SIINFEKL (green transparent). For instance, the SIINFAKL peptide is 
shifted to the bottom of the binding pocket and this could explain the incresed 
binding affinity of this analogue form. On the contrary SIIWFEKL, featuring a 
large side chain due to the tryptophan in position 4 (4TRP), might extrude more 
from the binding pocket when compared to SIINFEKL.  
The TCR recognizes the pMHC by binding for one third the peptide and for two 
thirds the MHC-I. Hence, studying the single residues might be poorly predictive. 
Thus, we decided to study how the whole portion of pMHC that faces TCR 
(hereafter referred as the pMHC landscape) changes when considering different 
mutated analogues of the same epitope. The analogue SIINFAKL, featuring a 
smaller alanine in position 6, features a more open conformation (Study II; 
Figure 2 C); in fact, the residues 4ASN and 7LYS seem to extrude more from the 
MHC binding pocket. In contrast, the presence of the tryptophan at position 4 in 
the epitope SIIWFEKL, reduces the aperture of the binding pocket even if the 
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large aromatic chain of the 4TRP extrudes from the whole pMHC complex. Hence 
the whole pMHC landscape appears in a more closed conformation (Study II; 
Figure 2 D) when compared to the native SIINFEKL-MHC complex (Study II; 
Figure 2 B). 
These observations widen the classical model that considers the peptide binding 
affinity for to the MHC molecule the major determinant of immune responses to 
the epitopes [92, 183, 184]. In fact, both peptides are able to modify the shape of 
the whole MHC portion that is read by the T-cells. These small differences might 
be then amplified in the downstream signaling within the T-cell, according to the 
kinetic proof-reading model of T-cell activation [185]. This aspect is important 
when considering the cross-reactivity model where a small mutation within the 
epitope sequence can cause major conformational changes to the whole MHC 
molecule and this ultimately causes the engagement of TCRs with suboptimal 
affinity to the native epitope, thus cross-reactive responses that might be beneficial 
in order to break the tolerance. 
 
4.11.1.2. Study and improvement of the TRP2180-188 epitope. 
TRP2 melanoma antigen, is a self-protein which is overexpressed in tumor cells. 
Therefore, numerous strategies have been implemented to improve its 
immunogenicity. Similarly, to our work on the SIINFEKL epitope, we improved 
the initial sequence with the EDIS framework and studied the in silico properties 
of the resulting heteroclitic peptides. 
We started by building the mutational library and screened the mutated epitopes 
looking for the best MHC binders (lowest IC50) and the most immunogenic ones. 
The majority of the analogues with a mutation in the first three positions showed 
a higher IC50 compared to the wild type TRP2180-188 sequence, thus worse binding 
to MHC (Study II; figure 6 A). Consistent to our previous modelling, a mutation 
to the anchor site (9th residue) would result in a high IC50 as well (SVYDFFVWX; 
9th group on the x axis). Interestingly, the predicted IC50 of peptides sharing a 
mutation at the 4th residue was not affected by the mutation, highlighting that 
residues that extrude from the binding pocket might not directly contribute to the 
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overall binding of the peptide to the MHC. However, the extruding residues 
contribute to the engagement of the TCR, as proven by the fact that mutations at 
the 4th position would lower the immunogenicity score of the resulting peptides 
(Study II; figure 6 B). Interestingly, of all the possible 162 mutated peptides, only 
12 analogues showed an improved immunogenicity score compared to the wild 
type TRP2 peptide (TRP2WT; Study II; supplementary figure 1 D, red dots). 
This might suggest that the TRP2WT may be already optimized for TCR 
recognition and that poor TCR stimulation might be caused by the tolerance 
towards this peptide rather than poor TCR engagement. From the pool of 
heteroclitic peptides we choose to focus on two epitopes that showed an increased 
affinity for H-2Kb, but avoiding mutations into the central regions of the peptide: 
SAYDFFVWL (TRP2 2A) and SVYDFFAWL (TRP2 7A). These analogues 
displayed a lower IC50 (Study II; figure 6 C left) and were predicted to be 
recognized as efficiently as the TRP2 WT epitope (Study II; figure 6 C right). 
Consistent with the in silico analysis, both analogues stabilized the MHC-I 
molecules on the surface of RMA-S cells at both low and high concentrations 
(Study II; figure 6 D, left and right respectively). 
To dissect how the whole pMHC complex would change in case of each mutated 
peptide, we performed molecular dynamics simulations (Study II; figure 6 E). 
When comparing TRP2WT, TRP2 7A and TRP2 2A peptides (Study II; figure 6 
E left) when inside the binding pocket we observed a different conformation of 
the whole pMHC complex. In particular, the first 3-4 amino acids of the peptides, 
which are in deep contact with the MHC-I pocket (Study II; figure 6 E right) 
have a different conformation, especially when considering the TRP2 2A peptide; 
hence, the whole pMHC structure is modified (Study II; figure 6 F). For instance, 
the presence of an alanine in position 7 of the TRP2 7A analogue, modifies the 
spatial orientation of phenylalanine and tryptophan at position 6 and 8, respectively 
(Study II; figure 6 F center). No major spatial changes were observed for the 
pMHC complex when we simulated the presence of the TRP2 2A peptide into the 
binding pocket of the H-2Kb molecule when compared to the TRP2 WT peptide 
(Study II; figure 6 F right). 
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4.11.2. In vitro validation of in silico data. 
The previous section of this study focuses on the prediction of MHC-binding 
affinity and immunogenicity by in silico tools based on artificial neural networks. As 
reliable as these tools are, they have some limitations and the data need to be 
validated by in vitro assays. Therefore, we performed MHC-binding assays to 
compare the affinity of the mutated analogues with the native epitope. In this assay, 
we used the TAP-deficient RMA-S cell line, which lacks H-2Kb molecules on the 
surface due to the failure to load peptides into the binding pocket. However, in 
presence of strong binders, the MHC molecules are stabilized and brought on the 
membrane of the cells. The pMHC complexes can be then detected by flow 
cytometry. Hence, the more H-2Kb molecules are found on the surface of RMA-
S cells, the stronger the binding of peptides to the MHC. As regards the analogues 
of the SIINFEKL peptide we observed a stronger presence of H-2Kb on the 
surface of RMA-S cells when they were incubated with SIINFAKL and 
SIIWFEKL (Study II; Figure 3A and 3B). When we studied the ability of these 
peptides to engage the SIINFEKL-specific TCR of OT-1 immune cells, we found 
that SIINFAKL induced the highest proliferation of CFSE labelled spleenocytes 
(Study II; Figure 3C). This demonstrates that a higher affinity to MHC leads to 
an increased proliferation of the epitope specific T-cells. Most importantly, these 
data support the idea that mutated epitopes, such as SIINFAKL, can still cross-
activate TCRs against the wild type sequence. Hence, we were able to select cross-
reactive peptides, which is an important aspect of the selection of heteroclitic 
peptides. 
Similarly, we also validated the predicted affinity from our study of TRP2 WT, 
TRP2 2A and TRP2 7A peptides. Consistently to our in silico analysis, both 
analogues showed a stronger stabilization of H-2Kb molecules on the surface of 
RMA-S cells, suggesting a stronger MHC-affinity (Study II; figure 6D). 
 
4.11.3. The improved epitopes show a higher efficacy against multiple melanoma 
models. 
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After evaluating the in silico and in vitro properties of the heteroclitic peptides 
selected according to the EDIS framework, we sought to investigate their efficacy 
in vivo upon established tumors. To this end, we used B16.OVA and B16F10 tumor 
cell lines, which represent the most aggressive models of syngeneic murine 
melanomas. 
Immunocompetent mice were engrafted with B16.OVA cells, then formed tumors 
were treated by intratumoral injection of saline solution (mock) or the peptides 
mounted onto the oncolytic adenovirus. By this mean, we used the oncolytic virus 
as an adjuvant according to the PeptiCRAd technology discussed in Study I with a 
different treatment schedule in order to maximize the differences between the 
usual SIINFEKL-PeptiCRAd or the formulation with SIINFAKL and 
SIIWFEKL. 
In these settings, therapeutic vaccination with the SIINFEKL, did not have a 
dramatic effect on the growth of tumors, although the mice showed a slight 
reduction of tumor volumes (Study II; Figure 4A). Compared to SIINFEKL 
treatment, a superior efficacy was achieved by treating mice with SIIWFEKL 
(p<0.05) or SIINFAKL (p<0.01).  
To evaluate whether or not treatment with the heteroclitic peptides would engage 
in a more beneficial way the antigen-specific cells we analysed the presence of 
SIINFEKL-specific T-lymphocytes within the tumors and lymphoid organs of 
treated mice. First, we observed that no major differences were found as regards 
the number of cytotoxic T-lymphocytes (CTLs, defined as CD19-CD3+CD8+ cells; 
Study II; figure 4B); however, when we looked at the specificity of lymphocytes, 
we found a larger number of epitope-specific T-lymphocytes into the tumors of 
mice treated with SIINFAKL (Study II; Figure 4C). This suggests a beneficial 
cross-response and expansion of antigen-specific lymphocytes that infiltrated the 
tumors. An inter-organ analysis (Study II; Figure 4D) revealed a lower affinity 
for the SIINFEKL epitope of TCR of larger populations of antigen-specific T-
lymphocytes (Pearson´s correlation analysis; p=0.0002). These data suggest that 
low-avidity T-cell clones are attracted within the tumor in larger numbers (Figure 
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4D; black dots) and this mechanism could be exploited to circumvent the 
tolerance when targeting different tumor antigens such as TAAs. 
The same improved efficacy was seen when testing the analogues of TRP2WT. 
Interestingly while one analogue did not mediate any anti-tumor efficacy, the 
TRP27A peptide reduced slightly but significantly the growth of the aggressive 
B16F10 tumors (Study II; Figure 7A) 
 
4.11.4. Combining improved shared antigens and neo-antigens derived epitopes 
increases the response rate. 
Therapeutic cancer vaccination proved to be an effective way to foster antigen-
specific immunological responses. However, targeting a single antigen might not 
be the optimal choice against fast-growing tumors that can easily accumulate 
mutations and down regulate immunogenic proteins or specific HLA molecules. 
Therefore, therefore we sought to investigate a multi-peptide approach that would 
target together a TAAs, such as TRP2, and a neo-antigen such as the ovalbumin 
protein of B16.OVA cells. In addition, we boosted the therapy by combining the 
wild type epitopes with the EDIS-derived forms that we studied before. Hence, 
tumor bearing mice were treated with either TRP2 WT + 7A analogue peptides, 
SIINFEKL + SIINFAKL analogue peptide or a combination of all four peptides 
together (multi-vaccine). The overall response of the groups was variable, although 
they all performed better than mock (Study II; supplementary figure 3 A). 
Nevertheless, by visualizing the single growth curves we can appreciate differences 
in the number of mice responding to the therapy. As shown in figure 7C of study 
II, the percentage of slow progressing tumors in mock group was 20 %, while it 
was slightly improved in TRP2 WT-7A and SIINFEKL-SIINFAKL groups. 
Interestingly, the overall response was increased up to 57 % among mice receiving 
the multi-peptide vaccine.  
These results prove that by targeting both TAAs and neo-antigens within the same 
therapy broadens the immune response, thus helping to overcome the clone 
variability and down-regulation of specific antigens.  
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4.12. Study III. Oncolytic vaccines increase the response rate to PD-L1 
checkpoint inhibitor 
In Study III we addressed the problem of the low response rate to checkpoint 
inhibitors among treated patients.  
Immune checkpoint inhibitors are able to protect T-lymphocytes from exhaustion 
and, in some cases, to revert their dysfunctional state. However, many patients fail 
to respond to therapy with ICIs due to the lack of pre-existing infiltration of T-
lymphocyte within the tumor. Therefore, the current challenge is to maximize the 
benefit that patients can have from this expensive treatment. For this reason, 
combining checkpoint inhibitors with active immunotherapy that would attract 
and activate lymphocyte is the main aim of combinational therapies. In this 
context, we decided to study if the oncolytic vaccine platform PeptiCRAd would 
improve the overall response to ICIs therapy.  
 
4.12.1. Evaluation of immunogenicity of B16OVA and 4T1 tumor models. 
We investigated if the widely used neo-antigen tumor model B16.OVA and the 
poorly immunogenic triple negative breast cancer model 4T1 would modulate the 
expression of PD-L1 in response to immunotherapy. To this end, the two cell lines 
were seeded and cultured overnight in absence or presence of IFNγ and the levels 
of PD-L1 on their surface was measured by flow cytometry. Both the cell lines 
express high levels of PD-L1 in their steady state. In fact, 67 % of B16.OVA cells 
and 60% of 4T1 cells stain positive for the immune checkpoint. Interestingly, upon 
exposure to IFNγ, the percentage of PD-L1 positive cells rose to 79 and 98 % of 
cells for B16.OVA (Study III; figure 1A) and 4T1 (Study III; figure 4) cell lines 
respectively. This aspect is very important as highlighted recently by Antony Ribas 
at the latest AACR 2017 conference as a result of their clinical study on mutations 
involving the IFN signalling pathway within the tumor cells [186]. The authors 
investigated clinical cases of acquired resistance to PD-1 therapy and described 
how tumor cells use IFNγ to upregulate their PD-L1 surface levels, thus protecting 
them from T-cell killing. Subsequently, tumor cells accumulate mutations that 
abrogate IFN signalling, exploiting other immune suppressive pathways; hence 
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anti-PD-1 or anti-PD-L1 therapy becomes ineffective. Although B16.OVA and 
4T1 cell lines represent imperfect murine tumor models, their ability to respond to 
pro-inflammatory stimuli and upregulate PD-L1 on their surface make them a 
relevant model to study immune checkpoint inhibitors. 
 
 
In addition, we characterized the T-lymphocytes that infiltrate the tumors formed 
in vivo by these cell line. In particular, we evaluated the presence of the PD-1 and 
TIM-3 markers on the surface. PD-1 receptor is absent from the surface of näive 
T-cells but it is readily upregulated upon TCR engagement [187] while TIM-3 is 
mostly associated with exhausted T-cells [188]. First, we observed that the 
expression of PD-1 is higher on CD8 T-lymphocytes when compared to CD4 T-
lymphocytes (Study III; figure 1 B). In particular, the expression of PD-1 on CD8 
T-lymphocytes is highest in the tumors than in lymphoid organs. Similar results 
were observed also within tumor formed by 4T1 cells as shown in Study III figure 
4C (right panel). In fact, we found that 80 % of CD8+ cells was positive for PD-
1 in the tumors, while less than 20 % of CD8+ cells was PD-1+ in secondary 
lymphoid organs. This gave us useful indications on the nature of the model and 
its responsiveness to checkpoint blockade.  
Next, we wanted to evaluate the relationship between different subsets of 
lymphocytes as regards the exhaustion and activation state. We classified T-
lymphcoytes as being antigen-experienced but not exhausted (PD-1+TIM-3-; Act) 
and as being exhausted (PD-1+TIM-3+; Ehx). Hence, we performed a correlation 
analysis according to Pearson's Coefficient. A positive coefficient, indicates a 
positive correlation, whether a negative coefficient indicates a negative correlation. 
Interestingly, we found that the presence of activated but non-exhausted CD4 T-
lymphocytes (Study III; figure 1 C, left side) positively correlated with the 
presence of activated CD8 T-lymphocytes within the tumor. On the contrary, the 
presence of exhausted CD4 T-lymphocytes positively correlated with the presence 
of exhausted CD8 T-lymphocytes.  
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Taken together these results show that the both B16.OVA and 4T1 models 
respond to IFNγ by upregulating PD-L1 expression on their surface and the in vivo 
formed tumors host CD8+ cells which express PD-1. These cells can be eventually 
target of the PD-L1 blockade and protected from exhaustion. 
 
 
4.12.2. Increasing the response to PD-L1 blockade in melanoma with oncolytic 
vaccines. 
Next, we studied if active immunotherapy would enhance the response to 
checkpoint inhibition. To this end, we combined PeptiCRAd targeting the model 
epitope SIINFEKL with injection of anti-PD-L1 antibody (i.e. Combo treatment). 
However, compared to Study I, the route of administration of PeptiCRAd was 
modified to mimic a non-injectable lesion model; hence, PeptiCRAd was 
administered subcutaneously rather than intratumorally. This different route of 
administration abolished the efficacy of the oncolytic vaccines, as shown in figure 
2A. The anti-PD-L1 treatment reduced the growth of tumors compared to 
controls, however, its combination with PeptiCRAd significantly increased the 
efficacy of anti-PDL1 therapy (purple curve) as represented also in the comparison 
of the area under the curve (Study III; figure 2 B). Mice in these two groups were 
re-challenged with parental B16 cells, and we observed a significantly reduced 
growth of tumors on mice receiving the Combo treatment (Study III; figure 2 
C). Interestingly, not only the median survival of mice was improved by 
combination therapy (36 days for Combo group versus 21.5 days for aPDL1 
group) but also number of complete responses was higher (Study III; figure 2 E). 
In fact, we registered 3/8 complete responses in Combo group versus only 1/7 
complete responses in aPDL1 group. The response rate was also improved, as 87,5 
% of mice treated with combo therapy showed a tumor volume lower than 1000 
mm3 compared to 42,8 % in aPDL1 group (Study III; Figure 2 F). 
The high prevalence of neutralizing antibodies against adenoviruses in the human 
population prompted us to investigate if the Combination therapy would be 
effective in pre-immunized mice. We observed no differences as regards the 
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overall tumor growth between pre-immunized mice (PEI-Combo) and naïve mice 
(Combo) as shown in Study III figure 2 G. The overall survival was not affected 
significantly as both therapies were more effective than mock (Study III; Figure 
2 H). 
 
4.12.3. Immunological effects of combining checkpoint inhibition with oncolytic 
vaccines. 
We investigated the immunological effects of the combination of anti-PD-L1 
therapy and PeptiCRAd. First, we explored the activation and exhaustion state of 
T-cells. In particular, we followed the same phenotypic scheme according to which 
activated but non-exhausted cells are PD-1+ and TIM-3-, while exhausted cells are 
PD-1+ and TIM-3+.  
As we show in figure 3 A of Study III we observed an increased presence of 
activated CD8+ T-lymphocytes (blue bars) in mice treated with Combo and 
PeptiCRAd compared to Mock (p<0.05). Accordingly, mice treated with placebo 
showed the highest percentage of exhausted TILs (green bars). Interestingly, cells 
positive only for the TIM-3 marker were not detected in our assay (red bars).  This 
is an important finding as is supports the theory that TIM-3 expression is 
consequential to the upregulation of PD-1 and that PD-1 resistant tumors might 
be treated with TIM-3 blockade. 
Subsequently, we studied the presence of antigen-specific T-lymphocytes. As 
described previously in Studies I and II, SIINFEKL-specific CD8+ T-cells can be 
detected by Pentamer staning. Hence, we analysed the presence of these cells 
within the tumor microenvironment. As we hypothesized, mice receiving the 
PeptiCRAd oncolytic vaccine (PeptiCRAd-OVA and Combo groups) showed a 
significantly increased presence of antigen-specific cells compared to control 
groups (Study III; figure 3 B). Interestingly, when we analysed the state of these 
SIINFEKL-specific CD8+ T-cells we observed a statistically significant increase 
in the ratio of activated to exhausted cells in mice treated with Combination 
therapy (p=0.0058) (Study III; Figure 3 C)  
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4.12.4. Triple negative breast cancer responds to oncolytic vaccines targeting 
MHC-I and II epitopes. 
Having demonstrated the beneficial effect of combining PD-L1 blockade with 
oncolytic vaccines in an immunogenic model, we sought to investigate if this 
combination would also be effective against a poorly immunogenic tumor. To this 
end, we decided to study a triple negative breast cancer (TNBC) model, such as 
the murine 4T1 and the human MD-MBA-436 cell lines. First, we studied the 
expression of MHC molecules in order to understand whether or not the poor 
immunogenicity could be explained by lack of MHC molecules on the surface. As 
shown in supplementary figures 1A and 1B of Study III, we found a sustained 
expression of both MHC-I and MHC-I molecules.  
The presence of MHC molecules on the surface of 4T1 cells confirmed that they 
might be targeted by T-cells. To this end, we decided to include in our oncolytic 
vaccine neo-epitopes that have been described in literature [189]. In particular, we 
investigated if the stimulation of both CD4+ and CD8+ T-cells would improve 
upon treatment with only CD4 or CD8 restricted peptides. Therefore, we 
engrafted Balb/c mice with 4T1 tumor cells and treated their tumors 9 days after 
with placebo solution (Mock) or PeptiCRAd with MHC-I-restricted peptides 
(PeptiCRAd+I) or with MHC-II-restricted peptides (PeptiCRAd+II) or a 
PeptiCRAd created with a mixture of both class I and II epitopes (PeptiCRAd-
I+II). Mice treated with the oncolytic vaccine targeting both class I and II epitopes 
showed a reduction of tumor volumes when compared to mock until day 15. 
However, due to heavy ulceration of tumors, mice had to be sacrificed. Hence, 
despite the marginally improved anti-tumor efficacy, the tumors could not be fully 
controlled (Study III; Figure 4 A). This prompted us to investigate if the reason 
could be a heavily immunosuppressive environment. Thus, we analysed the surface 
expression of PD-L1 molecule and found that the 4T1 cell line feature high 
expression of this immune checkpoint ligand, which is inducible upon exposure to 
IFNγ (Study III; Figures 4B, left and right panels). In addition, tumors of 
engrafted mice, showed a very high degree of staining, with almost 100% of 
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analysed cells being positive for PD-L1 on their surface (Figure 4C, left and right 
panels). 
To further understand if CD4+ and CD8+ T-cells could have been targeted by 
this inhibitory pathway, we analysed the expression of the PD-1 receptor. T-helper 
cells featured a higher expression of PD-1 within the tumor and draining lymph 
nodes compared to spleen (Figure 4D, left panel). In sharp contrast, we find the 
majority of PD-1+ CD8+ TILs in the tumor microenvironment. In fact, while 
only about 17% of CD8+ cells were PD-1+ in the spleen and draining lymph node, 
85% of CD8+ T-cells were PD-1+ in the tumor (Figure 4D, right panel). 
Taken together, these results show that it is possible to achieve an increased anti-
tumor response when stimulating both arms of the cellular immune response by 
treatment with both MHC-I and II epitopes. However, the poorly immunogenic 
tumors escape the growth control through immune suppressive pathways, such as 
the PD-1/PD-L1 axis. In this mode, PD-L1 is upregulated in response to the pro-
inflammatory signals mediated by IFNγ, and both CD4 and CD8 TILs are 
inhibited through the engagement of PD-1 receptor on their surface. 
 
4.12.5. Oncolytic vaccines increase the response to PD-L1 blockade in a model 
of triple negative breast cancer. 
The results from the previous in vivo experiment showed how poorly immunogenic 
tumors are resistant to advanced cancer vaccines and they activate immune 
suppressive pathways in order to limit the efficacy of immune responses. This 
aspect represents a strong rationale to combine oncolytic vaccines with PD-L1 
blockade to treat TBNC. In particular, recent studies highlighted how infiltration 
of immune cells might represent a predictive marker of response to ICIs. 
Therefore, the possibility to attract within the tumor immune cells with oncolytic 
vaccines can potentially increase the number of responders to ICIs. As shown in 
figure 5A of Study III, monotherapy with an anti-PD-L1 antibody increased the 
number of responding mice moderately compared to mock. In fact, only 37.5 % 
of treated mice showed a tumor volume lower of 200 mm3 at the endpoint. In 
contrast, mice receiving both anti-PD-L1 therapy and PeptiCRAd-I+II vaccine 
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responded in 62.5 % of the cases. This result highlights how it is extremely 
important to combine ICIs with active immune therapies that can activate and 
attract immune cells within the TME. In fact, tumors of mice treated with the 
combination treatment featured a more favourable CD8/CD4 ratio of cells. As 
shown in figure 5B of Study III with 96.86 % of lymphocytes being CD8+ and 
only 3.14% being CD4+. In addition, tumors of mice receiving aPD-L1 and 
PeptiCRAd-I+II were significantly more infiltrated with myeloid-derived 
suppressor cells with a neutrophil profile (defined as CD11b+ Ly6Ghigh and 
Ly6Cintermediate/high) which have been associated with direct cytotoxic activity against 
tumor cells (Study III; Figure 5C). 
 
4.12.6. Efficacy of combination of active immunotherapy and checkpoint 
blockade in a translational model of co-culture of human PBMCs and human 
tumor cell lines 
 
In order to evaluate the combination of active immunotherapy and checkpoint 
inhibition in a translational model, we performed a co-culture experiment featuring 
human PBMCs and human tumor cell lines. Mimicking a clinically relevant 
treatment schedule, we pre-stimulated the PBMCs with the oncolytic vaccine 
PeptiCRAd targeting the antigen MAGE-A1 (for the melanoma) or the antigen 
MAGE-A4 (for the TNBC), then we incubated the PBMCs with the tumor cell 
lines in presence or absence of anti-PD-L1 antibody. In both cases, the 
combination of the two therapies increased the killing activity of the PBMCs of 20 
and 40 % against the melanoma and the TBNC tumor cells respectively (Study 
III; Figure 5D). This experiment confirms that the activity of the anti-tumor T-
cells, primed with oncolytic vaccines, can be preserved by blocking the PD-1/PD-
L1 axis. Hence oncolytic vaccines and checkpoint inhibitors can synergize indeed 
and should be combined to maximize their efficacy. 
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CONCLUSIONS AND FUTURE PROSPECTS 
 
The last five years have seen an incredible expansion of the use of immunotherapy 
for the treatment of cancer with many first-in-class drugs being approved for the 
clinical use. Ipilimumab (aCTLA-4), Nivolumab (aPD-1), Yescarta (anti-CD19 
CAR-Tcells), Imlygic (Oncolytic Herpes Virus) are few examples of an expanding 
array of tools that oncologist can use to fight cancer by exploiting the patient´s 
own immune system. 
Unfortunately, achieving full efficacy by using only one of the above-mentioned 
approaches is difficult and combination therapies are expected to be the future of 
immune therapy. A remarkable example of how combining therapies can improve 
the outcome is testing of Imlygic with Pembrolizumab in patients with advanced 
melanoma [190] which is being tested in the KEYNOTE-034 clinical study 
sponsored by Amgen (www.clinicaltrial.gov). Despite few adverse events due to 
immune activation, the study is recording a striking 62% of confirmed objective 
response with a 33% of complete responses. 
 
The studies described in this thesis faced some of the limitations of oncolytic 
vaccines, cancer vaccines and checkpoint inhibitors. By improving the vaccine 
platforms available I expect an increased synergy with drugs that are able to 
reshape the tumor microenvironment, such as checkpoint inhibitors. However, I 
believe that immunotherapy should also take into account the personal 
immunogenic signatures of tumors. At the moment few technologies are available 
to discover neo-antigens: Whole-Exome Sequencing, total RNAseq or ligandome 
analysis. Although they have not been a topic of study of this thesis, our research 
group is focusing on ligandome analysis and its optimization. This will provide a 
platform that would give precise guidelines when designing oncolytic vaccines and 
it might represent the missing piece of the puzzle in the fight of cancer. 
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In conclusion, a multimodal approach that takes into consideration the tumor 
heterogeneity, patient immune profiling, neo-antigens and tumor 
microenvironment represents a promising direction that might potentially lead to 
an increased response rate among cancer patients. This aim should always be at 
the centre of our work as researchers and, most importantly, as human beings 
working to impact the society in a significant way. 
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ABSTRACT
The stimulation of the immune system using oncolytic adenoviruses (OAds) has attracted signiﬁcant
interest and several studies suggested that OAds immunogenicity might be important for their efﬁcacy.
Therefore, we developed a versatile and rapid system to adsorb tumor-speciﬁc major histocompatibility
complex class I (MHC-I) peptides onto the viral surface to drive the immune response toward the tumor
epitopes. By studying the model epitope SIINFEKL, we demonstrated that the peptide-coated OAd
(PeptiCRAd) retains its infectivity and the cross presentation of the modiﬁed-exogenous epitope on MHC-I
is not hindered. We then showed that the SIINFEKL-targeting PeptiCRAd achieves a superior antitumor
efﬁcacy and increases the percentage of antitumor CD8C T cells and mature epitope-speciﬁc dendritic
cells in vivo. PeptiCRAds loaded with clinically relevant tumor epitopes derived from tyrosinase-related
protein 2 (TRP-2) and human gp100 could reduce the growth of primary-treated tumors and secondary-
untreated melanomas, promoting the expansion of antigen-speciﬁc T-cell populations. Finally, we tested
PeptiCRAd in humanized mice bearing human melanomas. In this model, a PeptiCRAd targeting the
human melanoma-associated antigen A1 (MAGE-A1) and expressing granulocyte and macrophage colony-
stimulating factor (GM-CSF) was able to eradicate established tumors and increased the human MAGE-A1-
speciﬁc CD8C T cell population. Herein, we show that the immunogenicity of OAds plays a key role in their
efﬁcacy and it can be exploited to direct the immune response system toward exogenous tumor epitopes.
This versatile and rapid system overcomes the immunodominance of the virus and elicits a tumor-speciﬁc
immune response, making PeptiCRAd a promising approach for clinical testing.
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melanoma; oncolytic
adenovirus; oncolytic
vaccine; tumor epitopes
Introduction
OAds selectively kill tumor cells 1,2 countering tumor
growth and favoring the spreading of damage-associated
molecular patterns (DAMPs) that can, under certain
circumstances, lead to the activation of surrounding
antigen-presenting cells (APCs) 3,4 and some degrees of
expansion of tumor-speciﬁc T-lymphocytes.5 However, the
lack of sufﬁcient number of tumor-speciﬁc T cells and
immunosuppressive mechanisms limits the efﬁcacy of
OAds.6 More sophisticated oncolytic vectors encode for
immune-modulating molecules such as IL-23,7 TNFa,8
CD40L,9,10 or GM-CSF.5,11,12 In addition, to further
improve the speciﬁcity of the immune response, adenovi-
ruses encoding for tumor antigens have been designed.13
The efﬁcacy of these oncolytic agents, however, depends on
their persistence into the patients and their transduction
efﬁciency, which is a common limitation for all adenoviral
vectors used in clinical trials due to pre-existing immunity
14 and the rapid production of neutralizing antibodies.15 In
addition, the time required for the genetic manipulation of
the different viruses encoding for different antigens and the
consequent re-evaluation by the competent authorities
(FDA and/or EMEA) makes this approach incompatible
with next generation of personalized approaches that rely
on the identiﬁcation of patient-speciﬁc antigenic signatures
to adapt immunotherapeutic protocols.
To this end, we speciﬁcally developed a novel oncolytic
vaccine platform in which tumor peptides are not expressed by
the virus and are not part of the viral proteins, in contrast to
the vast majority of current approaches. The peptides are
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instead adsorbed onto the viral capsid, allowing for the efﬁcient
co-delivery of adjuvant (virus) and tumor-speciﬁc epitopes
(Fig. 1). Thus, the oncolytic virus acts as an “active” carrier that
is able to kill tumor cells and to boost the immunological
response against the chosen antigen. This method does not
involve chemical or genetic modiﬁcation of the virus, signiﬁ-
cantly increasing the rapidity and the versatility of the prepara-
tion. As a direct consequence, this system addresses the need
for tumor-speciﬁc and even personalized therapies that could
account for the expression of different antigens in different
patients or different antigens in different stages of the same
tumor.
In this study, we characterized the physical and biological
properties of Peptide-coated Conditionally Replicating Adeno-
viruses (PeptiCRAds). We demonstrated that by absorbing
tumor-speciﬁc MHC-I-restricted peptides onto the viral capsid,
we can direct the immunity toward the tumor, leading to a
signiﬁcantly increased efﬁcacy in different models of murine
melanoma and human melanoma in humanized mice. Pepti-
CRAd represents a novel oncolytic vaccine platform that is able
to fully exploit the immunogenicity of OAds and that can be
rapidly adapted to different antigens and tumors without any
genetic modiﬁcation.
Results
The negative charge of the adenovirus capsid can be used
to complex positively charged immunogenic peptides,
forming PeptiCRAd
Adenovirus capsids is negatively charged 16 bearing mostly
acidic/negative regions in the hexon protein (red and pale red
regions in Fig. S1), thus we hypothesized that MHC-I-restricted
peptides, modiﬁed to become positively charged, would bind to
the capsid of the virus via electrostatic interactions. We tested
our hypothesis by using the MHC-I epitope SIINFEKL derived
from chicken ovalbumin (OVA).17 The addition of a poly-
lysine (polyK) chain to the aminoacidic sequence increases the
net charge of the peptide from 0 to C6 mV at neutral pH
(Fig. 2A). Next, we coated APTES silica SiO2 sensor with OAds
(Fig. S2A) and we injected increasing concentrations of SIIN-
FEKL or polyK-SIINFEKL into the surface plasmon resonance
(SPR) system (Fig. 2B). No virus-peptide interaction was
observed with the unmodiﬁed neutral SIINFEKL (Fig. 2B,
dashed line), whereas a concentration-dependent interaction
was observed with the modiﬁed positive polyK-SIINFEKL
(Fig. 2B, solid line). In these experimental settings, we observed
a plateau when using solutions of peptide with a concentration
above 7 uM. We found that the binding model for these
Figure 1. Schematic of PeptiCRAd (Peptide-coated Conditionally Replicating Ade-
novirus). PeptiCRAd is a novel cancer vaccine platform that exploits the natural
immunogenicity of adenoviruses. OAds act as adjuvants for exogenous MHC-I
tumor epitopes that are loaded onto the viral capsid by electrostatic interactions.
These peptides could be known MHC-I epitopes or patient-derived tumor epitopes.
Therefore, PeptiCRAd retains all the properties of a conventional oncolytic adeno-
virus (direct tumor-killing ability and possibility to express immune-stimulating
molecules), however, it has a superior ability to stimulate a tumor-speciﬁc immune
response.
Figure 2. Physical characterization of the interaction between the modiﬁed MHC-I epitope SIINFEKL and OAd. (A) The net charge of SIINFEKL (dashed gray line, circles) or
polyK-SIINFEKL (black line, triangles) is shown as a function of pH. (B) SPR was used to study the interaction between Ad5D24 oncolytic virus and increasing concentra-
tions (0.15, 0.3, 0.6, 1.2, 2.4, 7.2, and 21.6 mM) of either SIINFEKL (dashed line) or polyK-SIINFEKL (solid line). (C) zeta potential (dashed gray line, left axis) and hydrody-
namic diameter (solid black line, right axis) of virus-peptide complexes. Time-dependent study of complexs zeta potential (D) and hydrodynamic diameter (E) after
incubation at room temperature. Representative results from two different experiments are shown. The data are plotted as the mean § SD (n D 3).
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electrostatic interactions is a complex one, since high goodness
of ﬁt (R2D0,997) is observed only when applying a co-operativ-
ity model to the data (Fig. S2B). In addition, according to this
model, we were able to estimate a binding constant of
2.88 £ 10¡6 M and a Hill coefﬁcient of C2.68 indicating a
positive co-operativity.
Next, we studied how the amount of peptide in the coating
reaction could affect the OAds-peptide complexes (Fig. 2C).
The lowest OAds: peptide ratio (1:5) was able to increase the
charge of the viral particles from ¡29.7 § 0.5 to C6.3 §
0.06 mV, although under these conditions, heavy aggregation
was observed, as indicated by an increase in the size of the com-
plexes (800 § 13.5 nm). Above 1:5, the net charge reached a
plateau-like kinetic as we measured zeta potentials of C17.5 §
0.2, C18.4 § 0.1 and C18 § 0.8 mV for the 1:50, 1:100 and
1:500 ratios, respectively. However, only at a ratio of 1:500 the
hydrodynamic diameter of the complex decreased (reaching
~120 nm), which represents the normal diameter of adenoviral
particles. The complex presented good stability and no signiﬁ-
cant decrease of zeta potential occurred 30 and 45 min after
incubation in the same conditions (Fig. 2D) compared to
15 min incubation. In addition, we report no aggregation at
these time points (Fig. 2E) but only an increase in the hydrody-
namic diameter which can be caused by the increased presence
of water molecules on the particle. To prove that interaction is
not restricted to polyK-SIINFEKL peptide, we complexed the
adenovirus with another modiﬁed peptide, the polyK-MAGE
A1 epitope. We observed an increase of the zeta potential
(Fig. S2C) compared to the naked adenovirus and no aggrega-
tion (Fig. S2D) of the particles.
Modiﬁed MHC-I epitopes adsorbed onto peptiCRAd are
efﬁciently cross presented
Next, we investigated whether the presence and the position of
the polyK chain could affect the efﬁciency of cross presentation
of the epitope on MHC-I. We pulsed ex vivo-cultured spleeno-
cytes (from C57BL/6 mice) with two different lysine-extended
versions: polyK-SIINFEKL (N-terminus extended) and SIIN-
FEKL-polyK (C-terminus extended). As a negative control, we
included extended SIINFEKL containing an amino caproic
(AHX) residue, which is a well-known analog of lysine that can
inhibit the proteolytic activity of the proteasome. We then
assessed the cross presentation of the mature form of the epi-
tope (SIINFEKL) on MHC-I by ﬂow cytometry.18
The 94.5% of the spleenocytes pulsed with the N-terminus-
extended peptide cross-presented SIINFEKL. In contrast, when
the spleenocytes were pulsed with the C-terminus-extended
SIINFEKL-polyK, the stained population decreased to 27.1%
(Fig. 3A). Based on these ﬁndings, we chose the N-terminus-
extended version (polyK-SIINFEKL) for further studies.
Next, we investigated if the adsorption of the modiﬁed SIIN-
FEKL onto the viral capsid could affect its cross presentation.
As in the previous experiment, we incubated mouse spleeno-
cytes with the polyK-SIINFEKL or with OVA-PeptiCRAd (i.e.
OAd coated with polyK-SIINFEKL). We found that all the con-
ditions allowed for efﬁcient MHC-I-restricted presentation of
the SIINFEKL peptide (Fig. 3B).
PeptiCRAd shows increased infectivity compared with
unmodiﬁed viruses
We investigated whether coating the viruses with modiﬁed pep-
tides would affect their biological properties. We chose to study
a human colorectal adenocarcinoma cell line (CACO-2)
expressing low levels of coxsackie and adenovirus receptor
(CAR) a human melanoma cell line expressing intermediate
levels of CAR (A2058) and another human melanoma cell line
expressing high levels of CAR (SK-MEL-2). PeptiCRAd showed
unaltered oncolytic activity compared to naked Ad5D24 virus
(Fig. 4A) in all cell lines; in addition we observed no toxic effect
upon cell viability due to the modiﬁed polyK-SIINFEKL
peptide.
Next, we evaluated the infectivity of PeptiCRAd by immu-
nocytochemistry (ICC; Fig. 4B). Whereas, we did not observe
any signiﬁcant difference in SK-MEL-2 cell line, when testing
Figure 3. Cross-presentation of modiﬁed SIINFEKL analogs on MHC-I adsorbed or not adsorbed onto the viral capsid. (A) C57BL/6 fresh spleenocytes were incubated with
SIINFEKL, the amino caproic acid-containing SIINFEKL-AHX-polyK, the C-terminus-extended SIINFEKL-polyK or the N-terminus-extended polyK-SIINFEKL. Cross presentation
was determined with APC anti-H-2Kb bound to SIINFEKL or isotype control antibodies. (B) Similar to (A), spleenocytes were infected with of OVA-PeptiCRAd, or incubated
with peptides SIINFEKL or polyK-SIINFEKL. The data are shown as the mean § SD (nD2). Signiﬁcance was assessed using the unpaired students t-test;  p < 0.01,
 p < 0.001.
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in vitro models with intermediate (A2058) and low (CACO-2)
levels of CAR, PeptiCRAd showed a signiﬁcant increase
(p < 0.05) in infectivity compared with the naked adenovirus.
Characterization of the anti-tumor immunity and efﬁcacy
of PeptiCRAd in a murine model of melanoma
To thoroughly study the antitumor efﬁcacy of PeptiCRAd, we
ﬁrst used a murine model of melanoma over-expressing
chicken OVA (B16-OVA).17 A pilot experiment was performed
using an OAd bearing the D24 deletion in E1A (Ad5D24) 2
coated with the modiﬁed poly-K-SIINFEKL. We observed a sig-
niﬁcantly reduced tumor growth in mice treated with Pepti-
CRAd (Fig. S3). Therefore, we investigated further this model
by using a CpG-rich OAd (Ad5D24-CpG) 19 to further boost
immunity (Fig. 5) through Toll-like receptor 9 activation. The
study groups included mice treated with OVA-PeptiCRAd,
with non-complexed Ad5D24-CpG and SIINFEKL (Ad5D24-
CpGCSIINFEKL), with naked Ad5D24-CpG, with SIINFEKL
peptide alone or with saline solution (mock).
Intratumoral injections of PeptiCRAd signiﬁcantly reduced
the tumor’s growth compared with treatment with saline
buffer, SIINFEKL peptide or the mixture of OAd and SIIN-
FEKL. At the end of the experiment, the average volume of the
tumors in the OVA-PeptiCRAd-treated mice was signiﬁcantly
lower than in all other groups (Fig. 5A).
Next, we studied the immunological background, hypothe-
sizing that the increased antitumor efﬁcacy could be explained
by a more efﬁcient CD8C T cell response. To this end, we ana-
lyzed spleens (Fig. 5B), tumors (Fig. 5C) and draining lymph
nodes (Fig. 5D) of mice 7 and 16 d after the start of the treat-
ment (early and late time points respectively). At early time
point, the CD8C response against the SIINFEKL epitope was
generally low in spleens (Fig. 5B, left) and tumors (Fig. 5C,
left), with mice treated with SIINFEKL peptide alone showing
an increased trend. Mice treated with OVA-PeptiCRAd did not
show any increased SIINFEKL response in spleens and tumors
while we detected a larger population of epitope-speciﬁc CD8C
T cells in the draining lymph nodes (Fig. 5D, left) compared to
all other groups. At the end of the experiment (day 16), we
observed that mice treated with OVA-PeptiCRAd showed an
increased percentage of pentamer speciﬁc CD8C T cells in
spleens, tumors and lymph nodes (Figs. 5B, 5C and 5D on the
right).
Next, we studied the correlation between the immunological
response and the antitumor effect (Fig. 5E). We found that data
would ﬁt best to a non-linear model. According to the expo-
nential model, a very good correlation between tumor volumes
and CD8C-response was found in spleens (R2C0.9995); in
tumors and lymph nodes the correlation was still high but
slightly lower than in spleens. Interestingly, in the correlation
analyses, the PeptiCRAd group consistently showed the small-
est tumor volume and the greatest immunological response.
Finally, we evaluated the effect of PeptiCRAd vaccination on
professional antigen presenting cells 7 and 16 d after the start
of the treatment (early and late time points respectively). In
particular, we were interested in the proportion of dendritic
cells (DCs; CD19¡ CD3¡ CD11cC) showing a mature pheno-
type (CD86high) and presenting the SIINFEKL peptide on
MHC-I. We hypothesized that these cells might be the ones
responsible for direct CD8C T cell activation through the cross-
presentation mechanism. At the late time point, mice treated
with PeptiCRAd showed a signiﬁcantly higher percentage of
mature SIINFEKL-presenting DCs (p< 0.05) than mice treated
with the non-complexed Ad5D24-CpGCSIINFEKL (Fig. S4B).
When both time points are considered, PeptiCRAd induced the
biggest increase of CD86high OVAC DCs, 9.67-fold change
(Fig. 5F).
Multivalent PeptiCRAd shows enhanced antitumor activity
toward distant, untreated melanomas
Next, we studied the efﬁcacy of PeptiCRAd upon non-treated
contralateral melanomas and whether targeting two tumor
Figure 4. PeptiCRAd retains intact oncolytic activity and displays increased infectivity in cell lines with low CAR expression. (A) cell viability assay in different cell lines. The
data are shown as the mean § SD (n D 3). (B) Infectivity assay by ICC. Cells have been infected with 10 vp/cell of either naked OAd or OVA-PeptiCRAd. The average num-
ber of spots per visual ﬁeld is presented (5 non-overlapping visual ﬁelds have been acquired and used for the generation of the means). Representative data from two
independent experiments are shown as the mean § SD (n D 2). Signiﬁcance was assessed using the unpaired t-test with Welch’s correction;  p < 0.05.
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Figure 5. Antitumor efﬁcacy of PeptiCRAd and immunological analysis of antigen-speciﬁc CD8C T cells and DCs. C57BL/6 mice (nD8–9) received 3£105 B16-OVA cells in
both ﬂanks. Treatment was initiated nine days later and included saline solution (mock), peptide alone (SIINFEKL), virus alone (Ad5D24-CpG), a mixture of virus and SIIN-
FEKL peptide (Ad5D24-CpGCSIINFEKL), and Ad5D24-polyK-SIINFEKL complex (OVA-PeptiCRAd). Mice were treated three times (on days 0, 2, and 7; black arrows). At day
7, before the third injection, mice from each group were sacriﬁced for early immunological analysis (nD 2–3). The late immunological analysis was performed on samples
collected at the end of the experiment (tumors and spleens n D 3–4; lymph nodes n D 2–3). (A) Average tumor volume is represented excluding mice sacriﬁced at day 7.
The percentage of SIINFEKL-PentamerC cells among CD19¡CD8C T-cells is reported for spleens (B), tumors (C) and draining lymph nodes (D) at early (left panels) and late
(right panels) time points. Samples from Ad5D24-CpG group were collected at day 12. Data are presented as the mean § SD. (E) The average tumor size at the end of
the experiment was plotted against the average percentage of SIINFEKL-PentamerC CD8C T cells at late time point. A correlation analysis was performed using a non-lin-
ear exponential model and the R square value is reported for each set of data. (E) Dendritic cells (CD19¡CD3¡CD11cC) showing a mature proﬁle (CD86high) and cross-pre-
senting SIINFEKL on their H2-Kb was determined in the spleens 7 and 16 d after the start of the treatment. The fold change between the two time points is presented.
Statistical analysis was done using unpaired Mann–Whitney test; p < 0.05, p < 0.01.
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antigens (via multivalent PeptiCRAd) would increase the over-
all efﬁcacy. Therefore, we chose two polyK-modiﬁed versions
of the tumor-speciﬁc MHC-I-restricted epitopes SVYDFFVWL
(TRP-2180-188; restricted to the murine MHC-I molecule H-
2Kb) and KVPRNQDWL (human gp10025-33, or hgp100;
restricted to the murine MHC-I molecule H-2Db 20), both
expressed by B16-F10 cells.21
We ﬁrst implanted 1£105 B16-F10 cells into the right
ﬂank of C57BL/6 mice (Fig. 6A). After 10 days, intratu-
moral treatments were initiated as follows: (i) saline solu-
tion (mock), (ii) naked oncolytic virus (Ad5D24-CpG),
(iii) single-coated hgp100-PeptiCRAd, (iv) single-coated
TRP-2-PeptiCRAd, and (v) double-coated TRP-2-
hgp100-PeptiCRAd. Two days after the last treatment, we
injected 3£105 B16-F10 cells into the left ﬂank of the
mice (Fig. 6A). The double-coated PeptiCRAd signiﬁ-
cantly reduced the growth of the primary tumors com-
pared with the other control groups (Fig. 6B). When
analyzing the size of the secondary-untreated tumors, we
observed an increased efﬁcacy of all three PeptiCRAds.
The overall growth of the secondary tumors was signiﬁ-
cantly reduced by the double-coated PeptiCRAd
(Fig. S5). In particular, the secondary tumors of mice
treated with TRP-2-hgp100-PeptiCRAd were signiﬁcantly
smaller compared with those in the controls receiving
saline solution (p < 0.01) or only Ad5D24-CpG (p <
0.05; Fig. 6C). Although not statistically signiﬁcant, the
improved antitumor efﬁcacy on the secondary melano-
mas was noticed also when comparing the double-tar-
geted PeptiCRAd to both the single-targeted ones.
To better clarify the mechanisms underpinning these results,
we performed a ﬂow cytometry analysis to study the speciﬁc
CD8C T cell populations. In mice treated with TRP-2-hgp100
PeptiCRAd, we observed the largest cumulative relative
response of epitope-speciﬁc CD8C T cells in mice treated with
TRP-2-hgp100-PeptiCRAd (Fig. 6D).
Taken together, these results demonstrate that the Pepti-
CRAd approach is effective against a less immunogenic and
more aggressive melanoma model. In addition, targeting multi-
ple antigens might be important to increase the outcome of this
therapeutic protocol.
PeptiCRAd displays enhanced efﬁcacy and antitumor
immunity in humanized mice bearing human tumors
Finally, we studied PeptiCRAd in a clinical-relevant model. To
this end, we ﬁrst engrafted triple-knockout mice (NOD.Cg-
Prkdcscid-IL2rgtm1Wjl/SzJ, or NSG) with the human melanoma
cell line SK-MEL-2 and then HLA-A3 matched human periph-
eral blood mononuclear cells (PBMCs) from a healthy donor
were injected into the same mice intravenously. One day after,
mice were treated with PeptiCRAd, uncoated virus or saline
solution. We chose an epitope derived from MAGE-A196-104
(SLFRAVITK) and modiﬁed it to allow for interaction with the
viral capsid (polyK-SLFRAVITK). To maximize the stimulation
of the engrafted human immune system, we selected an OAd
expressing human GM-CSF.5
As expected, both viruses performed better than the control
mock, however, we found the MAGE-A1 PeptiCRAd to be sig-
niﬁcantly more effective when compared to the uncoated virus
Figure 6. Targeting two tumor antigens with PeptiCRAd reduces the growth of both treated and untreated tumors. (A) C57BL/6 mice received 1£105 B16-F10 melanoma
cells on the right ﬂank and 3£105 B16-F10 cells on their left ﬂank two days after the last treatment. Only the right tumor was treated. (B) The growth of the primary
(right) tumor is presented as the mean § SD (n D 6–7). (C) The size of the secondary (left) tumors at the end of the experiment is reported for each individual mouse.
Tumor size oh hgp100-PeptiCRAd group is referred to day 11 before euthanasia of the group of mice. (D) The percentages of TRP-2- and hgp100-speciﬁc CD8C T cells in
spleens and inguinal lymph nodes form each mouse were normalized against mock, stacked into single columns and presented as the cumulative relative response for
each experimental group. Samples from hgp100-PeptiCRAd group were collected at day 11. Signiﬁcance was assessed by using the unpaired Mann–Whitney test; p <
0.05; p < 0.01.
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(Fig. 7A). In fact, we observed a rapid rejection of the tumors in
mice treated with PeptiCRAd as shown by the area under the
curve for each group of mice (Fig. 7B). Interestingly, when the
same experiment was repeated in mice without a human
immune system, no clear difference was observed between Pep-
tiCRAd and the uncoated virus (Fig. 7C) suggesting the impor-
tant role of the immune system in the efﬁcacy of our cancer
vaccine platform. To explore this hypothesis, we studied the
presence of human MAGE-A196-104-speciﬁc CD8
C T cells by
pentamer staining (Fig. 7D). We found the largest population
in the spleens of humanized mice treated with MAGE-A1
PeptiCRAd.
These data conﬁrm our previous ﬁndings: PeptiCRAd plat-
form is more effective than uncoated viruses as the oncolytic
activity cooperates synergistically with immune system activa-
tion, hence improving the efﬁcacy of oncolytic vaccine in a clin-
ically relevant model.
Discussion
Personalized approaches are necessary to increase the success
rate and, most importantly, to avoid the side effects associated
with powerful 22-24 but unspeciﬁc immunotherapies.25 OAds
are an attractive platform thanks to their natural immunoge-
nicity. However, the time required for the genetic and struc-
tural manipulation of these viruses represent a major limitation
for their use in personalized approaches. Therefore, we focused
on the development of a new and versatile cancer vaccine plat-
form based on OAds coated with MHC-I epitopes.
Coating the viral capsid with different polymers and materi-
als is a widely used approach to increase the infectivity of
adenoviruses 26 or to reduce the interaction with neutralizing
antibodies. The rationale behind our system is different since
we aim at improving conventional OAds by using them as
tumor killing adjuvants for the peptides used to coat their sur-
face. We ﬁrst demonstrated that positive tumor epitopes bind
the negative viral capsid electrostatically and that the modiﬁed
MHC-I epitope (i.e. polyK-SIINFEKL) can be cross presented.
Interestingly, the position of the polyK chain in the peptide
sequence has an important effect on the cross presentation. In
fact, C-terminus-extended epitopes are cross presented with a
signiﬁcantly lower efﬁciency compared with their N-terminus-
extended counterparts. These results can be explained by con-
sidering that classical and non-classical cross-presentation
mechanisms cooperate inside APCs. In fact, while the C-termi-
nus-extended epitope need to undergo the classical protea-
some-dependent cross-presentation pathway,27 the N-terminus
extended versions can take advantage of a faster alternative
pathway thanks to the presence of amino peptidases into the
phagosomes from the endoplasmic reticulum.28 Hence, our
results are consistent with other studies showing that the
sequences ﬂanking a mature epitope affect its cross
presentation.29
We found that the infectivity of PeptiCRAd is enhanced in
cell lines with low CAR expression. Previous studies demon-
strated that the surface modiﬁcation could affect the transduc-
tion efﬁcacy of adenoviral vectors.16,30,31 In the case of
PeptiCRAd, the positive peptides bring multiple residues of
lysine that can neutralize the acidic/negative zones of the viral
Figure 7. Efﬁcacy of PeptiCRAd in humanized mice bearing human melanomas. Humanized and non-humanized mice bearing SK-MEL-2 human melanomas were treated
with one of the following: (i) saline solution (mock), (ii) Ad5D24-GM-CSF, and (iii) MAGE-A1 PeptiCRAd. The tumor volume of the humanized mice (A) is presented as the
mean § SD (n D 3). (B) The area under the curve (AUC) relative to the size of the tumors of humanized-mice is presented. (C) The tumor volume of non-humanized mice
(nD 2) is reported as the mean § SD. (D) Percentage of MAGE-A1-speciﬁc CD8C T cell population is presented as the mean § SD (n D 2). Mann-Whitney test; p< 0.05.
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capsid. Hence, with less interference, the remaining positive
areas could now favor the interaction of the capsid with the
negative cell membrane and this phenomenon becomes
important when the expression of CAR is limited.
To study the antitumor efﬁcacy of the immunogenicity of
OAds dissociated from the oncolysis, we chose a murine model
of melanoma in which the human adenovirus serotype 5 is
unable to replicate.8 Mice treated with OVA-PeptiCRAd
showed a signiﬁcantly decreased tumor growth and a larger
antigen-speciﬁc immune response compared to control. Similar
results have been reported for naked armed oncolytic viruses.8
However, in all our experiments PeptiCRAd was more effective
than naked OAds. Our data suggest that the increased efﬁcacy
of PeptiCRAd could be due to mediated by a modulation of
APCs that could uptake the virus-epitope complex. This would
eventually cause the maturation of these cells, mainly due to
the adenoviral-danger signals, and the cross presentation of the
epitopes that are bound to the viral surface. In fact, we showed
in vivo that the proportion of DCs that were activated and
cross-presenting SIINFEKL was signiﬁcantly increased in the
group of mice treated with PeptiCRAd. These results are con-
sistent with current knowledge of other vaccine systems 32 and
with a recent work showing that adjuvant-antigen complexes
are more effective than the single components because of supe-
rior targeting of APCs and, in particular, DCs.33 These results
clearly show that the immunogenicity of OAds provides antitu-
mor efﬁcacy in absence of oncolysis, which was thought to be
the only mode of action of OAds.
Next, we studied a more relevant tumor model by using
B16-F10 tumors and targeting real tumor antigens rather
than an artiﬁcial one (i.e. chicken OVA). We found that
targeting two tumor antigens results in a broader immuno-
logical response that could explain the increased efﬁcacy of
TRP-2-hgp100-PeptiCRAd in controlling the growth of dis-
tant untreated tumors. Targeting multiple tumor antigens is
important to limit the escape of malignant cells from
immune surveillance 34 and to manage the variability of
tumor cells.35 In fact, clinical trials have shown that patients
who responded to multiple tumor epitopes are signiﬁcantly
more likely to experience stable disease or a partial
response.36 In addition, the multivalent approach is particu-
larly useful if the tumor down regulates one antigen or one
type of HLA during the therapy.37
Finally, we used a clinically relevant in vivo model: mice
bearing human melanomas and engrafted with a human
immune system. This was still not an optimal solution as the
development of graft-versus-host responses and the decrease of
functional engrafted immune cells restricted the experimental
window. For this reason, we started the treatment even if
tumors showed a smaller volume compared to other experi-
ments. Nevertheless, humanized mice represent the only model
that allows for the study of both immunological properties and
oncolytic activity of human OAds. We observed that Pepti-
CRAd could completely cure melanomas of all humanized
mice, whereas in non-humanized mice, PeptiCRAd lost its
advantage over the normal OAd. These interesting results high-
light once again the complex interaction between OAds and the
immune system. We have to consider that the immunity
attempts to clear the OAds from the host, playing in this sense
against the oncolytic virus and in favor of the tumor. Therefore,
in absence of the immune system, both viruses are effective,
whereas in presence of the immune system PeptiCRAd has a
signiﬁcant advantage. In support of this, the analysis of the epi-
tope-speciﬁc CD8C T cell population revealed an increased
anti-MAGE-A1 response in mice treated with MAGE-A1 Pep-
tiCRAd compared to other control groups. In this sophisticated
model, we could appreciate the synergistic relationship between
oncolysis and the immunogenicity of oncolytic viruses. In 2006,
it was shown that cells infected by OAds undergo a particular
cell death program that is characterized by autophagy and
spreading of immunogenic signals (ATP and HMGB1 release
and calreticulin exposure).38 Along the same line of research,
recent studies attempted to exploit the immunogenic cell death
(ICD) promoted by OAds to increase the efﬁcacy of cancer
virotherapy.8,39 We conclude that PeptiCRAd system largely
beneﬁts from the oncolytic activity of OAds but does not relies
on it completely.
In summary, tumor-speciﬁc MHC-I-restricted epitopes can be
complexed to an OAd, and these particles can act as a novel
oncolytic vaccine platform. The possibility to target multiple
antigenic entities simultaneously, improves upon the lack of
speciﬁcity of most current immunotherapies. The clear advantage
of this approach is its versatility, as no genetic and structural
modiﬁcations of OAds are needed foster a powerful tumor-spe-
ciﬁc response and eventually re-direct it to other antigens. This
gives the PeptiCRAd platform a clear advantage upon the classic
antigen-expressing oncolytic vectors when considering highly
personalized cancer vaccine immunotherapies.
Materials and methods
Cell lines, reagents, and human samples
The human lung carcinoma cell line A549, the human CACO-2,
the human malignant melanoma cell line SK-MEL-2, the human
melanoma cell line HS294T and the mouse melanoma cell line
B16-F10 were purchased from the American Type Culture Col-
lection (ATCC; Manassas, VA, USA). The cell line B16-OVA,17
a mouse melanoma cell line expressing chicken OVA, was kindly
provided by Prof. Richard Vile (Mayo Clinic, Rochester, MN,
USA). All cell lines were cultured under appropriate conditions.
SIINFEKL (OVA257-264), polyK-SIINFEKL, SIINFEKL-
polyK, polyK-AHX-SIINFEKL, polyK-SVYDFFVWL (TRP-
2180-188), polyK-KVPRNQDWL (hgp10025-33), and polyK-
SLFRAVITK (MAGE-A196-104) peptides were purchased from
Zhejiang Ontores Biotechnologies Co. (Zhejiang, China).
The net charge of peptides was calculated by the Peptide
Property Calculator Ver. 3.1 online tool.40
The HLA genotype of the SK-MEL-2 cell line was HLA-
A03 - 26; B35 - 38; C04 - 12. Buffy coat from a healthy
donor was also obtained from the Finnish Red Cross service,
and the genotype was determined as HLA-A03 - 03; B07 -
27; C01 - 07.
OAd preparation
All OAds were generated, propagated, and characterized using
standard protocols, as previously described.41
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All viruses used in this study have been previously reported:
Ad5D24 is an adenovirus that features a 24-base-pair deletion
(D24) in the E1A gene,2 Ad5D24-CpG is an OAd bearing a
CpG-enriched genome in the E3 gene,19 and Ad5D24-GM-CSF
is an OAd expressing GM-CSF under the control of the viral
E3 promoter.5
PeptiCRAd complex formation
All PeptiCRAd complexes described in this work were prepared
by mixing oncolytic viruses and polyK-epitopes at a 1:500 ratio
according to the following protocol: (i) for each microliter of
viral preparation used, the corresponding number of micro-
grams of protein present was calculated; (ii) then, for each
microgram of viral protein, 500 mg of peptide was added; (iii)
after vortexing, the mixture was incubated at room temperature
(RT) for 15 min; and (iv) the solution was vortexed and used
for assays or animal injections. New PeptiCRAds were prepared
before each experiment using fresh reagents. All dilutions of
virus and peptides required before incubation were performed
in sterile Milli-Q water adjusted to pH 7.4. The PeptiCRAds
were then diluted with the buffer required by the assay.
Zeta potential and dynamic light scattering (DLS) analysis
Samples were prepared as described in the previous section.
Each sample was then vortexed and diluted to a ﬁnal volume of
700 mL with sterile Milli-Q water adjusted to pH 7.4, after
which the sample was transferred to a polystyrene disposable
cuvette to determine the size of the complexes. Afterward, the
sample was recovered from the cuvette and transferred to a
DTS1070 disposable capillary cell (Malvern, Worcestershire,
UK) for zeta potential measurements. All measurements were
performed at 25C with a Zetasizer Nano ZS (Malvern).
Surface plasmon resonance
Measurements were performed using a multi-parametric SPR
NaviTM 220A instrument (Bionavis Ltd, Tampere, Finland).
Milli-Q water with its pH adjusted to 7.4 was used as a running
buffer. A constant ﬂow rate of 30 mL/min was used throughout
the experiments, and temperature was set to C20C. Laser light
with a wavelength of 670 nm was used for surface plasmon
excitation.
A sensor slide with a silicon dioxide surface was activated by
3 min of plasma treatment followed by coating with APTES
((3-aminopropyl)triethoxysilane) by incubating the sensor in
50 mM APTES in toluene solution for 1 h. The sensor was then
placed into the SPR device, and the OAds were immobilized in
situ on the sensor surface of the test channel by injecting
50 mg/mL OAds in Milli-Q water (pH 7.4) for approximately
12 min, followed by a 3 min wash with 20 mM CHAPS (3-[(3-
cholamidopropyl)dimethylammonio]-1-propanesulfonate).
The second ﬂow channel was used as a reference and was
injected with Milli-Q water (pH 7.4), followed by washing with
CHAPS. The baseline was observed for at least 10 min before
sample injections. PolyK-SIINFEKL or SIINFEKL was then
injected into both ﬂow channels of the ﬂow cell in parallel, with
increasing concentrations.
Viability assay
MTS assay was performed according to the manufacturer’s pro-
tocol (CellTiter 96 AQueous One Solution Cell Proliferation
Assay; Promega, Nacka, Sweden). Spectrophotometric data
were acquired with Varioskan Flash Multimode Reader
(Thermo Scientiﬁc, Carlsbad, CA, USA).
Infectivity assay by ICC
Tumor cells were seeded at 2.0£105 cells per well on 24-well
plates in three or ﬁve replicates. The following day, the cells
were infected with 10 vp/cell. The plates were then centrifuged
for 90 min at 1,000 rcf at 37C, followed by incubation for
48 h. Infectivity analysis was performed using the anti-hexon
monoclonal antibody (Novus Biologicals, Littleton, CO, USA),
diluted 1:2,000. For each well, ﬁve images of non-overlapping
ﬁelds were acquired using an AMG EVOS XL microscope
(AMG group, Life Technologies). The following formula was
used to determine the infectious titer:
Infectious titerD x  well area
field area
 1
dilution factor
 1 mL
volume of dilution applied
:
For the infectivity comparisons, the data are presented as the
average number of spots in each ﬁeld.
Cross-presentation experiment
2£106 spleenocytes in 800 mL of 10% RPMI-1640 culture
media were incubated with 200 mL of SIINFEKL, polyK-SIIN-
FEKL, SIINFEKL-polyK, or SIINFEKL-AHX-polyK peptide
dilution (0.19 mg/mL). Alternatively, 7.9£109 vp mixed with
37.5 mg of polyK-SIINFEKL (OVA-PeptiCRAd) in 200 mL of
10% RPMI-1640 was applied. The PeptiCRAd complex was
prepared as described previously. After 2 h of incubation cells
were washed and stained with either APC anti-mouse H-2Kb
bound to SIINFEKL or APC Mouse IgG1, k Isotype Ctrl (BioL-
egend, San Diego, CA, USA), and the samples were analyzed by
ﬂow cytometry.
Animal experiments and ethical permits
All animal experiments were reviewed and approved by the
Experimental Animal Committee of the University of Helsinki
and the Provincial Government of Southern Finland. C57BL/6
mice were obtained from Scanbur (Karlslunde, Denmark), and
immunodeﬁcient triple-knockout NOD.Cg-Prkdcscid-
IL2rgtm1Wjl/SzJ mice were obtained from Jackson Laboratories
(Bar Harbor, ME, USA).
For the efﬁcacy experiments 3£105 B16-OVA or 1£105
B16-F10 or 2£106 SK-MEL-2 cells were injected subcutane-
ously on the ﬂanks of mice. Three treatment injections were
performed on established tumors.
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Flow cytometry analysis
Flowcytometry analysis was performed using a BD LSR II (BD
Biosciences) or a Gallios (Beckman Coulter) ﬂow cytometer
and FlowJo software (Tree Star, Ashland, OR, USA). Epitope-
speciﬁc T cells were studied using MHC Class I Pentamers
(ProImmune, Oxford, UK). Other antibodies used included the
following: murine and human Fc block CD16/32 (BD Phar-
Mingen); FITC anti-mouse CD8C and FITC anti-human CD8C
(ProImmune); PE/Cy7 anti-mouse CD3e, PE/Cy7 anti-mouse
CD19, FITC anti-mouse CD11c, PerCp/Cy5.5 anti-mouse
CD86, APC anti-mouse H-2Kb bound to SIINFEKL and APC
Mouse IgG1, k Isotype Ctrl (BioLegend). All staining proce-
dures were performed according to the manufacturer’s
recommendations.
Statistical analyses and correlation models
Statistical analysis was performed using GraphPad Prism 6
(GraphPad Software, Inc.., La Jolla, CA, USA). A detailed
description of the statistical methods used to analyze the data
from each experiment can be found in each ﬁgure caption. For
correlation analysis presented in Fig. 5A, a non-linear regres-
sion was used: exponential one phase decay. The model is
described by the equation
Y D Y0¡ Plateauð Þ£ e ¡K £ Xð ÞC Plateau:
Y0 is the Y value when X (time) is zero. It is expressed in the
same units as Y. Plateau is the Y value at inﬁnite times,
expressed in the same units as Y. K is the rate constant,
expressed in reciprocal of the X axis time units. If X is in
minutes, then K is expressed in inverse minutes.
For models of virus-peptide interaction presented in Fig. S2
the following equations have been used:
One-site binding model Y D Ymax £ ½P
K C ½P
Co-operative binding model Y D Ymax ½P
a £ .Kco/a
1C ½Pa £ .Kco/a
Y D SPR response, Ymax D SPR response at saturation, [P]D
concentration of poly K-SIINFEKL, K D 1/Kco D binding con-
stant, a D Hill coefﬁcient describing co-operativity of the inter-
action (a > 1, positive co-operativity; a < 1, negative co-
operativity).
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ABSTRACT
Tolerance toward tumor antigens, which are shared by normal tissues, have often limited the efﬁcacy of
cancer vaccines. However, wild type epitopes can be tweaked to activate cross-reactive T-cell clones,
resulting in antitumor activity. The design of these analogs (i.e., heteroclitic peptides) can be difﬁcult and
time-consuming since no automated in silico tools are available. Hereby we describe the development of
an in silico framework to improve the selection of heteroclitic peptides. The Epitope Discovery and
Improvement System (EDIS) was ﬁrst validated by studying the model antigen SIINFEKL. Based on artiﬁcial
neural network (ANN) predictions, we selected two mutant analogs that are characterized by an increased
MHC-I binding afﬁnity (SIINFAKL) or increased TCR stimulation (SIIWFEKL). Therapeutic vaccination using
optimized peptides resulted in enhanced antitumor activity and against B16.OVA melanomas in vivo. The
translational potential of the EDIS platform was further demonstrated by studying the melanoma-
associated antigen tyrosinase related protein 2 (TRP2). Following therapeutic immunization with the EDIS-
derived epitope SVYDFFAWL, a signiﬁcant reduction in the growth of established B16.F10 tumors was
observed, suggesting a break in the tolerance toward the wild type epitope. Finally, we tested a multi
vaccine approach, demonstrating that combination of wild type and mutant epitopes targeting both TRP2
and OVA antigens increases the antitumor response.
In conclusion, by taking advantage of available prediction servers and molecular dynamics simulations,
we generated an innovative platform for studying the initial sequences and selecting lead candidates with
improved immunological features. Taken together, EDIS is the ﬁrst automated algorithm-driven platform
to speed up the design of heteroclitic peptides that can be publicly queried online.
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Introduction
Immunotherapy is widely recognized for its potential and
several studies have demonstrated that tumor-reactive T-cells
are present among the naive repertoire. For this reason, pep-
tide vaccination using cytotoxic T-lymphocyte (CTL) epito-
pes has been evaluated in different preclinical and clinical
studies.1-3
Peptide-based cancer vaccines represent a focused approach
that can take into account the inter-patient variability of the
neoplastic disease. Nevertheless, ﬁnding a candidate target
might not be sufﬁcient for a successful therapy.4 While neo-
antigens represent the optimal target for cancer immunother-
apy, their discovery is not applicable to all clinical settings due
to economic and technological limitations. Thus, different clas-
ses of tumor antigens have been investigated, such as tumor-
associated antigens (TAAs). These proteins are not exclusively
found in tumor tissues, hence they can only be targeted by spe-
ciﬁc T-cells with low-afﬁnity T-cell receptors (TCRs) survive
the thymic selection.5 These potential self-reactive clones are
kept inactivated by the peripheral tolerance.6 In addition, the
tumor cells are known to downregulate the major histocompat-
ibility complex (MHC) molecules to evade immune surveil-
lance.7 The above-mentioned scenario makes TAAs a difﬁcult
target for cancer immunotherapy, however, TAAs still repre-
sents the largest class of tumor antigens available8 and they are
used into preclinical and clinical applications despite their non-
optimal nature as speciﬁc targets.9
T-cells are by nature cross-reactive and one speciﬁc clone can
recognize other highly similar sequences.10-12 In fact, if T-cells
were monospeciﬁc, an enormous number of lymphocytes would
be needed to confer protection against foreign antigens. Mathe-
matical modeling has shed light on the redundancy of this sys-
tem,13 suggesting that one T-cell might recognize as much as
106 minimal epitopes.14 One of the consequences of this model
is that one peptide might be recognized by multiple clones, espe-
cially if they feature low-avidity TCRs. This hypothesis is
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supported by previous studies where modiﬁed epitopes (i.e., het-
eroclitic peptides) were found to be more immunogenic than the
original ones. In fact, the presence of amino acid changes in pro-
teins of malignant cells can create epitopes that are able to drive
antitumor responses.15 Chen et al. generated mutated forms of
the NY-ESO-1 peptide, demonstrating their immunological efﬁ-
cacy.16 Similarly, mutated MHC class-II peptides from the
gp100 antigen have been generated and their relative efﬁcacy
was studied in humans. The results showed that even minor
changes in the sequence of the peptides led to variable
responses.17 Recently, Hoppes and colleagues replaced natural
amino acids with non-proteinogenic residues and generated
improved variants of the SVYDFFVWL peptide derived from
the tyrosinase-related protein 2 (TRP2) antigen.18
Although the exact mechanism is not completely under-
stood, the current knowledge suggests that the analogs may
have an increased afﬁnity for human leukocyte antigen (HLA)
molecules. However, it is not clear whether heteroclitic peptides
act by providing a more potent stimulus to a tolerized epitope-
speciﬁc T-cell, or if they are able to stimulate other clones, such
as low avidity ones, that had not been tolerized.
In this study, we describe the development and validation of
the Epitope Discovery and Improvement System (EDIS). The
advantage of this approach relies on the integration of predictions
using several ANN in combination with molecular dynamics sim-
ulations (MDSs). While developed to optimize the sequence of
tumor associated antigens, overcoming tolerance, this framework
could also be used to improve the sequence of peptides.
By studying a classic model peptide, the SIINFEKL epitope
from chicken ovalbumin (OVA), we investigated in silico, in
vitro and in vivo properties of the two analogs SIINFAKL and
SIIWFEKL. In particular, we predicted and modeled their inter-
action with the murine allele H-2Kb to understand how the
mutations affect the binding with MHC-I. Then we evaluated
both their therapeutic efﬁcacy upon established B16-OVA mel-
anomas and the immunological response.
While being an optimal strategy, targeting neo-antigens is not
always possible, therefore the use of TAAs is widespread into the
clinical setting. To mimic this scenario, we decided to study the
murine syngeneic tumor antigen TRP2. Interestingly, immuno-
logical responses against the TRP2 antigen have been evaluated
in different studies on melanoma patients.19 In fact, TRP2-spe-
ciﬁc CTL clones have been identiﬁed among tumor inﬁltrating
lymphocytes.20 In addition, Reynolds and colleagues detected
TRP2 reactive T-cells in the peripheral blood of patients.21
Therefore, we decided to study the tumor epitope SVYDFFVWL
(TRP2180–188) from this TAA. Among the two heteroclitic pepti-
des that we evaluated, one was able to reduce the growth of
established B16F10 tumors more efﬁciently than the wild type
TRP2180–188 epitope. Finally, we demonstrated that targeting
TAAs, neo-antigens combination of wild type peptides and their
mutated versions results in an increased antitumor efﬁcacy.
In conclusion, a ﬁne equilibrium between the mutation of
epitopes and immunological properties needs to be considered
when selecting heteroclitic peptides for cancer vaccines.
Hereby, we show that the integration of multiple in silico plat-
form can improve the accuracy of the prediction of peptide
properties allowing for a more efﬁcient screening and selection
of CTL epitope-analogs.
Results
Developing an in-silico platform that predicts the effect
of amino acid changes on the immunogenicity of MHC-I
epitopes
Prediction servers offer the possibility to estimate several
immunological properties of putative MHC-I epitopes. These
technologies allow for the screening of sequences obtained
from mass-spectrometry analysis of proteins to search for pep-
tides suitable for cancer immunotherapy. This versatile and
scalable platform, however, has never been used for the
methodic research of heteroclitic peptides.
We started by generating an in silico library of analogs of
SIINFEKL, a frequently used model antigen in immunological
studies. To this end, each position was mutated with each natu-
ral amino acid. Then we run the library into two different pre-
diction servers. The NetMHC 4.0 Server from the Center for
Biological Sequence analysis (CBS) was used to predict the
binding afﬁnity (IC50 values) of peptides to the murine MHC-I
allele H-2Kb.22,23 In addition, the class I immunogenicity pre-
diction server available at the Immune Epitope Database and
Analysis Resource (IEDB)24 was used to predict the recognition
of the peptide-MHC-I (pMHC-I) complexes by TCRs and
immunogenicity scores (IS) were acquired for each analog.
As shown in Fig. 1A, the lateral chains of the SIINFEKL pep-
tide (blue) have a speciﬁc orientation into space. While residues
1, 2, 3, 5 and 8 are sunk into the MHC-I binding pocket, residues
4, 6 and 7 extrude from the pocket, hence can be recognized by
the T-cells. Therefore, we hypothesized that mutations in MHC-I
anchors would signiﬁcantly change the IC50 values, while replac-
ing residues 4, 6 and 7 would not hinder the MHC-I binding
afﬁnity. As represented in Fig. 1B, all analogs sharing a mutation
at the ﬁrst (XIINFEKL; blue) or second (SXINFEKL; red) posi-
tion, have a much higher IC50 (i.e., lower afﬁnity). The group of
analogs sharing a mutation at the eight residue (dark blue),
known to be an important binding anchor,25 feature the highest
IC50 mean value, highlighting the importance of such residue in
the binding of SIINFEKL peptide to the MHC-I molecule. Con-
sistent with our hypothesis, no signiﬁcant changes to the IC50
were observed for the analogs sharing a mutation at position 4
(SIIXFEKL; purple) and 7 (SIINFEXL; brown). Interestingly,
most of the substitution at position 6 (SIINFXKL; gray) would
result in a lower IC50 (i.e., higher afﬁnity). By analyzing the effect
of each amino acid as substitute of the native one (Suppl. 1A) we
could conclude that, amino acids with big lateral chains, such as
glutamic acid (E), aspartic acid (D) or lysine (K) would cause a
reduced afﬁnity, no matter which position was used for modifying
the native sequence. Regarding the recognition of the epitope by
the TCR, the immunogenicity score (IS) did not vary when the
ﬁrst three positions (Fig. 1C; 1, 2 and 3 on x axis) were changed,
while aa variations at position 4, 5, 6 and 7 had signiﬁcant effects
on the IS. In fact, most of the analogs with a substitution at posi-
tion 6 (SIINFXKL, gray) showed a lower score, compared with
the group of analogs with changes in position 7 (SIINFEXL); var-
iations in position 4 gave mixed results as proven by the wider
distribution of the data (Fig. 1C, purple group).
Taken together, these data suggested that the 4th position
was not crucial in determining the IC50, but might be very
important for the recognition of the TCR. Similarly, changes in
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position 6 might result in an improved MCH-I afﬁnity, but a
generally lower immunogenicity.
To elucidate what is the contribution of each parameter to
the immunological response we further evaluated two analogs
with different properties. By plotting the IC50 values of all the
analogs (Fig. 1D) we could observe a group of analogs with a
higher afﬁnity than SIINFEKL (IC50 < 17 nM). Among these,
the SIINFAKL peptide was predicted to bind the MHC-I with
the highest afﬁnity, with an IC50 of 3 nM whereas the SIIW-
FEKL analog also resulted in a lower IC50 value (13 nM)
compared with SIINFEKL. As previously discussed, the analog
bearing a change in the 6th position (SIINFAKL) showed a
lower IS (Fig. 1E) while the analog with a mutation at the 4th
position (SIIWFEKL) showed an improved IS.
Crystal structures of pMHC complexes deliver the most reli-
able data regarding the conformation and orientation of pepti-
des into the binding pockets. However, resolved structures are
not available for most of the pMHC complexes. Hence, we used
MDSs to compare the conformation of peptides when inside
the MHC binding pocket. As shown in Fig. 2A, SIINFAKL
Figure 1. In silico screening of the mutational library of SIINFEKL. (A) Graphical representation of SIINFEKL peptide (violet) into the binding pocket of the H-2Kb MHC-I
molecule (transparent gray). The backbone of the peptide is visualized in green and the lateral groups in blue. Lateral groups facing the MHC-I binding pocket or emerg-
ing from the pocket are indicated. In silico prediction of the binding afﬁnity (B) or the immunogenicity score (C) of the analogs of SIIINFEKL. The analogs were grouped
according to the position of the mutation (left panels). Alternatively, the analogs were grouped according to the aminoacid used to mutate each position (right panels).
The red-dotted line, represents the IC50 and the immunogenicity score of the wild type sequence. (D) The afﬁnity scores of the whole library were plotted and indicating
analogs with a higher or lower afﬁnity than the wild type SIINFEKL. The speciﬁc peptides SIINFAKL and SIIWFEKL are highlighted and their IC50 values are indicated. (E)
The immunogenicity predictions for the H-2Kb allele are displayed for the wild type SIINFEKL and two speciﬁc analogs.
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Figure 2. Molecular dynamics simulation to unravel conformational changes of epitope-MHC-I complexes. (A) Comparison of spatial conformation epitopes inside the
MHC-I binding pocket. SIINFEKL (green transparent), SIINFAKL (red solid) and SIIWFEKL (cyan solid) are compared by superimposition. Molecular dynamics simulations
were run for 300 ns, and the most representative states are shown. Left panel: SIINFEKL and SIINFAKL; central panel: SIINFEKL and SIIWFEKL; right panel SIINFAKL and
SIIWFEKL. The conformational landscape of the epitope-MHC-I complexes (SIINFEKL, B; SIINFAKL, C; SIIWFEKL, D) are shown from two angles: C-terminal of epitope (left
panels) and side views (right panels; epitopes are oriented from N-terminal on the left to C-terminal on the right). The extruding residues, responsible for contacting T-
cell receptors are highlighted by yellow captions showing the position and abbreviation for the aminoacid. The structure and orientation of the mutated residue for SIIN-
FAKL and SIIWFEKL peptides are highlighted by the yellow structure of the sidechains.
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(left panel, red solid) is shifted to the bottom of the binding
pocket compared with the wild type SIINFEKL (green transpar-
ent). This explains the increased predicted binding afﬁnity of
this peptide for the H-2Kb molecule. On the contrary, SIIW-
FEKL (Fig. 2A, central panel; cyan solid) features a large side
chain due to the tryptophan in position 4 (4TRP). This allows
for a higher extrusion of the peptide from the MHC pocket
when compared with either SIINFEKL (central panel, green
transparent) or SIINFAKL (right panel, red solid).
The TCR recognizes the pMHC by binding for one third the
peptide and for two thirds the MHC-I. Hence, gathering infor-
mation about the single residues of the epitope which are extrud-
ing from the binding pocket might be poorly predictive.
Therefore, we decided to study how the whole portion of pMHC
that faces TCR (hereafter referred as the pMHC landscape)
changes conformation when using different analogs of the same
epitope. The wild type epitope SIINFEKL (Fig. 2B) features an
asparagine in position 4 (4ASN), a glutamic acid in position 6
(6GLU) and a lysine in position 7 (7LYS) which extrude from
the binding pocket. The analog SIINFAKL features a smaller ala-
nine in position 6 and this mutation affects the orientation of the
other residues as well. As shown in Fig. 2C, the whole binding
pocket seems to have a more opened conformation; in addition,
when comparing the 4ASN and 7LYS present in both the SIIN-
FEKL and SIINFAKL peptides, they seem to extrude more in the
latter one. In contrast, the insertion of the tryptophan in the
position 4 largely affects the whole pMHC landscape. Fig. 2D
shows the peptide SIIWFEKL into the binding pocket. The large
side chain of the 4TRP residue is evidently extruding from the
binding pocket, with the MHC pocket being more closed, thus
limiting the TCR access to the peptide (Fig. 2D, side view).
In silico properties predicted by EDIS correlate
with experimental in vitro data
In our in silico screening both SIINFAKL and SIIWFEKL ana-
logs are predicted to have an improved MHC-I binding afﬁnity,
with the latter expected to be better recognized by the TCR. To
validate these ﬁndings, we performed an in vitro binding assay
using RMA-S cells. These cells bear mutations in the antigen-
processing machinery, hence they are almost devoid of surface
H-2Kb molecules.26 However, the addition of exogenous epito-
pes can stabilize the a chains and the b2 macroglobulin of the
MHC-I molecule, thus the binding afﬁnity is proportional to
the amount of H-2Kb on the membrane. We observed a signiﬁ-
cant increase in the amount of H-2Kb on cells incubated with
SIINFAKL and SIIWFEKL at both high (Fig. 3A; 1 mg/mL) and
low concentrations (Fig. 3B; 0.1 mg/mL) when compared with
the wild type SIINFEKL. This experimentally conﬁrms that the
analog peptides do have a higher afﬁnity for MHC-I compared
with the native epitope.
Next, we sought to investigate whether or not the selected
analogs would increase the proliferation of T-cells. To this end,
CFSE labeled OT-I splenocytes, containing exclusively
SIINFEKL-speciﬁc CD8C T-cells, were incubated with the three
peptides. After 3 d of incubation, we determined the amount of
proliferating CD3CCD8C T-cells (i.e., with a diluted CSFE ﬂuo-
rescence) by ﬂow cytometry. As expected both the SIINFEKL
and the SIIWFEKL peptides were able to stimulate the prolifer-
ation of the cells signiﬁcantly more than the negative control.
Interestingly, incubation with SIINFAKL resulted in a signiﬁ-
cantly increased proliferation of OT-I T-cells compared with
the other peptides. This ﬁnding conﬁrms the presence of cross-
reactivity and the ability of the mutant analogs to stimulate the
population of lymphocytes recognizing the native epitope,
which is a crucial property for any heteroclitic peptide.
Analogs selected with the EDIS framework show improved
antitumor activity in vivo compared with the native
epitope
We then investigated whether the two mutant analogs would be
immunologically active in a therapeutic cancer vaccine
approach. To this end, we treated 9-d established B16-OVA
tumors with the three peptides using the previously described
cancer vaccine platform PeptiCRAd.27
In these settings, the therapeutic intra-tumor vaccination
with SIINFEKL resulted in a slightly reduced tumor growth
Figure 3. Experimental validation of in silico predictions of the MHC-I binding afﬁnity. RMA-S cells were pre-incubated for 1 h at 4C. Then, 4 £ 106 cells were incubated
for 2 h with one of the indicated peptides at two different concentrations (A) 1 mg /mL or (B) 0.1 mg/mL in a volume of 1 mL. The presence of H-2Kb molecules on the
membrane was measured by ﬂow cytometry and normalized against cells incubated with no peptide (negative control). (C) OT-I splenocytes were labeled with CFSE dye.
Then, 3 £ 104 cells were incubated with different stimuli for 72 h in a volume of 200 mL of complete media. Then the percentage of proliferating (i.e., CFSE diluted)
CD3CCD8C T-cells was determined by ﬂow cytometry; data was normalized against positive control Concanavalin A (deﬁned as 100% of proliferation). All the data are
represented as mean § SD; Signiﬁcance was assessed by One-way ANOVA with Tukey’s post hoc test; p < 0.05,  p <0.01.
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(Fig. 4A) compared with mice treated with saline solution or
the adjuvant alone. In contrast, a superior antitumor efﬁcacy
was achieved by therapeutic vaccination with either SIIWFEKL
(p < 0.05) or SIINFAKL (p < 0.01) as can be appreciated also
by the single tumor curves (Fig. S2A) and by the increased dou-
bling time of tumors treated with these peptides (Fig. S2B).
Flow cytometry analysis revealed no major differences in the
number of CD19¡CD3CCD8C CTLs in secondary lymphoid
organs or tumors (Fig. 4B). However, a signiﬁcant increase in the
amount of SIINFEKL-speciﬁc CTLs (i.e., antitumor T-cells) was
observed in the tumors of mice treated with the SIINFAKL pep-
tide (Fig. 4C). This suggested a beneﬁcial cross-response and the
expansion of SIINFEKL-speciﬁc cells that inﬁltrated the tumors.
Following the hypothesis that clones with low-avidity TCRs
might be crucial in the antitumor responses avoiding tolerance,
we performed an inter-organ correlation analysis among all the
groups by comparing the percentage of SIINFEKL-speciﬁc
T-cells with their avidity for the pMHC-I complexes. The avidity
of T-cells for the pMHC-I complexes was measured by consider-
ing the afﬁnity of TCRs for SIINFEKL-Pentamers, since high
avidity clones would capture more Pentamers and have stronger
ﬂuorescence signal, i.e., a higher geometrical mean ﬂuorescence
intensity (gMFI). Interestingly, we observed a clear negative cor-
relation (Fig. 4D): larger populations of SIINFEKL-speciﬁc CTLs
showed also the lowest ﬂuorescence intensity of staining (Pear-
son’s correlation analysis; p D 0.0002). These data suggests that
low-avidity T-cell clones are attracted into the tumor (Fig. 4D;
black dots) in larger numbers and this mechanism could be
exploited in different settings to circumvent the tolerance when
targeting different tumor antigens such as TAAs.
Taken together these ﬁndings demonstrate that therapeutic
vaccination with heteroclitic peptides signiﬁcantly improves
immune response resulting in a reduced growth of aggressive
B16OVA tumors. In addition, Pentamer staining suggested
that SIINFEKL-speciﬁc T-cell clones can be cross-stimulated
by using the SIINFAKL mutant analog. Finally, the avidity of
stimulated CTL clones seems to negatively correlate with their
expansion/proliferation.
The heteroclitic analogs SIINFAKL and SIIWFEKL can cross-
stimulate a response against the native epitope SIINFEKL
To achieve antitumor activity, the clones stimulated by
immunization using heteroclitic peptides must recognize the
Figure 4. Antitumor response and in vivo efﬁcacy of SIINFEKL mutated analogs. (A) B16OVA cells were injected into both ﬂanks of female C57BL6/J mice (2.5 £ 105 cells/
ﬂanks). Mice (eight per group) were treated with PBS (Mock), Ad5D24-CpG human adenovirus (Adjuvant), and either SIINFEKL, SIINFAKL or SIIWFEKL peptides complexed
to the virus-adjuvant. Intra-tumor injections were made on day 9, 11, 13 as represented by the asterisks on the x axis. Tumor volumes were measured every 2–3 d by a
digital caliper. Tumor volumes normalized against the values on the 9th day are presented as the mean § SEM; signiﬁcance was calculated by Two-way ANOVA with
Tukey’s post hoc test. Spleens, tumors and draining lymph nodes were collected to determine to percentage of (B) total CD8C T-cells (CD19¡CD3CCD8C) or (C) SIINFEKL-
speciﬁc T-cells (double positive PentamerCCD8C gated on CD19¡CD3C). (D) A correlation analysis was performed by plotting for each mouse the % of antigen-speciﬁc T-
cells against the intensity of the signal (gMFI) of such population. Data from spleens (empty triangles), draining lymph nodes (empty squares) and tumors (black dots) are
presented. Log transformed values were used to compute the Pearson’s correlation coefﬁciencies; p-value for the correlation is 0.0002.
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native epitope which is displayed by the tumor cells. For
this reason, an analysis of cross-reactivity of the immune
response was performed by IFNg ELISPOT assay on sam-
ples collected from animals described in the previous
experiment.
As expected, splenocytes from mice treated with SIINFEKL
reacted ex vivo to SIINFEKL (Fig. 5A; left graph), with two
mice showing a hyper-response (>500 SFU/well). A certain
degree of cross-response toward the native SIINFEKL was
observed in mice treated with SIIWFEKL also (Fig. 5A, left
graph, 2/4 cases). Mice immunized with SIINFAKL also cross-
responded to SIIWFEKL peptide (Fig. 5A, right graph; 3/4
cases). Consistently to our previous observations, splenocytes
of mice treated with SIINFAKL cross-responded to SIINFEKL
peptide (Fig. 5A, left graph, 4/4 cases) and this explains its anti-
tumor efﬁcacy.
Next, we analyzed the size of the spots as an indirect mea-
sure of the amount of IFNg produced by the single activated
T-cells in response to the different MHC-I epitopes. Spleno-
cytes of mice immunized with SIINFAKL produced large spots
when re-pulsed with all the peptides, demonstrating a broad
response (Fig. 5B). Nevertheless, as shown in Fig. 5C, when
using SIINFEKL to re-stimulate the splenocytes (independently
from the initial immunization) we observed the largest spots,
suggesting that the efﬁcacy of SIINFAKL is not achieved by
hyper-stimulation of the TCR.
An heteroclitic peptide designed with EDIS was able
to break the tolerance toward B16F10 melanomas
One of the main challenge that cancer vaccines strategies face is
the paucity of antigens which are exclusively present on tumor
Figure 5. Cross-reactivity of the immunological responses elicited by the mutated analogs of SIINFEKL. Splenocytes from mice treated with SIINFEKL, SIINFAKL or
SIIWFEKL (presented in Fig. 4, here indicated on the x axis), were assayed for cross-responses to the peptides. 3 £ 105 cells were incubated with 100 ng of each indicated
peptide for 72 h and the IFNg response was determined by ELISPOT assay. (A) The number of Spot-Forming Units (SFU) is normalized to 1 £ 106 cells. The red-dotted
line represents the background of the assay (splenocytes incubated with PBS). (B) The cumulative size of the spots from mice of the same group (same column) in
response to different stimuli (bars of different colors) is shown. Data is shown as mean § SEM. C) The average spot size across all the groups in response to each peptide
is represented. Data is shown as the mean § SEM; One-way ANOVA with Tukey’s post hoc test was used to calculate the statistical signiﬁcance.
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cells. Melanoma-associated antigen TRP2 features epitopes that
can bind with high afﬁnity to the MHC-I; however, either
peripheral tolerance or absence of T-cell clones with TRP2-
high avidity TCRs prevents rejection of tumors upon therapeu-
tic vaccination with the SVYDFFVWL epitope.
First, we studied the properties of the wild type epitope
in silico. As described for SIINFEKL, we changed each position
with one of the other natural amino acids, and grouped the
analogs based on the mutated position (for example group 1:
XVYDFFVWL; group 2: SXYDFFVWL; group 3:
SVXDFFVWL; etc.). This provided useful insights in the con-
tribution of each position to the stability of this speciﬁc
pMHC-I complex and its immunogenicity. As shown in
Fig. 6A, most of the analogs with a mutation in one of the ﬁrst
three positions display an inferior afﬁnity toward H-2Kb (i.e.,
higher IC50) compared with the WT peptide (represented by a
dashed line). According to the predictions, mutations at either
the 7th or 8th residue result in increase of binding afﬁnity,
while changes at the 9th position results in decreased binding
in 100% of the cases, as shown by a higher IC50 of all these
peptides (SVYDFFVWX group; 9th on x axis). Interestingly,
position 4 seems to not affect the overall binding. The central
residues are essential for TCR recognition, and this is proved
by the overall lower predicted immunogenicity for most of the
analogs sharing a mutation in these positions when compared
with the natural epitope (Fig. 6B). Only few analogs display a
higher immunogenicity score than TRP2 WT (dashed line). As
shown also in Fig. S1D (red dots), only 12 analogs from a total
of 162 were predicted to have a better immunogenicity. This
observation suggested us that the sequence may be already opti-
mized for TCR recognition and that poor TCR stimulation
might be caused by the tolerance toward this peptide. There-
fore, we focused on contacting other low-afﬁnity TCR that sur-
vived the thymic selection. For this reason, we choose two
analogs with an increased predicted afﬁnity for H-2Kb but
avoiding mutations in the central region: SAYDFFVWL (TRP2
2A) and SVYDFFAWL (TRP2 7A). These analogs displayed a
lower IC50 (Fig. 6C, left) and were predicted to be recognized
as efﬁciently as the TRP2 WT epitope (Fig. 6C, right). Consis-
tent with the in silico analysis, both analogs stabilized the
MHC-I molecules on the surface of RMA-S cells at both low
and high concentrations (Fig. 6D, left and right respectively).
Molecular dynamics simulation of these analogs revealed
that the mutations would change the conformation of the pep-
tides (Fig. 6E). The central residues extruding from the MHC-I
molecule have a different orientation when comparing TRP2
WT, TRP2 7A and TRP2 2A peptides (Fig. 6E, left). In addi-
tion, the portion of the peptide which is in deep contact with
the MHC-I pocket (Fig. 6E, right) has a different conformation,
especially when considering the TRP2 2A peptide. These spatial
changes result into differences of the pMHC structure which is
supposed to be in contact with the TCR (Fig. 6F). For instance,
the presence of the small alanine in position 7 of the TRP2 7A
analog, affects the spatial orientation of phenylalanine and
tryptophan at positions 6 and 8, respectively (Fig. 6F, central).
No major spatial changes were observed for the pMHC com-
plex when we simulated the presence of the TRP2 2A peptide
into the binding pocket of the H-2Kb molecule when compared
with the TRP2 WT peptide (Fig. 6F, right).
Next, we used the aggressive melanoma model B16F10 to
test whether the selected variants would elicit an antitumor
response. As expected, immunization with TRP2 WT did not
affect the tumor growth (Fig. 7A). Similarly, treatment with
TRP2 2A did not result in any signiﬁcant change in tumor pro-
gression. Interestingly, mice immunized with TRP2 7A peptide
showed a signiﬁcant slower tumor growth when compared
with mock-treated mice (p D 0.0015), or mice treated with
either TRP2 WT (p < 0.0001) or TRP2 2A (p < 0.0001).
Subsequently, we studied the immunological responses in
treated mice. As shown in Fig. 7B (left panel), treatment with
native peptide (i.e., TRP2 WT) weakly increased the immune
response toward the antigen compared with mock-treated
mice, conﬁrming a degree of tolerance toward this sequence.
Immunization with the TRP2 2A peptide did not result in any
major response. Interestingly, mice immunized with TRP 7A
showed a signiﬁcantly higher cross-response against the TRP2
WT epitope.
Taken together these data demonstrated that TRP2 7A was
able to break the tolerance toward the WT peptide. In addition,
we also observed a high direct-response against TRP2 7A in
mice treated with TRP2 7A (Fig. 7B, central panel). This sug-
gested the absence of tolerance toward this peptide.
Finally, we investigated the efﬁcacy of a multi-peptide vac-
cine, composed of wild type and modiﬁed epitopes targeting
TAAs and neo-antigens. In particular, we asked whether or not
targeting both classes of antigens would be beneﬁcial, when
using heteroclitic peptides and wild type epitopes. Therefore,
we chose a challenging model by treating 10-d established B16.
OVA tumors with either TRP2 WT C 7A analog peptides,
SIINFEKL C SIINFAKL peptides or a combination of all four
peptides (multi-vaccine). The study groups that received the
therapeutic vaccines showed varying degrees of response
(Fig. S3A). As shown by the individual tumor growth curves in
Fig. 7C, the percentage of slowly progressing tumors was higher
in the group that received the multi vaccine therapy. In fact,
57% of mice in the multi-peptide vaccine group had tumor vol-
umes that were below 400% of the starting volume. The analy-
sis of the growth of the tumors (by using the area under the
curve) revealed that all the study groups performed signiﬁ-
cantly better than mock (Fig. S3B). This observation suggests
that a multi-targeted approach that takes into account clone
variability and downregulation of speciﬁc antigens may be
more effective when compared with narrow treatments target-
ing single antigens.
Discussion
Tumor antigens can be generally divided into tumor-speciﬁc
antigens (TSAs) or TAAs. TSAs comprise antigens that are
exclusively expressed by tumors cells, while TAAs are expressed
also in healthy tissue. Identiﬁcation of unique TSAs is difﬁcult
to achieve, hence targeting TAAs represents a more feasible
approach. Most of TAAs, such as MAGE-A128 or TRP-2,29 are
self-antigens present in healthy tissues, thus tolerance mecha-
nisms prevent immune responses against them. Mutated forms
of wild-type epitopes (i.e., heteroclitic peptides), have proved to
be a valuable tool to break the tolerance or hyperstimulate tol-
erant T-cells.5,16,30 Careful theoretical design together with in
e1319028-8 C. CAPASSO ET AL.
Figure 6. In silico study of the mutational library of the epitope TRP2180–188. The mutational library of the epitope SVYDFFVWL (TRP2 WT) was screened in silico for MHC-I
binding afﬁnity (A) or immunogenicity (B) for the allele H-2Kb. The analogs were grouped according to the position of the mutation (left panels) or according to the ami-
noacid used to mutate each position (right panels). C) The IC50 (left) and Immunogenicity score (right) of the analogs SVYDFFAWL (TRP2 7A) and SAYDFFVWL (TRP2 2A)
predicted in silico are represented. (D) RMA-S cells were pre-incubated for 1 h at 4C. Then, 4 £ 106 cells were incubated for 2 h with one of the indicated peptides at
two different concentrations 0.1 mg/mL (left) or 1 mg/mL (right) in a volume of 1 mL. The presence of H-2Kb molecules on the membrane was measured by ﬂow cytome-
try and normalized against cells incubated with no peptide (negative control). Data is represented as the mean§ SEM; Unpaired student’s t-test, p< 0.05, p< 0.01. E)
Comparison of spatial conformation epitopes inside the MHC-I binding pocket: TRP2 WT (orange), TRP2 7A (green) and TRP2 2A (purple). Molecular dynamics simulations
were run for 300 ns, and the most representative states are shown. 3/4 view (left panel) and side view (right panel). The mutated residues are colored in red. (F) The con-
formational landscapes of the epitope-MHC-I complexes are shown from peptide C-terminal perspective. The extruding residues, responsible for contacting T-cell recep-
tors are highlighted by yellow captions showing the position and abbreviation for the aminoacid. The a chain of the MHC is represented in transparent white.
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Figure 7. Breaking the tolerance to TRP2 tumor antigen and evaluation of multivaccine therapy. (A) B16-F10 melanoma cells were injected into both ﬂanks of female C57BL6/J
mice (1.5£ 105 cells/ﬂank). Mice (eight per group) were treated with PBS (Mock), Ad5D24-CpG human adenovirus (Adjuvant), and either TRP2 WT, TRP2 7A or TRP2 2A peptides
complexed to the virus-adjuvant. Intra-tumor injections were made on day 9, 11 and 13 (asterisks on the x axis). Tumor volumes normalized against the values on the 9th day and
are presented as the mean§ SEM (data from two independent experiments); signiﬁcance was calculated by Two-way ANOVA with Tukey’s post hoc test. (B) Splenocytes were col-
lected from mice and they were assayed for cross-responses to the peptides. 4 £ 105 cells were incubated with 100 ng of indicated stimuli for 72 h and the IFNg response was
determined by ELISPOT assay. The number of Spot-Forming Units (SFU) is normalized to 1 £ 106 cells. The red-dotted line represents the background of the assay (splenocytes
incubated with PBS). Data is presented as mean§ SEM; Signiﬁcance was calculated by using One-way ANOVA with Tukey’s post hoc test; p< 0.05,p< 0.01, p< 0.001. (C)
B16OVA bearing mice were treated on day 10, 12 and 14 with PBS (mock), a combination of TRP2 WT and 7A peptides, a combination of SIINFEKL and SIINFAKL peptides and a
multitherapy featuring all four different epitopes together. Tumor volumes normalized against the values on the 10th day. A threshold of 400% of initial volume on day 10 was
chosen to distinguish between fast (solid line) and slow (dotted line) progressing tumors. Percentages of slow progressing tumors are indicated near the graph of each group.
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silico and in vitro screening is necessary to evaluate the mutated
analogs, making the process time-consuming and cumbersome.
Previous studies have reported contradictory ﬁndings where
the correlation between the in vitro and the in vivo observations
resulted to be poor.31 Therefore, new approaches to optimize
the screening process are needed. In this study we established
an in silico framework by using CBS and IEDB prediction serv-
ers, which are usually used to ﬁnd MHC epitopes inside protein
sequences.32 Hereby, we propose an innovative use of this tools
to screen mutational libraries of deﬁned MHC-I epitopes. In
addition, we implemented molecular dynamic simulations in
our pipeline, to further validate the initial data.
By grouping the analogs based on the mutated amino acid
we evaluated the contribution of each position to the overall
stability the pMHC-I–TCR interactions. This visualization of
data allows for an easy and fast comparison of the native
sequence (SIINFEKL or SVYDFFVWL) with all the analogs.
Using this approach, we demonstrated that very few amino
acids in very speciﬁc positions led to an increased MHC-I afﬁn-
ity (i.e., lower IC50; red dots in Fig. S1A and C), while the
insertion of amino acids with large lateral chains (E, F, I or W)
resulted into analogs with improved immunogenicity scores
(Fig. S1B and C; red dots). Our data highlights that modiﬁca-
tions of the TCR-facing residues, such as positions 4 or 6, led to
heteroclitic peptides with improved MHC-I afﬁnity. These
observations widen the classical model where non-anchor resi-
dues would poorly affect the overall IC50.25,33,34 In fact, both
SIINFAKL and SIIWFEKL analogs showed an improved afﬁn-
ity for MHC in silico and in vitro. It is worth noticing that
pMHC-I complexes can change their structure after binding
the TCR. Downstream signals seem to amplify small discrepan-
cies between similar peptides, according to the kinetic proof-
reading model of T-cell activation.10 This leads to a cross-reac-
tivity model where one TCR can recognize different peptides
and one peptide can be recognized by many TCRs.
An innovative aspect of our work consists in the integration
of data from different in silico techniques. However, in our
experience data from immunogenicity prediction is much more
difﬁcult to interpretate. In fact, we did not observe a strong cor-
relation between the predicted immunogenicity and the degree
of proliferation of antigen speciﬁc lymphocytes in vitro. This
ﬁnding suggests that the prediction of the immunogenicity is
much more challenging since in silico prediction algorithms do
not take into account the poly-clonality of T-cell responses. In
fact, in vivo validations demonstrated that both analogs were
able to reduce the growth of B16.OVA tumors. Consistent with
our in vitro results, the best MHC-I binder (i.e., SIINFAKL)
proved to be the most effective in vivo (Fig. S2C). We speculate
that peptides with increased MHC-I afﬁnity were able to inter-
act with a wider variety of T-cell clones. This hypothesis is sup-
ported by the fact that immunization with SIINFAKL peptide
resulted in an increased cross-reactivity. Interestingly, despite
not observing any hyper-stimulation of TCRs, we report an
increased proliferation of OT-1 cells. We believe that this effect
is mediated by the higher afﬁnity of the peptide for the MHC-I,
hence a prolonged availability on the surface of APCs. We sug-
gest that the beneﬁcial responses achieved by treatment with
heteroclitic peptides may derive from their ability to evoke a
poly-clonal response rather than hyper-stimulation of the
speciﬁc T-cell clone against the native epitope. Messaoudi and
colleagues have previously investigated some analog epitopes in
their work, such as SIINFAKL, showing that the different
pMHC-I conformation has important effects on the recogni-
tion of the complex by speciﬁc TCR-like antibodies.35 However,
they did not investigate the immunological consequences. In
lack of crystal structures of analogs into the MHC binding
pocket, we performed MDSs. We could appreciate differences
into the orientation of the peptides into the binding pocket,
and most importantly different conformational changes of the
pMHC complexes. Consistently, the SIIWFEKL peptide, which
did not show any priming of OT-I T-cells, was the analog
showing markedly different pMHC conformation when com-
pared with SIINFEKL. This ﬁnding, supports the use of molec-
ular dynamics simulation as a tool to understand
immunological properties of heteroclitic peptides.
In this manuscript, we highlight the importance of consider-
ing both the MHC-I afﬁnity and TCR recognition during the in
silico design of heteroclitic peptides. This is also supported by
the work of Romero and colleagues who studied two epitopes
from the MART-1/Melan-A antigen. In particular, by placing a
strong anchor at position 2 of the natural epitopes, they were
able to increase the afﬁnity for HLA-A02. However, while one
peptide was also better recognized by speciﬁc CTL clones, the
other peptide lost the ability to engage TCRs of the same
clones.36
Subsequently, we applied this in silico analysis to the antigen
TRP2. This self-protein is a melanocyte lineage marker; there-
fore, a degree of tolerance limits its use as cancer vaccine target.
Other groups have previously described mutated forms of the
main H-2KbH-2Kb restricted epitope TRP2180–188 (TRP2 WT).
While immunological responses were achieved, as proved by
the expansion of TRP2 WT-speciﬁc T-cells, tumor growth was
not affected; this suggests a strong tolerance against this self-
peptide.31 By using the EDIS framework we selected two ana-
logs predicted to have an improved MHC-I afﬁnity and a simi-
lar immunogenicity score compared with the WT epitope. The
7A and 2A analogs were studied by MDSs and the 7A-MHC
complex resulted to be similar to the WT-MHC. In fact, thera-
peutic vaccination with TRP2 7A led to a reduced tumor
growth and an increased cross-response. Targeting TAAs is
challenging as most of the TAAs-speciﬁc T-cells recognize sub-
dominant epitopes, while very few T-cell clones recognize the
dominant epitopes. In addition, these clones are characterized
by a lower afﬁnity for the pMHC complex and they might be
kept in a tolerogenic state.4 Our ﬁndings demonstrate that het-
eroclitic peptides target low-afﬁnity T-cell clones through
cross-stimulation of their TCRs.
Finally, we investigated whether combining wild type and
mutated forms of the same epitope could increase the efﬁcacy
of therapeutic vaccination. To this end we directly compared
TRP2 WT C 7A therapy with SIINFEKL C SIINFAKL therapy;
in addition, we also tested a combination of all four peptides.
Responses could be observed in all the treatment groups, how-
ever, by targeting both TRP2 and SIINFEKL antigens with
combination therapy (Multi-vaccine group) we achieved a
response in a higher percentage of treated animals. This sug-
gests that targeting both TAAs and neo-antigens within the
same therapeutic window, may increase the efﬁcacy of cancer
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vaccines. This represents a convenient approach to limit
immune evasion due to antigen loss and maximize the efﬁcacy
of the treatment.
In conclusion, we demonstrated that combination of the
available prediction servers and MDSs provides useful insights
into different aspects of the MHC-I-epitope–TCRs interactions.
Considering the reciprocal inﬂuence between MHC-I afﬁnity
and TCR recognition of any given epitope is becoming increas-
ingly important. In particular, our study provides an open
innovative framework that can be used by other researchers as
starting point for an improved design of mutant epitopes with
higher clinical efﬁcacy. The in silico platform in its version 1.0
can be freely used by following the link https://github.com/ani
ketsh/EDIS_platform.git.
Materials and methods
In silico analysis of heteroclitic peptides
The wild type sequence of the epitope was substituted in each
position with all other natural amino acids. The virtual library
of analogs was then run into ANN based prediction servers to
estimate the MHC-I binding afﬁnity (NetMHC 4.0 Server from
the Center for Biological Sequence analysis22,23) and the class I
immunogenicity (Immune Epitope Database and Analysis
Resource24). The results were ranked according to MHC-I
binding afﬁnity and binders with an IC50 lower than the one
displayed by the wild type epitope were considered for further
studies. Data on class I immunogenicity was taken into account
when considering peptides with similar MHC-I afﬁnity. Lead-
candidates were then studied by molecular dynamics simula-
tion by simulating their interaction with the MHC-I binding
pocket (in the a-chain) for 300 ns. The most represented struc-
ture was considered the most stable and chosen as the most
predictive conformation of the peptide-MHC-I complex.
Cell lines and peptide reagents
The mouse melanoma cell line B16-F10 was purchased from
the American Type Culture Collection (ATCC; Manassas, VA,
USA). The cell line B16.OVA,37 a mouse melanoma cell line
expressing chicken OVA, was kindly provided by Prof. Richard
Vile (Mayo Clinic, Rochester, MN, USA). RMA-S cell line38
was a kind gift of Prof. Toos Daemen (University of Groningen,
Groningen, Netherlands). All cell lines were cultured under
appropriate conditions.
SIINFEKL (OVA257–264), SIINFAKL, SIIWFEKL,
SVYDFFVWL (TRP-2180–188), SVYDFFAWL, SAYDFFVWL
and all their poly-K extended versions were purchased from
Zhejiang Ontores Biotechnologies Co. (Zhejiang, China) at a
purity of >90%.
Molecular histocompatbility complex (MHC) class-I
stabilization assay
The antigen processing-defective mutant cell line RMA-S
express a very limited amount of MHC-I molecules on their
surface, and they are devoid of peptides. The addition of exoge-
nous epitopes can stabilize the processing machinery and
increase the amount of H-2Kb on the membrane. 2 £ 106
RMA-S cells were incubated with indicated peptides at a con-
centration of 0.1 of 1 mg/mL in 2 mL of total volume. After
1.5 h of incubation at C37C, cells were washed with PBS and
ﬁxed in 4% formalin for 15 min at C4C. Cells were then
washed again with PBS and centrifuged at 1,200 rpm for 5 min.
The pellet was stained with a PE-labeled anti-H-2Kb antibody
(Biolegend, San Diego, CA, USA). Cells were washed two times
and suspended in 400 mL of PBS. The amount of H-2Kb on the
membrane was quantiﬁed by a Gallios ﬂow cytometer (Beck-
man Coulter). gMFI was normalized to the negative control
(RMA-S cells incubated without peptide).
Carboxyﬂuorescein succinimidyl ester (CFSE) proliferation
assay with OT-I splenocytes
The CD8C T-cells of C57BL/6-Tg(TcraTcrb)1100Mjb/Crl (OT-
I) mice (Charles River) have a T-cell receptor speciﬁc for the
OVA-derived class I epitope SIINFEKL.39 Spleens were col-
lected from OT-I mice and were gently disrupted through
70 mM cell strainers and single cell suspensions were frozen in
10% DMSO at ¡80C. On the day of the assay, splenocytes
were thawed, washed and resuspended in PBS. Then, spleno-
cytes were added with CFSE (Sigma-Aldrich) diluted 1:100 in a
volume of 1.1 mL of PBS for 10 min at C37C. Labeled cells
were washed two times in 10 mL of PBS and then resuspended
in complete media. CFSE-labeled OT-I splenocytes were incu-
bated for 72 h with indicated stimuli (13 mM for peptides and
0.1 mg /mL for Concanavalin A) in 230 mL in 96 multiwell
plates (V-bottom shaped). Samples were washed and incubated
with Fc Block (Biolegend) and then stained with APC-labeled
anti-CD8C and PE-labeled anti-CD3 antibodies. Cells were
washed two times, resuspended in 400 mL and analyzed by
ﬂow cytometry.
Animal experiments and immunizations
C57BL/6J (H-2Kb and H-2Db) mice have been obtained from
Scanbur (Denmark) at 4–6 weeks of age. Mice have been kept
in air-isolated cages with unlimited access to food. All proce-
dures have been carried in a level 2 biosafety cabinet under ster-
ile conditions. Mice have been anesthetized using isoﬂuorane
vaporizers. Subcutaneous tumor models have been made by
injecting 2.5 £ 105 B16.OVA or 1.5 £ 105 B16-F10 tumor cells
(when 80% conﬂuent in T175 ﬂasks) on the ﬂanks of each
mouse in 100 mL of non-supplemented RPMI-1640 media.
When the tumors reached an average diameter of 3–5 mm
(usually 9–10 d) treatments were initiated after blind randomi-
zation of mice. Details about each treatment schedule are fully
given in the ﬁgure legends. All animal experiments were
reviewed and approved by the Experimental Animal Commit-
tee of the University of Helsinki and the Provincial Govern-
ment of Southern Finland.
For therapeutic immunization, we used immunogenic onco-
lytic human adenoviruses serotype 5 (unable to replicate in
murine tumors) as adjuvants for enhanced toll-like receptor
stimulation.27,40,41 Brieﬂy, MHC-I epitope sequences were elon-
gated at the N-terminus with additional lysines to increase their
net charge. This modiﬁcation does not hinder the cross-
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presentation of the epitopes.27 Then 20 mg of peptide was
mixed with 1 £ 109 viral particles of negatively charged adeno-
viruses to allow the formation of virus-peptide complexes.
Then the peptide-virus complex was administered intra-tumor-
ally in 50 mL of natrium chloride solution.
Enzyme linked immunospot (ELISPOT) IFNg assay
Spleens have been collected from mice, disrupted and passed
through a 70 mm cell strainer. They were stored in ¡80C in
10% DMSO. On the day of the assay, splenocytes were quickly
thawed at C37C. Samples were transferred into falcon tubes
and 8 mL of complete media was slowly added. Cells were cen-
trifuged to eliminate residual DMSO and resuspended in serum
free CTL media supplemented with 1% L-glutamine and benzo-
nase (50 U/mL). Samples were counted and viability was
assayed by Trypan-Blue staining. Samples viability ranged from
80% up to 95%. Splenocytes were plated at a concentration of
2.5 £ 105 or 3 £ 105 cells/well (refer to ﬁgure legends). Cells
have been stimulated with 50 or 200 ng of peptides of interest
in 200 mL of ﬁnal volume. PBS C 1% DMSO and Concanavalin
A have been used as negative and positive controls respectively.
Stimulation was performed for 72 h in incubators (37C, 5%
CO2). Afterwards, the plates have been processed according to
manufacturer’s instructions (CTL Immunospot, Bonn, Ger-
many). The analysis of the plates (digital images production
and spot evaluation) has been outsourced to CTL Immunospot.
Statistical analysis
Statistical signiﬁcance was determined using GraphPad Prism 6
(GraphPad Software, Inc., La Jolla, CA, USA). A detailed
description of the statistical methods used to analyze the data
from each experiment can be found in each ﬁgure legend.
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Abstract 
Activation of immune checkpoint pathways and limited T- cell infiltration result in immunological 
escape of tumors. Although immune checkpoint inhibitors are currently approved for several types of 
cancers, the response rate is often limited by the lack of tumor specific T-cells within the malignant 
tissue. Therefore, new combinatorial strategies are needed to enhance the clinical benefit of immune 
checkpoint inhibitors.  
We have previously developed PeptiCRAd, an oncolytic vaccine platform capable of directing the 
immune response toward tumor epitopes. In this study, we evaluated whether the platform could be 
used to increase the response rate to checkpoint inhibitors in both highly immunogenic and poorly 
immunogenic tumors, such as melanoma and triple negative breast cancer (TNBC). 
We report here that anti-PD-L1 therapy in combination with PeptiCRAd significantly reduced the 
growth of melanomas and increased the response rate to checkpoint inhibition. In fact, we registered a 
higher rate of complete responses among mice treated with the combination. This approach promoted 
the presence of non-exhausted antigen-specific T-cells within the tumor in comparison to anti-PD-L1 
monotherapy. Furthermore, we found that targeting both MHC-I and II restricted tumor epitopes was 
necessary to decrease the growth of the poorly immunogenic TNBC model 4T1 and that combination 
with PD-L1 blockade increased the number of responders to checkpoint inhibition. Finally, the 
described strategy was validated in a translational in vitro model using HLA matched human PBMCs 
and tumor cell lines. Consistent to our previous results, improved cytotoxicity was observed with 
combination of PeptiCRAd and anti-PD-L1. 
These results demonstrate that oncolytic virus based cancer vaccine can significantly improve the 
response rate to checkpoint blocking antibodies in the context of immunogenic and non-immunogenic 
tumors.  
INTRODUCTION  
The tumor microenvironment (TME) dampens anti-tumor responses by enhancing 
immunosuppressive circuits. Among these, inhibition of dendritic cells 1, attraction of myeloid derived 
suppressor cells (MDSCs) 2-3 and recruitment of regulatory T cells (Tregs) 4 are effective strategies that 
malignant cells use to evade immune surveillance. In addition, antigen-specific T-cells that infiltrate 
tumors and recognize tumor antigens are effectively inactivated by immune checkpoint pathways 5-6. 
These pathways are promoted by ligation of inhibitory receptors (IRs) and are involved in the 
phenomenon of T-cell exhaustion. Some of these receptors, such as Programmed cell death-1 (PD-1), 
are upregulated on T-cells after their priming (antigen-experiences T-cells) and serve as a physiological 
negative feedback to resolve immune responses 7. However, chronic exposure to cognate antigens in 
combination with sustained signalling via IRs results in T-cell dysfunction and anergy (i.e. exhaustion) 8. 
Interestingly, this mechanism is often exploited by tumor cells to disrupt T-cell responses 6. Therefore, 
reverting or preventing the exhaustion of anti-tumor T cells by blocking IRs with monoclonal 
antibodies (i.e. immune checkpoint inhibitors, ICIs) has led to clinical responses in several cancer 
indications since receiving FDA approval FDA 9-11. 
Although immune checkpoint blockade has been shown to induce durable responses and long-term 
remissions, many patients fail to respond or develop resistance over time 9. The absence of tumor 
specific immunity and/or the poor infiltration of immune cells into the tumor results into 
unresponsiveness to ICI therapy 12. This represents a strong rationale for the combination of 
checkpoint inhibition and active immunotherapy in order to turn an immunologically “cold” tumor 
into a “hot” one 13-14. 
 
The natural immunogenicity of viruses combined with their oncolytic activity favours the induction of a 
pro-inflammatory environment 15. Oncolytic viruses are able to foster a specific anti-tumor immune 
response 16 and thus represent optimal candidates for combination with ICI therapy. The first approved 
oncolytic virus T-VEC is currently being evaluated in combination with ipililmumab (anti-CTLA4) in a 
phase II trial (NCT01740297) and with pembrolizumab (anti-PD-1) in a phase Ib/III trail 
(NCT02263508) in melanoma patients 17.  Traditional oncolytic viruses such as T-VEC might prevent 
optimal treatment results with ICI by skewing the immune response toward viral antigens rather than 
tumor antigens, causing the checkpoint blockade to affect mainly anti-viral T cells and thus leading to 
faster virus clearance from tumors. Instead of traditional oncolytic viruses, we propose to combine 
Programmed death-ligand 1 (PD-L1) blockade with PeptiCRAd, an improved oncolytic vaccine 
platform that we have previously described18. This platform is based on oncolytic viruses coated with 
tumor-specific peptides using electrostatic interactions (18). We have previously shown that loading 
major histocompatibility complex I (MHC-I) restricted peptides onto the immunogenic viral capsid can 
promote tumor-specific immune responses in humanized mice bearing human melanoma tumors (18). 
In this study, we evaluated the feasibility of PeptiCRAd in context of checkpoint inhibition in vitro using 
HLA matched human peripheral blood mononuclear cells (PBMCs) with tumor cell lines and in vivo 
using two different syngeneic mouse tumor models representing two distinct tumor types: highly 
immunogenic melanoma and poorly immunogenic triple negative breast cancer (TNBC). 
RESULTS 
The murine B16.OVA tumor model contains PD-1+ TILs, making it a suitable model for 
checkpoint inhibition studies 
Immunotherapy studies require models which are responsive to modulation of tumor 
microenvironment by using cancer vaccines or checkpoint inhibitors. Therefore, we characterized the 
syngeneic B16.OVA melanoma model expressing the xeno-antigen ovalbumin, which is a widely used 
model antigen in immunological studies. By using flow cytometry, we observed that majority of 
B16.OVA cells express PD-L1 on their surface at steady state in vitro. However, upon exposure to 
interferon γ (IFNγ), the percentage of PD-L1 positive cells increased from 67 % to 79 % (Figure 1A, 
left) and the expression level of PD-L1 on the cells (represented by the geometric mean fluorescence 
intensity, gMFI) increased as well (Figure 1A, right). Next, we studied the phenotype of tumor-
infiltrating lymphocytes (TILs) in B16.OVA tumors engrafted subcutaneously in C57BL/6J mice. We 
found that both CD4+ and CD8+ T-cells expressed PD-1 on their cell surface. However, CD8+ T-
cells featured significantly higher levels of PD-1 compared to CD4+ T-cells (Figure 1B, left). 
Interestingly, we found profound differences in the PD-1 staining on CD8+ T-cells upon analysis of 
different organs. In fact, CD8+ TILs feature significantly higher levels of PD-1 compared to CD8+ T-
cells found in secondary lymphoid organs (spleen or tumor-draining lymph nodes) of tumor bearing 
mice (Figure 1B, right).  
The differences in the phenotypic state of TILs prompted us to evaluate a possible correlation between 
different T-cell populations within the tumor. In this analysis, we define PD-1+TIM-3- cells as active 
and antigen experienced (i.e. Act) whereas PD-1+TIM-3+ cells are defined as antigen experienced but 
exhausted (i.e. Exh). As shown in figure 1C we report the Pearson´s coefficients for the correlation 
between different subsets. A positive value indicates a positive correlation, while a negative value 
suggests a negative one. The presence of Activated CD4+ T-cells within the tumor positively correlates 
with an increased number of Activated CD8+ T-cells in the very same tumor. Vice versa, we found 
that the number of Exhausted CD4+ T-cells correlates with an increased number of Exhausted CD8+ 
T-cells. These finding suggests that there might be an underlying link between activation and 
exhaustion states of different sub-populations of T-cells. 
 
The response rate to PD-L1 blockade is increased by combination with oncolytic vaccines in 
vivo. 
Despite achieving complete responses in some cases, many patients do not benefit from the expensive 
treatment. Desert tumors (i.e. cold tumors) are less responsive than tumors featuring high presence of 
TILs (i.e. hot tumors). Therefore, we sought to investigate how to improve the response to checkpoint 
inhibition by combining active immunotherapy such as an oncolytic vaccine platform (i.e. PeptiCRAd) 
with anti-PD-L1 therapy. 
Mimicking a non-injectable lesion model, we treated B16.OVA-bearing mice with intraperitoneal 
administration of anti-PD-L1 antibody (aPD-L1) alone or in combination with subcutaneous injections 
of OVA-targeting PeptiCRAd (i.e. OVA-PeptiCRAd). PD-L1-blocking antibody slowed down the 
tumor growth compared to mock-treated mice, however, the combination with active immunotherapy 
(i.e. Combo group) increased the efficacy of the treatment significantly (Figure 2A). The primary 
tumors featured a significantly slower growth-kinetics as represented by the area under the curve 
analysis (AUC, figure 2B). Interestingly, the combination treatment was able to significantly reduce the 
growth of secondary tumors in a contralateral model (Figure 2C). This demonstrated that the oncolytic 
vaccine was able to create a beneficial, systemic immune response that together with the ICI reduced 
the growth of both primary and secondary tumors. When compared to mock, the overall survival of 
mice was improved by aPD-L1 therapy (median survival 29 days; figure 2D). However, the 
combination therapy was able to significantly increase the median survival of mice up to 36 days. Most 
importantly, complete responses were observed in 35.7 % of the mice in the combo group versus only 
14.2 % of mice in the aPD-L1 group. In addition to complete responders, 87.5 % of combo-treated 
mice had a tumor volume lower than 1000 mm3 compared to 42.8 % of the cases in the aPD-L1 group 
(figure 2E). Taken together these data demonstrates that the combination of immune checkpoint 
inhibitors with oncolytic vaccines improves the number of responders.  
Despite the fact that PeptiCRAd platform is designed to induce anti-tumor immunity, the high 
prevalence of adenovirus among the human population prompted us to study whether pre-existing 
immunity (PEI) could affect the efficacy of PeptiCRAd as an active immune therapy in combination 
with PD-L1 blockade. We found that the efficacy of the combination treatment was largely the same 
between pre-immunized mice (PEI-Combo group) and naïve mice (Combo) as shown in figure 2G 
and that PEI did not reduce the overall survival of treated mice (figure 2H).  
 
Immunological synergy between PD-L1 blockade and the oncolytic vaccine PeptiCRAd 
The previously described results in B16.OVA-bearing mice clearly demonstrated a benefit in combining 
checkpoint inhibitors with active immunotherapy. In order to gain insights into the phenotype of 
tumor infiltrating CTLs, we performed a series of flow cytometric assays. First, we investigated the 
activation and exhaustion state of CD3+CD8+ TILs by defining activated T cells as PD-1+TIM-3- and 
terminally exhausted T cells as PD-1+TIM-3+. Interestingly, TIM-3 single positive cells were not 
detected in any sample, suggesting that the presence of this marker is linked to the presence of PD-1 
(Figure 3A, central red section). All the immunotherapies increased the number of PD-1+ T-cells 
(figure 3A, left blue section), with PeptiCRAd and Combo treatment showing significantly more 
activated TILs than mock. Consistently, the immunotherapy treatments favoured the reduction of 
exhausted PD-1+TIM-3+ T-cells compared to mock (figure 3A, right green section). Analysis of T 
cell specificity revealed that only mice receiving the oncolytic vaccine (i.e. PeptiCRAd and Combo 
groups) showed a significantly increased presence of OVA-specific CD8+ TILs compared to mock 
treatment (Figure 3B). As shown in figure 3C, this tumor-specific population featured an increased 
ratio of activated and exhausted cells in mice receiving combination treatment (activated/exhausted 
ratio 2.541; p=0.0058) compared to other groups. This demonstrates that the aPD-L1 + PeptiCRAd 
treatment favoured the presence of activated OVA-specific T-cells upon exhausted OVA-specific T-
cells. 
 
Co-stimulation of CD4+ and CD8+ T-cells response elicits antitumor efficacy in triple negative 
breast cancer. 
Triple negative breast cancer (TNBC) lacks common tumor antigens and is considered poorly 
immunogenic. Nevertheless, we found a sustained expression of MHC-I molecules on both murine 
(supplementary figure 1A) and human (supplementary figure 1B) tumor cell lines. To this end, we 
decided to optimize our oncolytic vaccine platform to target MHC-I and MHC-II restricted tumor 
antigens simultaneously (available in Material and Methods).  
We investigated whether stimulating both CD8+ and CD4+ T cell responses would give any advantage 
over stimulating only one type of response. To this end, we treated tumor-bearing mice with 
PeptiCRAds coated either with an MHC-class I epitope (PeptiCRAd-I), with an MHC-class II epitope 
(PeptiCRAd-II) or with both class I and II peptides (PeptiCRAd I+II). While both single coated 
PeptiCRAds showed a modest growth inhibition of 4T1 cells engrafted subcutaneously in Balb/c mice, 
treatment with the PeptiCRAd I+II showed a significant reduction in tumor growth at day 15 when 
compared to mock (figure 4A). Nevertheless, the therapeutic vaccination with this approach did not 
lead to the full control of tumors. Following flow cytometric analysis, 4T1 tumor cells were found to 
express high levels of PD-L1 both in vitro (figure 4B) and in vivo (figure 4C). We found the 4T1 tumor 
model to modulate the expression of PD-L1 in response to IFN𝛾 in vitro (Figure 5B) and this may 
explain the resistance of tumor cells to the treatment despite the infiltration of tumors with CD8+ and 
CD4+ T-cells. We further characterized the phenotype of TILs in 4T1 tumors and found that both 
CD4+ and CD8+ TILs expressed PD-1, while the proportion of PD-1+ cells was higher in the CD8+ 
subset (figure 5D). Interestingly, we found statistically significant differences in the PD-1 status on 
CD8+ T-cells while analysing different organs. In fact, higher proportion of CD8+ T-cells found in 
tumors were PD-1+ compared to T-cells found in the spleen or draining lymph nodes (figure 4D, 
right). This analysis suggests that the strong tumor immunosuppressive environment might limit the 
efficacy of oncolytic vaccines. 
 
The combination of PD-L1 blockade and PeptiCRAd boosts anti-tumor efficacy against TNBC 
by modulating the immunosuppressive tumor microenvironment. 
In order to further investigate the possible benefits of combining aPD-L1 with the oncolytic vaccine, 
Balb/c mice were engrafted with 4T1 cells and treated with aPD-L1 monoclonal antibody in 
combination with the PeptiCRAd coated with MHC-I and II epitopes. As shown in Figure 5A, 
treatment with PD-L1 blockade only resulted in a response rate of 37.5 % of the treated mice. In 
contrast, 62.5 % of mice treated with the PeptiCRAd I+II and aPD-L1 responded to therapy. 
Tumors were collected and immunological analyses were performed. Compared to aPD-L1 alone, the 
co-administration of PeptiCRAd I+II increased the percentage of CD8+ TILs while reducing CD4+ 
TILs (Figure 5B).  
Next, we decided to investigate the immunological environment possibly affecting therapeutic 
outcomes the strong immunosuppressive TME in 4T1 mammary carcinoma model features the 
presence of myeloid-derived suppressor cells (MDSCs) 2, 19-20. Hence, we evaluated the infiltration of 
tumors by the neutrophilic N-MDSC (Ly6Ghigh and Ly6C intermediate/high) subtype 19. Tumors treated with 
PeptiCRAd I+II and + aPD-L1 showed statistically higher neutrophil infiltration compared to control 
groups (Figure 5C). This is relevant observation as it has been suggested that neutrophils can limit the 
tumor growth through their cytotoxic activity 21. 
Finally, to reproduce the findings in a clinically relevant in vitro model, we stimulated human PBMCs 
from healthy donors with oncolytic vaccines and co-incubated them with target (tumor) cells to 
evaluate T-cell mediated killing in the presence or absence of aPD-L1 (details about HLA phenotyping 
and matching of human samples are available in the material and methods section and in Table 1). The 
PBMCs were pulsed with PeptiCRAd targeting tumor associated antigens from human melanoma 
(MAGE A1) or TNBC (MAGE A4) 22-24. Interestingly, in both cases we observed a statistically 
significant difference in the killing ability of PBMCs. In particular, the cytotoxic activity of PBMCs was 
enhanced in presence of anti-PD-L1 antibody (Figure 5D). 
In conclusion, our data demonstrates that PeptiCRAd can promote antigen-specific T cell responses 
which are beneficial for checkpoint inhibition therapy, thus providing a strong rationale for a 
combinatorial approach. 
 
 
DISCUSSION 
 
Under physiological conditions, immune checkpoint pathways maintain self-tolerance and help in 
resolving the inflammation after the clearance of pathogens 25. However, cancer cells use these anti-
inflammatory receptors to dysregulate CD8+ and CD4+ T-cells 14, 25-26. The infiltration of immune cells 
within the tumor tissue represents a favourable prognostic factor, as it often reflects an undergoing 
immune response. Immune-infiltrated tumors are defined as “hot”, while poorly infiltrated tumors are 
defined as “cold”. The distinction between these two scenarios is becoming more and more important 
to estimate the risk-to-benefit ratio of expensive therapies such as ICIs. In fact, despite the remarkable 
results that this class of drugs has achieved in many studies in terms of overall survival, the response 
rates are still limited. For instance, the phase III clinical study that led to the approval of Ipilimumab 
registered a response rate of only 10.9% and a disease control rate of 28.5%. Similarly, the PD-1 
blocking antibody Nivolumab has been tested in a variety of tumors such as non-small cell lung cancer, 
melanoma and renal cell carcinoma with response rates ranging from 18 to 27 %. Another independent 
study revealed an encouraging response rate of 51 % in patients with advanced melanoma, although 
only 9 % of the patients experienced complete responses 9. The need to increase the response rate to 
checkpoint inhibition prompted us to study their combination with oncolytic vaccines which are 
suitable candidates because of their natural immunogenicity 27; in addition, the lysis of cancer cells 
might reveal hidden antigens and enhance their immune presentation 16, 28. In 2015, the Food and Drug 
Administration approved the use of an oncolytic herpes simplex virus (HSV)-1 for the treatment of 
melanoma 29. Similarly, to this virus, we have previously demonstrated that our oncolytic vaccine 
platform (i.e. PeptiCRAd) is able to induce potent antigen-specific responses and T-cell infiltration 18. 
Here we demonstrated that oncolytic vaccines increase the response rate of checkpoint inhibition. We 
propose a mode of action where the oncolytic vaccine fosters the induction of antigen-specific T-cells 
while the immune checkpoint inhibitor prevents their dysregulation within the TME. In fact, we 
observed an increased response rate among melanoma bearing-mice as regards the growth of primary 
and secondary untreated tumors when receiving a combination of anti-PD-L1 antibody and 
PeptiCRAd. In fact, their tumors were infiltrated with antigen-specific T-cells with the majority being 
antigen-experienced but non-exhausted. In addition, we confirmed that PEI against adenovirus does 
not impair the response to the combinational therapy, which is an important aspect for patients that 
received previous treatment with oncolytic vaccines or present PEI to other viral platforms. Similar 
results have been recently described in a clinical study of Pembrolizumab with T-VEC. Although being 
characterized by a small sample size, this phase Ib study revealed an impressive 62 % response rate in 
patients with metastatic melanoma. Consistently with our results, the tumors of patients showed an 
increased infiltration of T-cells 30 that might be caused by the viral treatment.  
After the clinical success of checkpoint inhibition against melanoma, several studies suggested their use 
to treat different types of cancer. However, in these cases there is an even stronger need for T-cell 
infiltration and an underlying immune response 31. A recent study showed how oncolytic virotherapy 
helps in overcoming PD-1 resistance by inducing neo-antigen specific T-cells following oncolysis of the 
tumor tissue 32. Therefore, we investigated if our oncolytic vaccine platform in combination with PD-
L1 blockade could be effective against a poorly immunogenic tumor model, such as TNBC. First, we 
were able to demonstrate the benefit of targeting both CD4 and CD8 epitopes at the same time. This 
correlates with studies where engagement of the T-helper compartment has been shown to increase the 
efficacy of cancer vaccine strategies 33-34. Aarntzen and colleagues have demonstrated that combining 
CD4 and CD8 epitopes improves median progression-free survival of patients with stage III and IV 
melanoma with detectable antigen-specific responses among skin-infiltrating lymphocytes 35. Similar 
approaches featured the production of longer peptides including both CD4 and CD8 epitopes. The 
CD4+ T-helper cells support CTLs by production of IL-2 and they increase the efficacy of antigen 
presentation by licensing DCs through the CD40/CD40L pathway 36. We have previously 
demonstrated that the PeptiCRAd platform increased the maturation of DCs; our data supports the 
hypothesis that including CD4 epitopes improves the control of tumor growth. Combination of this 
platform with PD-L1 blockade increased the number of mice responding to checkpoint inhibition from 
35 %, observed with aPD-L1, up to 62 % with combination therapy. 
The crosstalk between cancer and immune system plays a pivotal role in the tumor regression or 
progression 13. The lack of appropriate models prompted us to investigate our strategy in a clinically 
relevant model. To this end, in according to data from literature 37, we have established an in vitro co-
culture system for TNBC and melanoma models with HLA-matched PBMCs: we observed an 
improved killing ability of oncolytic vaccine-pulsed PBMCs in presence of PD-L1 antibody. 
Clinical studies are now focusing on turning cold tumors into hot tumors, hence providing the 
blockade of immune checkpoints with the immunological support they need. In addition, the 
engagement of T-helper cells should not be overlooked despite the limited availability of shared CD4 
epitopes. However, recent progress in whole exome sequencing, RNAseq and ligandome analysis opens 
new possibilities for neo-antigen identification. For this reason, highly versatile platforms, such as 
oncolytic vaccines are suitable for multi-targeted approaches, enabling increased response rates to 
checkpoint inhibitors in cancer patients. 
 
MATERIALS AND METHODS 
Cell lines and reagents 
The cell line B16-OVA, a mouse melanoma cell line expressing chicken OVA, was kindly provided by 
Prof. Richard Vile (Mayo Clinic, Rochester, MN, USA).  The human malignant melanoma cell line SK-
MEL-2 were purchased from the American Type Culture Collection (ATCC; Manassas, VA, USA). 
Mouse breast cancer cell line (4T1) and human breast cancer cell line (MDA-MB-436) were purchased 
from the American Type Culture Collection (ATCC; Manassas, VA, USA) All cell lines were cultured 
according to ATCC recommendations. The cells were cultured in RPMI-1640 high glucose and 
DMEM low glucose respectively and supplemented with 10 % FBS ,1 % antibiotics and 1 % of L-
Glutamine. All cells were grown in 37°C, 5 % CO2 in a humidified atmosphere. 
PBMC were purchased from Immune Spot (Bonn, Germany) and HLA matched with SK-MEL2 and 
MDA-MB-436. 
Murine and human interferon  used in the vitro experiment were purchased from Sigma Aldrich and 
used both at final concentration of 10 ng/mL. The anti-mouse and anti-human PD-L1 (B7-H1) 
monoclonal antibody was purchased from Bio X Cell. 
The following peptides were used through the study: poly-K-SIINFEKL (KKKKKKSIINFEKL), 
Tmtc2 (KKKKQGVTVLAVSAVYDIFVFHRLKMKQILP), 
Wdr11(KKKKKKKKKKNDEPDLDPVQELIYDLRSQCDAIRVTK), Zfr 
(KKAHIRGAKHQKVVTLHTKLGKPIPSTEP), Adamts9 
(KKKKKKKDYTAAGFSSFQKLRLDLTSMQIITTD), Pan HLA-DR reactive epitope (PADRE) 
(KKKKAKFVAAWTLKAAA), Mageb-1/Mageb-2 (KKKKKKAGTSIQHTLKDPI) and MAGE A4 
(KKKKKKKKWVQENYLEY) were purchased from Zhejiang Ontores Biotechnologies Co. 
(Zhejiang, China) 
 
PBMCs killing assay of target tumor cells 
All the PBMCs used in this work were cultured with human IL-2 at a final concentration of 3.3 ng/ml 
per 0.15x106 cells and pulsed with PeptiCRAd as described in the experimental procedure for 2 days. 
The PBMCs were added to the cells at ratio 10:1 and after 5 days the viability was evaluated by MTS 
assay in according to the manufacturer´s protocol (CellTiter 96 Aqueous One Solution Cell 
Proliferation Assay; Promega, Nacka, Sweden). Spectrophotometric data were acquired with Varioskan 
Flash Multimode Reader (Thermo Scientific, Carlsbad, CA, USA). 
 
Animal Experiments and ethical permits 
All animal experiments were reviewed and approved by the Experimental Animal Committee of the 
University of Helsinki and the Provincial Government of Southern Finland (license number 
ESAVI/9817/04.10.07/2016) 
Female BALB/cOlaHsd mice 4-6 weeks old were obtained from Envigo (Harlan, USA) and used as a 
syngeneic mouse tumor model of breast cancer. 3x105 4T1 cells were injected subcutaneously in the 
right flank. For the melanoma syngeneic model, we used 4-6 weeks old female C57BL/6J mice 
engrafted subcutaneously with 3x105 B16.OVA cells. Details about the schedule of the treatment can 
be found in the figure legends. Viral dose was 1x109 vp/tumor complexed with 20 µg of the chosen 
epitope. Checkpoint inhibitors were give intraperitoneally at a dose of 200 µg/mouse. 
Flow Cytometry  
The antibodies used are the following: TruStain Fc block anti-mouse and anti-human CD16/32 
(BioLegend); FITC anti-mouse CD8 (ProImmune); APC anti-mouse CD4 (BioLegend); PE-anti-mouse 
and anti-human CD279/PD-1 (BioLegend); PE/Cy7 anti-mouse TIM-3 (BioLegend); Percp/Cy5.5 
anti-mouse CD3 (BioLegend); APC anti-mouse H2Kd (BioLegend); APC anti-mouse I/A-I/E 
(BioLegend); PE-anti-human and mouse CD274 B7-H1 (PD-L1) (BioLegend) ; PE anti-human HLA-
A, B,C (BioLegend); FITC anti-mouse Cd11b (BD Pharmingen); PE anti-mouse Ly6G (BD 
Pharmingen); APC anti-mouse Ly6C (BD Pharmingen). The data were acquired using BD Accuri 6C 
plus (BD) or Gallios (Beckmann Coulter) flow cytometers. Data analyzed using FlowJo software v10 
(Ashland, Oregon, USA). 
 
PeptiCRAd complex formation 
Oncolytic adenovirus and polyK epitope (Ontores, Zhejiang, China) were mixed to prepare the 
PeptiCRAd complex. We mixed polyK epitope with Ad-5-D24-CpG for 15 minutes at room 
temperature and after that we use this complex to treat the mice. More details about the stability and 
formation of the complex can be found in our previous study 18. 
 
HLA genotyping and PBMCs samples 
The DNA extraction was performed according to the manufacturer´s protocol (QIAamp DNA Mini 
Kit 50 Qiagen); the HLA-A, B and DRB1 was analysed on high resolution (4digit Sanger´s sequencing) 
by the Finnish Red Cross. The results of the genotypization can be found in table 1. 
Cryopreserved PBMCs were purchased from the cryo-bank available at CTL (Cellular Technology 
Limited) and were used under the license number ESAVI/9817/04.10.07/2016. 
 
Statistical Analysis  
Statistical analysis was performed using Graphpad Prism 6.0 software (Graphpad Software Inc., La 
Jolla, CA USA). For animal experiment, 2way ANOVA with Tukey´s multiple comparisons test was 
used and P<0.05 was considered statistically significant. All results are expressed as the mean ± 
standard error of the mean (SEM). Details about the statistical tests for each experiment can be found 
in the correspondent figure legend.  
REFERENCES 
 
1. Loskog, A.; Ninalga, C.; Totterman, T. H., Dendritic cells engineered to express CD40L 
continuously produce IL12 and resist negative signals from Tr1/Th3 dominated tumors. Cancer 
immunology, immunotherapy : CII 2006, 55 (5), 588-97. 
2. Youn, J. I.; Nagaraj, S.; Collazo, M.; Gabrilovich, D. I., Subsets of myeloid-derived suppressor 
cells in tumor-bearing mice. J Immunol 2008, 181 (8), 5791-802. 
3. Kodumudi, K. N.; Woan, K.; Gilvary, D. L.; Sahakian, E.; Wei, S.; Djeu, J. Y., A novel 
chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in 
tumor bearers. Clinical cancer research : an official journal of the American Association for Cancer Research 2010, 
16 (18), 4583-94. 
4. Chaudhary, B.; Elkord, E., Regulatory T Cells in the Tumor Microenvironment and Cancer 
Progression: Role and Therapeutic Targeting. Vaccines (Basel) 2016, 4 (3). 
5. Smahel, M., PD-1/PD-L1 Blockade Therapy for Tumors with Downregulated MHC Class I 
Expression. Int J Mol Sci 2017, 18 (6). 
6. Zhang, L.; Gajewski, T. F.; Kline, J., PD-1/PD-L1 interactions inhibit antitumor immune 
responses in a murine acute myeloid leukemia model. Blood 2009, 114 (8), 1545-52. 
7. Reiser, J.; Banerjee, A., Effector, Memory, and Dysfunctional CD8(+) T Cell Fates in the 
Antitumor Immune Response. J Immunol Res 2016, 2016, 8941260. 
8. Fuertes Marraco, S. A.; Neubert, N. J.; Verdeil, G.; Speiser, D. E., Inhibitory Receptors Beyond 
T Cell Exhaustion. Frontiers in immunology 2015, 6, 310. 
9. Callahan, M. K.; Wolchok, J. D., At the bedside: CTLA-4- and PD-1-blocking antibodies in 
cancer immunotherapy. J Leukoc Biol 2013, 94 (1), 41-53. 
10. Liu, J.; Zhang, S.; Hu, Y.; Yang, Z.; Li, J.; Liu, X.; Deng, L.; Wang, Y.; Zhang, X.; Jiang, T.; Lu, 
X., Targeting PD-1 and Tim-3 Pathways to Reverse CD8 T-Cell Exhaustion and Enhance Ex Vivo T-
Cell Responses to Autologous Dendritic/Tumor Vaccines. Journal of immunotherapy 2016, 39 (4), 171-80. 
11. Zitvogel, L.; Kroemer, G., Targeting PD-1/PD-L1 interactions for cancer immunotherapy. 
Oncoimmunology 2012, 1 (8), 1223-1225. 
12. O'Donnell, J. S.; Long, G. V.; Scolyer, R. A.; Teng, M. W.; Smyth, M. J., Resistance to 
PD1/PDL1 checkpoint inhibition. Cancer Treat Rev 2017, 52, 71-81. 
13. Sharma, P.; Hu-Lieskovan, S.; Wargo, J. A.; Ribas, A., Primary, Adaptive, and Acquired 
Resistance to Cancer Immunotherapy. Cell 2017, 168 (4), 707-723. 
14. Sharma, P.; Allison, J. P., Immune checkpoint targeting in cancer therapy: toward combination 
strategies with curative potential. Cell 2015, 161 (2), 205-14. 
15. Alemany, R.; Cascallo, M., Oncolytic viruses from the perspective of the immune system. Future 
Microbiol 2009, 4 (5), 527-36. 
16. Aurelian, L., Oncolytic viruses as immunotherapy: progress and remaining challenges. Onco 
Targets Ther 2016, 9, 2627-37. 
17. Swart, M.; Verbrugge, I.; Beltman, J. B., Combination Approaches with Immune-Checkpoint 
Blockade in Cancer Therapy. Frontiers in oncology 2016, 6, 233. 
18. Capasso, C.; Hirvinen, M.; Garofalo, M.; Romaniuk, D.; Kuryk, L.; Sarvela, T.; Vitale, A.; 
Antopolsky, M.; Magarkar, A.; Viitala, T.; Suutari, T.; Bunker, A.; Yliperttula, M.; Urtti, A.; Cerullo, V., 
Oncolytic adenoviruses coated with MHC-I tumor epitopes increase the antitumor immunity and 
efficacy against melanoma. Oncoimmunology 2016, 5 (4), e1105429. 
19. Ali, K.; Soond, D. R.; Pineiro, R.; Hagemann, T.; Pearce, W.; Lim, E. L.; Bouabe, H.; 
Scudamore, C. L.; Hancox, T.; Maecker, H.; Friedman, L.; Turner, M.; Okkenhaug, K.; 
Vanhaesebroeck, B., Inactivation of PI(3)K p110delta breaks regulatory T-cell-mediated immune 
tolerance to cancer. Nature 2014, 510 (7505), 407-411. 
20. Bunt, S. K.; Sinha, P.; Clements, V. K.; Leips, J.; Ostrand-Rosenberg, S., Inflammation induces 
myeloid-derived suppressor cells that facilitate tumor progression. J Immunol 2006, 176 (1), 284-90. 
21. Fridlender, Z. G.; Sun, J.; Kim, S.; Kapoor, V.; Cheng, G.; Ling, L.; Worthen, G. S.; Albelda, S. 
M., Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. 
Cancer cell 2009, 16 (3), 183-94. 
22. Cabezon, T.; Gromova, I.; Gromov, P.; Serizawa, R.; Timmermans Wielenga, V.; Kroman, N.; 
Celis, J. E.; Moreira, J. M., Proteomic profiling of triple-negative breast carcinomas in combination with 
a three-tier orthogonal technology approach identifies Mage-A4 as potential therapeutic target in 
estrogen receptor negative breast cancer. Mol Cell Proteomics 2013, 12 (2), 381-94. 
23. Mathe, A.; Wong-Brown, M.; Morten, B.; Forbes, J. F.; Braye, S. G.; Avery-Kiejda, K. A.; Scott, 
R. J., Novel genes associated with lymph node metastasis in triple negative breast cancer. Sci Rep 2015, 
5, 15832. 
24. Stagg, J.; Allard, B., Immunotherapeutic approaches in triple-negative breast cancer: latest 
research and clinical prospects. Ther Adv Med Oncol 2013, 5 (3), 169-81. 
25. Pardoll, D. M., The blockade of immune checkpoints in cancer immunotherapy. Nature reviews. 
Cancer 2012, 12 (4), 252-64. 
26. Sharma, P.; Allison, J. P., The future of immune checkpoint therapy. Science 2015, 348 (6230), 
56-61. 
27. Kohlhapp, F. J.; Kaufman, H. L., Molecular Pathways: Mechanism of Action for Talimogene 
Laherparepvec, a New Oncolytic Virus Immunotherapy. Clinical cancer research : an official journal of the 
American Association for Cancer Research 2015. 
28. Andtbacka, R. H.; Kaufman, H. L.; Collichio, F.; Amatruda, T.; Senzer, N.; Chesney, J.; 
Delman, K. A.; Spitler, L. E.; Puzanov, I.; Agarwala, S. S.; Milhem, M.; Cranmer, L.; Curti, B.; Lewis, 
K.; Ross, M.; Guthrie, T.; Linette, G. P.; Daniels, G. A.; Harrington, K.; Middleton, M. R.; Miller, W. 
H., Jr.; Zager, J. S.; Ye, Y.; Yao, B.; Li, A.; Doleman, S.; VanderWalde, A.; Gansert, J.; Coffin, R. S., 
Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. 
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2015, 33 (25), 2780-8. 
29. Rehman, H.; Silk, A. W.; Kane, M. P.; Kaufman, H. L., Into the clinic: Talimogene 
laherparepvec (T-VEC), a first-in-class intratumoral oncolytic viral therapy. Journal for immunotherapy of 
cancer 2016, 4, 53. 
30. Haanen, J., Converting Cold into Hot Tumors by Combining Immunotherapies. Cell 2017, 170 
(6), 1055-1056. 
31. Galon, J.; Fox, B. A.; Bifulco, C. B.; Masucci, G.; Rau, T.; Botti, G.; Marincola, F. M.; Ciliberto, 
G.; Pages, F.; Ascierto, P. A.; Capone, M., Immunoscore and Immunoprofiling in cancer: an update 
from the melanoma and immunotherapy bridge 2015. Journal of translational medicine 2016, 14, 273. 
32. Woller, N.; Gurlevik, E.; Fleischmann-Mundt, B.; Schumacher, A.; Knocke, S.; Kloos, A. M.; 
Saborowski, M.; Geffers, R.; Manns, M. P.; Wirth, T. C.; Kubicka, S.; Kuhnel, F., Viral Infection of 
Tumors Overcomes Resistance to PD-1-immunotherapy by Broadening Neoantigenome-directed T-
cell Responses. Molecular therapy : the journal of the American Society of Gene Therapy 2015, 23 (10), 1630-40. 
33. Cho, H. I.; Celis, E., Design of immunogenic and effective multi-epitope DNA vaccines for 
melanoma. Cancer immunology, immunotherapy : CII 2012, 61 (3), 343-51. 
34. Galaine, J.; Borg, C.; Godet, Y.; Adotevi, O., Interest of Tumor-Specific CD4 T Helper 1 Cells 
for Therapeutic Anticancer Vaccine. Vaccines (Basel) 2015, 3 (3), 490-502. 
35. Aarntzen, E. H.; De Vries, I. J.; Lesterhuis, W. J.; Schuurhuis, D.; Jacobs, J. F.; Bol, K.; 
Schreibelt, G.; Mus, R.; De Wilt, J. H.; Haanen, J. B.; Schadendorf, D.; Croockewit, A.; Blokx, W. A.; 
Van Rossum, M. M.; Kwok, W. W.; Adema, G. J.; Punt, C. J.; Figdor, C. G., Targeting CD4(+) T-
helper cells improves the induction of antitumor responses in dendritic cell-based vaccination. Cancer 
research 2013, 73 (1), 19-29. 
36. Melief, C. J.; van der Burg, S. H., Immunotherapy of established (pre)malignant disease by 
synthetic long peptide vaccines. Nature reviews. Cancer 2008, 8 (5), 351-60. 
37. Van Voorhis, W. C., Coculture of human peripheral blood mononuclear cells with 
Trypanosoma cruzi leads to proliferation of lymphocytes and cytokine production. J Immunol 1992, 148 
(1), 239-48. 
   
Figures & Table legend 
Figure 1. Characterization of the immunological properties of the B16.OVA model and its 
suitability for immune checkpoint inhibition studies. 
A) B16.OVA melanoma cells were incubated for 24 hours with or without murine IFNγ. On the 
following day cells were stained for the presence of PD-L1 and analyzed by flow cytometry. An isotype 
antibody served as negative control. The percentage of PD-L1+ positive cells (left panel) and the 
geometrical mean fluorescence intensity (gMFI; right panel) are plotted as the mean ± SEM. B) 
Analysis of immunological samples collected from C57BL/6J female mice engrafted with B16.OVA 
tumors. The expression of the marker PD-1 on the surface of CD3+CD4+ and CD3+CD8+ tumor 
infiltrating cells (left panel). PD-1 expression on CD3+CD8+ cells in different organs. Statistics are 
done by using the Student´s t-test; *** p<0,001, **** p<0,0001. C) Activated (Act) (PD-1+TIM3-) or 
Exhausted (Exh) (PD-1+TIM-3+) lymphocytes were defined within the CD4+ or CD8+ populations 
by flow cytometry. The Pearson´s coefficient of correlation between all populations was then 
calculated. A positive coefficient represents a positive correlation, while a negative coefficient 
represents a negative correlation. 
 
Figure 2. Combination of oncolytic vaccines and PD-L1 blockade increases the response to 
checkpoint inhibition.  
B16.OVA bearing female C57BL/6J mice (n=7-8) were treated with saline solution (mock), OVA-
PeptiCRAd oncolytic vaccine (day 6, 8 and 10, sub-cutaneously), 100 ug of anti-PD-L1 blocking 
antibody (aPD-L1) three times per week or a combination of the two monotherapies (Combo). A) 
Tumor volumes are plotted as the mean ± SEM. B) The area under the curves relative to the tumor 
growth of mice was calculated and plotted as the mean ± SEM. C) At day 28 long-term survivors were 
re-challenged on the left flank with B16 melanoma tumor cells (300000 cells/mouse). Volumes of the 
secondary tumors of long-term survivors are presented as mean ± SEM. E) Survival curve relative to 
the experiment presented in A. The percentage of tumor-free mice is indicated for aPD-L1 and Combo 
groups. The median survival of each group is reported in the table below the graph. F) The volumes of 
the primary tumors at day 35 are reported for each mouse to define the responders VS non-responders. 
Threshold of 1000 mm3 was set to define the response. The percentage of responders is reported below 
the x axis. G) C57BL/6J mice pre-immunized with the oncolytic adenovirus (PEI-COMBO) or naïve 
mice (Combo) were engrafted with B16.OVA tumor cells. Both groups received the combination of 
oncolytic vaccine PeptiCRAd and aPD-L1 with standard regiment used previously. Tumor volume is 
presented as the mean ± SEM. H) Survival of the groups is presented and median survival reported. 
For tumor growth curves statistic were calculated by Two-Way ANOVA with Tukey´s post-test. The 
log rank Mantel-Cox analysis was used to calculate the p value of the survival curves. For the bar 
graphs the Student´s t-test was used. * p<0.05, ** p<0.005, *** p<0,001, **** p<0,0001. 
Figure 3. Induction of antigen specific cells by oncolytic vaccines synergizes with the 
inhibition of PD-1/PD-L1 interactions reshaping the immunological background. 
Tumor samples were collected from mice treated with the aPD-L1+OVA-PeptiCRAd combination 
presented in figure 2. CD3+CD8+ tumor infiltrating lymphocytes were evaluated for antigen specificity 
(SIINFEKL-Pentamers) and their state (PD-1 and TIM-3 expression) by flow cytometry. A) 
Percentages of single positive PD-1+ (blue) or TIM-3+ (red) or double positive PD-1+TIM-3+ (green) 
CD8+ TILs are plotted by Tukey box and whiskers for each group of animals. Analysis done by Two-
Way ANOVA. B) The percentage of OVA specific CD8+ TILs was assayed by Pentamer Staining and 
it is plotted as the mean ± SEM. Analysis done by One-way ANOVA C) The ratio between Activated 
(PD-1+) and Exhausted (PD-1+TIM-3+) OVA-specific CD8+ TILs was calculated for each mouse. 
The ratio is reported on top of each bar. A statistical test was performed to assess if the ratio was 
significantly different than 1. The p-values for each group are reported below the graph. 
 
 
Figure 4. Antitumor activity of different PeptiCRAd formulations and immunological 
background analysis. 
(A) Balb/c mice (n=7) received 3x105 4T1 cells in the right flank. Treatments were initiated on 
established tumor (9 days after implantation) and the mice were treated three times (on days 9, 11 and 
13, black arrow). The average volume is represented in the tumor´s growth curve as mean ± SEM 
(statistical analysis 2way ANOVA with Tukey´s multiple comparisons test. *p<0.05). (B) PD-L1 level 
in 4T1 are reported. The cells were stimulated with INF overnight. On the following day, the cells 
were stained for PD-L1 and analyzed by flow cytometry. The percentage of PD-L1 positive cells (left 
panel) and the geometrical mean fluorescence intensity (gMFI; right panel) are plotted as the mean ± 
SEM (statically analysis unpaired t-test. p<0.05). C) PD-L1 level in tumor from mice bearing 4T1 
tumor is described. The percentage of PD-L1+ positive cells (left panel) and the geometrical mean 
fluorescence intensity (gMFI; right panel) are plotted as the mean ± SEM. D) PD-1+ T cell infiltration 
in tumors, spleens and lymph nodes from mice bearing 4T1 tumor is shown (statically analysis unpaired 
t-test. p<0.05). The flow cytometry analysis was performed in tumor, spleen and lymph node samples 
collected from mice and frozen. We used anti-mouse PE-PD-1, anti-mouse Percp/Cy5.5 CD3, anti-
mouse FITC-CD8 and anti-mouse APC- CD4. The percentage of PD-1 positive cells is plotted as the 
mean ± SEM (statically analysis unpaired t-test. p<0.05). 
Figure 5. Anti-tumor activity PD-L1 blockade and PeptiCRAd mediated and immune 
modulation in tumor microenvironment. 
(A) The single tumor growth curves for single mouse and one graph for each group are reported. 
Responders are defined in percentage (displayed next to each graph) as mice that show an absolute 
volume lower than 200 mm3. (B) Flow cytometry analysis of CD4 and CD8 T cells in tumor samples 
from the animal groups is presented. (C) At the end of the experiment the tumors were collected and 
analyzed for the PMN-MDSCs infiltration. The analysis was executed considering the intermediate 
value of Ly6C+ signal, identifying the neutrophil population as as Ly6Ghigh and Ly6C intermediate/high. (D) 
Human PBMCs HLA matched with tumor cell lines were pulsed with PeptiCRAd-MAGEA1 (for SM-
MEL-2) or PeptiCRAd-MAGEA4 (for MDA-MB-436) in presence of human IL2. After 2 days, the 
PBMCs were added to target tumor cell lines, in presence or not of anti-PD-L1 antibody. After 5 days 
cell viability was measured and the percentage of killing was calculated. Results are presented as the 
mean ± SEM. Statistical significance was calculated with the Student´s t-tests; * p<0,05. 
 
Supplementary Figure 1. 
4T1 and MDA-MB-436 cell line are solid models for immunotherapeutic studies.  (A) MHC-I level in 
4T1 is shown. The cells were seeded at final number of 3x105 in 5mL and the day after INF- was 
added to medium at final concentration of 10 ng/mL overnight. The flow cytometry analysis was 
performed using anti-mouse APC-H2Kd. (B) MHC-I level in 4T1 tumor is reported. Tumor were 
staining with anti-mouse APC H2Kd and flow cytometry was perfomed. (C) HLA-A, B, C level is 
described in MDA-MB-436. We seeded the cells at final number of 4x10^5 cells and the day after we 
stimulated the cells over night with human INF- at final concentration of 10 ng/ml. The flow 
cytometry analysis was executed using anti-human PE-HLA-A, B, C. The percentage of MHC-I 
positive cells (left panel) and the geometrical mean fluorescence intensity (gMFI; right panel) are 
plotted as the mean ± SEM (statically analysis unpaired t-test. p<0.05). 
 
 
  
Table 1. HLA genotyping analysis in MDA-MB-436  
DNA genomic was extracted from MDA-MB-436 and analyzed by Finnish Red Cross with the 
Sanger´s sequencing on high resolution (4 digit) for HLA-A, B (MHC-I) and DRB1 (MHC-II). 
 
   
Sample HLA Aplotype 
PBMCs for SK-MEL-2 
 
A 
B 
C 
03:26 
35:38 
04:12 
PBMCs for MDA-MB-436 A 01:01 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 B 
DRB1                                                              
08:01 
03:01 
 
MDA-MB-436 
 
 
A 
B 
DRB1 
01:01 
08:01 
03:01 
SK-MEL-2 A 
B 
C 
03:26 
35:38 
04:12 






